 
PROTOCOL
BiomedicalProtocol # 14-5529H
 Date Printed: 01/30/[ADDRESS_556143] 6
Funding 8
Expedited Paragraphs 9
Purpose,Study Procedures,Background 11
Radioisotopes or Radiation Machines 18
Medical Equipment for Human Subjects and Laboratory Animals; Investigatiional Devices [ADDRESS_556144] Population (a-g) [ADDRESS_556145] Population (h-m) [ADDRESS_556146] 31
Informed Consent 32
Assent Background 33
HIPAA 33
Attachments 35
Obligations 40
 
PROTOCOL
BiomedicalProtocol # 14-5529H
 Date Printed: 01/30/2019
Event History 41
Page 1 of 47 1
PROTOCOL
BiomedicalProtocol # 14-5529H
 Date Printed: 01/30/2019
Protocol Title: Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
Clinical Research Protocol Title: Dapagliflozin  Augments The Favorable Adaptation ToEndurance Exercise Training
Protocol Type: Biomedical
Date Submitted: 11/01/2018
Approval Period: 11/06/2018-11/05/2019Important Note:
This Print View may not reflect all comments and contingencies for approval. Please check the
comments section of the online protocol.Questions that appear to not have been answered may not have been required for this submission.Please see the system application for more details.
----------------------------------------------------------------------------------------------------
* * * Continuing review * * *
 
7RUHQHZ\RXUSURWRFRO&RPSOHWHWKLVRQHSDJHIRUP,IQHFHVVDU\XSGDWHDQ\VHFWLRQVRIWKHSURWRFRO
WKDWQHHGWREHXSGDWHGIRUWKHXSFRPLQJ\HDUHJFKDQJHLQSHUVRQQHOORFDWLRQ(OHFWURQLFDOO\VLJQWKHDSSOLFDWLRQE\FOLFNLQJLQWKHFKHFNER[RQWKHERWWRPRIWKH2EOLJDWLRQVSDJH5HPHPEHUWRFOLFN6XEPLW)RUPDQGFRQILUP\RXULQWHQWWRVXEPLWE\FOLFNLQJ2.VRWKDWWKH,5%DGPLQLVWUDWRUVUHFHLYH\RXUDSSOLFDWLRQ<RXPXVWDQVZHUHDFKTXHVWLRQ,QSXW1$WRDQVZHUDQ\TXHVWLRQVWKDWDUHQRWDSSOLFDEOH127('RFXPHQWVWKDWFRQWDLQPXFKRIWKHLQIRUPDWLRQUHTXLUHGWRDQVZHUWKHSDUWLFLSDQWQXPEHUTXHVWLRQVEHORZFDQEHIRXQGLQWKH(YHQW+LVWRU\VHFWLRQRIHDFKSURWRFRO7KHVWDWXVRQ\RXUKRPHSDJHZLOOEH6XEPLWWHGWR,5%ZKHQ\RXUVXEPLVVLRQLVVXFFHVVIXO,[ZIP_CODE]$17,IWKH'HSDUWPHQW+HDGKDVFKDQJHGVLQFH\RXUODVWDSSURYDOSOHDVHEHVXUHWRXSGDWHWKH'HSDUWPHQW+HDGOLVWLQJRQWKHSHUVRQQHO,QIRUPDWLRQVFUHHQRI\RXUSURWRFRO
 
 6X[COMPANY_003]U\1XPEHURI3DUWLFLSDQWV$VVRFLDWHGZLWKWKH3URWRFROb
b
bb bb bDb 7RWDOQXPEHURISDUWLFLSDQWVDSSURYHGWRGDWH

 
bb bb bEb 1XPEHURISDUWLFLSDQWVVWXGLHGVLQFHWKHODVWDSSURYDOGDWH

 
bb bb bFb 7RWDOQXPEHURISDUWLFLSDQWVVWXGLHGVLQFHWKHEHJLQQLQJRIWKHSURMHFW

 
bb bb bGb 1XPEHURISDUWLFLSDQWVUHPDLQLQJWRVWXG\WRWDOQXPEHURISDUWLFLSDQWVDSSURYHG/(66WKH
WRWDOQXPEHURISDUWLFLSDQWVVWXGLHGWRGDWH

 
bb bb bHb 3OHDVHH[SODLQLIWKHUHLVDGLVFUHSDQF\LQSDUWLFLSDQWQXPEHUVHJPRUHSDUWLFLSDQWV
UHVSRQGHGWRDVXUYH\WKDQKDGEHHQDSSURYHG
  
 bDb 5HDVRQVDQGQXPEHURIZLWKGUDZDOVIURPWKHUHVHDUFKERWKVXEMHFWDQGLQYHVWLJDWRULQLWLDWHG
VLQFHWKHODVWDSSURYDOGDWH
QRQHVWXGLHGVLQFHODVWDSSURYDO
 
Page 2 of 47 2
PROTOCOL
BiomedicalProtocol # 14-5529H
 Date Printed: 01/30/2019
Protocol Title: Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
Clinical Research Protocol Title: Dapagliflozin  Augments The Favorable Adaptation ToEndurance Exercise Training
Protocol Type: Biomedical
Date Submitted: 11/01/2018
Approval Period: 11/06/2018-11/05/2019Important Note:
This Print View may not reflect all comments and contingencies for approval. Please check the
comments section of the online protocol.Questions that appear to not have been answered may not have been required for this submission.Please see the system application for more details.
----------------------------------------------------------------------------------------------------
bb bb bEb 1XPEHURIVXEMHFWVORVWWRIROORZXSVLQFHWKHEHJLQQLQJRIWKHVWXG\

 
bb bb bFb 3OHDVHVX[COMPANY_003]UL]HDQ\SURWRFROGHYLDWLRQVYLRODWLRQVRUXQDQWLFLSDWHGSUREOHPV83VDGYHUVH
HYHQWV$(VVLQFHWKHODVWFRQWLQXLQJUHYLHZRURULJLQDODSSURYDOLIWKLVLV\RXUILUVWFRQWLQXLQJ
UHYLHZ3OHDVHLQGLFDWHLIDQ\RIWKHXQDQWLFLSDWHGSUREOHPVHYHQWVDUHEHLQJUHSRUWHGWRWKH,5%IRUWKHILUVWWLPH,I\RXKDYHRUZLOOPDNHFKDQJHVWR\RXUSURWRFRODVDUHVXOWRIDQ\XQDQWLFLSDWHGSUREOHPHYHQWRUDGYHUVHHYHQWSOHDVHVX[COMPANY_003]UL]HWKRVHFKDQJHVLQ4XHVWLRQEHORZ
3OHDVHVHH$(ORJ1RGHYLDWLRQRFFXUUHGVLQFHWKHODVWDSSURYD OSHULRG
b
 bb bb bHb &RPSODLQWVDERXWWKHUHVHDUFKGXULQJWKHODVW\HDU
QRQH
 
 $VX[COMPANY_003]U\RIDQ\UHFHQWILQGLQJVOLWHUDWXUHRURWKHUUHOHYDQWLQIRUPDWLRQHVSHFLDOO\SHUWDLQLQJWR
ULVNVLIDSSOLFDEOH
QRQH
 
 'HVFULSWLRQRIWKHUHPDLQGHURISURMHFW
1'R\RXSODQWRUHFUXLWPRUHVXEMHFWV"
b
<,I1RKDYHDOOVXEMHFWVFRPSOHWHGDOOUHVHDUFKUHODWHGLQWHUYHQWLRQV"1RWH3URWRFROVPXVWEHUHQHZHGWRFRQWLQXHUHFUXLWLQJSDUWLFLSDQWVDQGRUFROOHFWGDWDIURPDOUHDG\UHFUXLWHGSDUWLFLSDQWV
b
<$UH\RXRQO\SHUIRUPLQJGDWDDQDO\VLV"127(,I\RXDUHDQDO\]LQJGDWDZLWKQRLGHQWLILHUVLH\RXFDQQRWOLQN\RXUGDWDWRLQGLYLGXDOV\RXFDQFORVH\RXUSURWRFROE\VXEPLWWLQJD)LQDO5HSRUW
 
1'RHVWKLVSURWRFROKDYHD'DWD6DWHW\0RQLWRULQJ%RDUG'60%"
 
,I\RXGRKDYHD'60%KDYHUHSRUWVEHHQVXEPLWWHGWRWKH,5%DQGRUWKH6SRQVRU"8SORDGDQ\'60%UHSRUWVWKDWKDYHQRW\HWEHHQVXEPLWWHGWRWKH,5%VLQFHWKHDSSURYDORUODVWFRQWLQXLQJUHYLHZ
b
 6X[COMPANY_003]UL]HDOODSSURYHGFKDQJHVLQWKHSURWRFROVLQFHWKHODVWFRQWLQXLQJUHYLHZRUVLQFHWKHRULJLQDO
DSSURYDOLIWKLVLV\RXUILUVWFRQWLQXLQJUHYLHZ)RUH[DPSOH+DYH\RXDPHQGHG\RXUSURWRFROGXULQJWKHSDVW\HDU"$UH\RXUHTXHVWLQJWRPDNHDQ\FKDQJHVIRUWKHXSFRPLQJ\HDU"+DYH\RX
Page 3 of 47 3
PROTOCOL
BiomedicalProtocol # 14-5529H
 Date Printed: 01/30/2019
Protocol Title: Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
Clinical Research Protocol Title: Dapagliflozin  Augments The Favorable Adaptation ToEndurance Exercise Training
Protocol Type: Biomedical
Date Submitted: 11/01/2018
Approval Period: 11/06/2018-11/05/2019Important Note:
This Print View may not reflect all comments and contingencies for approval. Please check the
comments section of the online protocol.Questions that appear to not have been answered may not have been required for this submission.Please see the system application for more details.
----------------------------------------------------------------------------------------------------
GXULQJWKHSDVW\HDU"$UH\RXUHTXHVWLQJWRPDNHDQ\FKDQJHVIRUWKHXSFRPLQJ\HDU"+DYH\RXLQFOXGHGDQ\FKDQJHVDVDUHVXOWRIDQXQDQWLFLSDWHGSUREOHPHYHQWRU$GYHUVHHYHQWV$("+DYHWKHUHEHHQDQ\SHUVRQQHOFKDQJHVLQWKHSDVW\HDULQFOXGLQJDFKDQJHLQGHSDUWPHQWKHDG"
1RQH
 
bbbbbbbbb
,IQHFHVVDU\SURFHHGWRWKHDSSURSULDWHVHFWLRQVRIWKHSURWRFRODQGPDNH\RXUUHTXHVWHGFKDQJHV5HPHPEHUWKDWLI\RXDUHUHTXHVWLQJWRUHYLVHDGRFXPHQWWKDWLVDOUHDG\DWWDFKHG\RXPXVWGHOHWHWKHDOUHDG\DWWDFKHGGRFXPHQWDQGXSORDGWKHUHYLVHGGRFXPHQW
 
b /LVWRI3URWRFRO6HFWLRQVDQGTXHVWLRQVWKDWKDYHEHHQFKDQJHGPRGLILHG
1RQH
---------------------------------------------------------------------------------------------
* * * Personnel Information * * *
IMPORTANT NOTE: Mandatory Personnel on a protocol are: Principal Investigator [INVESTIGATOR_152605]. Onlythe Principal Investigator [INVESTIGATOR_152606]; although other personnel listed on the protocol can create theprotocol. Human Subjects Protection Training is mandatory for Principal Investigator, Co-Principal Investigator,and Key Personnel (as defined by [CONTACT_4289]). Training must be updated every three (3) years.
 Principal Investigator  [INVESTIGATOR_438841]
1DPHRI3ULQFLSDO,QYHVWLJDWRU
)DFXOW\6WDIIRU3RVWGRF'HJUHH 7LWOH
%HOO&KULVWRSKHU 3K' $VVRFLDWH3URIHVVRU
(PDLO 3KRQH )D[
&KULVWRSKHU%HOO#&ROR6WDWH('8  
'HSDUWPHQW1DPH &DPSXV'HOLYHU\&RGH b
+HDOWKDQG([HUFLVH6FLHQFH  b
+XPDQ6XEMHFWV7UDLQLQJ&RPSOHWHG"3,VPXVWFRPSOHWHWUDLQLQJHYHU\WKUHH\HDUV <
 
CO-Principal Investigator
1DPHRI&R3ULQFLSDO,QYHVWLJDWRU
7KLVFRXOGEHDQRWKHUIDFXOW\RUD0DVWHU
VRU3K'VWXGHQW'HJUHH 7LWOH
0HOE\&KULV 'U3+ 3URIHVVRU
Page 4 of 47 4
PROTOCOL
BiomedicalProtocol # 14-5529H
 Date Printed: 01/30/2019
Protocol Title: Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
Clinical Research Protocol Title: Dapagliflozin  Augments The Favorable Adaptation ToEndurance Exercise Training
Protocol Type: Biomedical
Date Submitted: 11/01/2018
Approval Period: 11/06/2018-11/05/2019Important Note:
This Print View may not reflect all comments and contingencies for approval. Please check the
comments section of the online protocol.Questions that appear to not have been answered may not have been required for this submission.Please see the system application for more details.
----------------------------------------------------------------------------------------------------
(PDLO 3KRQH )D[
&KULV0HOE\#FRORVWDWHHGX 
'HSDUWPHQW1DPH &DPSXV'HOLYHU\&RGH b
)RRG6FLHQFH	+XPDQ1XWULWLRQ  b
+XPDQ6XEMHFWV7UDLQLQJ&RPSOHWHG"7UDLQLQJLVUHTXLUHGIRU&R3,7UDLQLQJPXVWEHXSGDWHGHYHU\WKUHH\HDUV <
1RWUDLQLQJGDWDLVDYDLODEOH
 
Additional Co-Principal Investigator
1DPHRI$GGLWLRQDO&R3ULQFLSDO
,QYHVWLJDWRU'HJUHH 7LWOH
*DU\/XFNDVHQ 0' 0HGLFDO0RQLWRU
(PDLO 3KRQH )D[
JDU\OXFNDVHQ#XFKHDOWKRUJ
'HSDUWPHQW1DPH &DPSXV'HOLYHU\&RGH&68RURIIFDPSXVPDLOLQJDGGUHVVb
 b
+XPDQ6XEMHFWV7UDLQLQJ&RPSOHWHG"7UDLQLQJLVUHTXLUHGIRU&R3,7UDLQLQJPXVWEHXSGDWHGHYHU\WKUHH\HDUV<
 
Department Head  Mandatory
1DPHRI'HSDUWPHQW+HDG 'HJUHH 7LWOH
%UDXQ%DUU\ 3K' 3URIHVVRU
(PDLO 3KRQH )D[
%DUU\%UDXQ#FRORVWDWHHGX 
'HSDUWPHQW1DPH &DPSXV'HOLYHU\&RGH b
+HDOWKDQG([HUFLVH6FLHQFH  b
+XPDQ6XEMHFWV7UDLQLQJ&RPSOHWHG""7UDLQLQJLVQRWUHTXLUHGIRU'HSDUWPHQW+HDG6HOHFW1RLI\RXGRQRWNQRZLI\RXU'HSDUWPHQW+HDGKDVFRPSOHWHGWUDLQLQJRUQRW <
 
Administrative Contact
[CONTACT_3490] 5 of 47 5
PROTOCOL
BiomedicalProtocol # 14-5529H
 Date Printed: 01/30/2019
Protocol Title: Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
Clinical Research Protocol Title: Dapagliflozin  Augments The Favorable Adaptation ToEndurance Exercise Training
Protocol Type: Biomedical
Date Submitted: 11/01/2018
Approval Period: 11/06/2018-11/05/2019Important Note:
This Print View may not reflect all comments and contingencies for approval. Please check the
comments section of the online protocol.Questions that appear to not have been answered may not have been required for this submission.Please see the system application for more details.
----------------------------------------------------------------------------------------------------
1DPHRI$GPLQLVWUDWLYH&RQWDFW3URMHFW'LUHFWRURU/DE&RRUGLQDWRU'HJUHH 7LWOH
%LHOD/DXULH %6 5HVHDUFK$VVRFLDWH,,,
(PDLO 3KRQH )D[
/DXULH%LHOD#FRORVWDWHHGX  
'HSDUWPHQW1DPH &DPSXV'HOLYHU\&RGH b
+HDOWKDQG([HUFLVH6FLHQFH  b
+XPDQ6XEMHFWV7UDLQLQJ&RPSOHWHG"7UDLQLQJLVQRWUHTXLUHGIRU$GPLQLVWUDWLYH&RQWDFWV <
1RWUDLQLQJGDWDLVDYDLODEOH
 
---------------------------------------------------------------------------------------------
* * * Subject Population * * *
 
 Subject Population(s) Checklist
bbbbbbbÂ„b6HOHFW$OO7KDW$SSO\1RWHWKDWWKLVLV\RXU7DUJHWHG3RSXODWLRQ
;b$GXOW9ROXQWHHUV
b'HFLVLRQDOO\&KDOOHQJHG(OGHUO\
;b(PSOR\HHV
b)HWXVHVb/RQJ7HUP3DWLHQWVb0HQWDOO\'LVDEOHGb0LQRUVXQGHUb3UHJQDQW:RPHQb3ULVRQHUVb6ROGLHUV
;b6WXGHQWV
b2WKHULHQRQ(QJOLVK6SHDNLQJRUDQ\SRSXODWLRQWKDWLVQRWVSHFLILHGDERYH
bbbbbbb
---------------------------------------------------------------------------------------------
* * * Study Location * * *
 
Page 6 of 47 6
PROTOCOL
BiomedicalProtocol # 14-5529H
 Date Printed: 01/30/2019
Protocol Title: Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
Clinical Research Protocol Title: Dapagliflozin  Augments The Favorable Adaptation ToEndurance Exercise Training
Protocol Type: Biomedical
Date Submitted: 11/01/2018
Approval Period: 11/06/2018-11/05/2019Important Note:
This Print View may not reflect all comments and contingencies for approval. Please check the
comments section of the online protocol.Questions that appear to not have been answered may not have been required for this submission.Please see the system application for more details.
----------------------------------------------------------------------------------------------------
 
Study Location(s) Checklist
bbbbbbbb6HOHFW$OO7KDW$SSO\127(&KHFN2WKHUDQGLQSXWWH[W,I\RXUVWXG\ORFDWLRQLVQRWOLVWHGRU,I\RXZRXOGOLNHWROLVWGHWDLOVRI\RXUDOUHDG\FKHFNHGORFDWLRQHJVSHFLILFVFKRROZLWKLQDVFKRROGLVWULFW
$LPV&RPPXQLW\&ROOHJH&RORUDGR'HSDUWPHQWRI3XEOLF+HDOWK	(QYLURQPHQW
;&RORUDGR6WDWH8QLYHUVLW\
&RORUDGR6WDWH8QLYHUVLW\3XHEOR&DPSXV'HQYHU3XEOLF6FKRROV
*UHHOH\(YDQV6FKRRO'LVWULFW
3RXGUH6FKRRO'LVWULFW8QLYHUVLW\RI&RORUDGR+HDOWK1RUWK)RUPHUO\3RXGUH9DOOH\+HDOWK6\VWHP39+65RFN\0RXQWDLQ1DWLRQDO3DUN7KRPSVRQ6FKRRO'LVWULFW8QLYHUVLW\RI&RORUDGR%RXOGHU8QLYHUVLW\RI&RORUDGR&RORUDGR6SULQJV8QLYHUVLW\RI&RORUDGR'HQYHU8QLYHUVLW\RI&RORUDGR+HDOWK6FLHQFHV&HQWHU8QLYHUVLW\RI1RUWKHUQ&RORUDGR2WKHU,QWKHER[EHORZOLVW\RXUVWXG\ORFDWLRQLIQRWFKHFNHGDERYH<RXPD\DOVROLVWGHWDLOVRI\RXU
DOUHDG\FKHFNHGORFDWLRQHJVSHFLILFVFKRROZLWKLQDVFKRROGLVWULFW
bbbbbbb
---------------------------------------------------------------------------------------------
* * * General Checklist * * *
 
General Checklist
bbbbbbbb6HOHFW$OO7KDW$SSO\
;3URSRVHG6WDUW'DWHFDQQRWEHEHIRUH,5%DSSURYDO 2QUHFHLSWRI,5%$SSURYDO
;6SRQVRUHG3URMHFW&KHFNLI\RXZLOOEHIXQGHG25LI\RXKDYHRUSODQWRVXEPLWDJUDQWDSSOLFDWLRQLQDVVRFLDWLRQZLWKWKLVSURWRFRO
16)6SRQVRUHG3OHDVHXSORDGPDQGDWRU\'DWD0DQDJHPHQW3ODQLQWKH$WWDFKPHQWVHFWLRQ
;)'$RU(3$UHJXODWHGUHVHDUFK3OHDVHFRQWDFWWKH&684XDOLW\$VVXUDQFH0DQDJHU&DW%HQVDWWRGHWHUPLQHLI\RXUVWXG\LVXQGHU*RRG/DERUDWRU\*RRG&OLQLFDORU*RRG0DQXIDFWXULQJ3UDFWLFHV*/3*&3*03
b7UDLQLQJ*UDQW
Page 7 of 47 7
PROTOCOL
BiomedicalProtocol # 14-5529H
 Date Printed: 01/30/2019
Protocol Title: Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
Clinical Research Protocol Title: Dapagliflozin  Augments The Favorable Adaptation ToEndurance Exercise Training
Protocol Type: Biomedical
Date Submitted: 11/01/2018
Approval Period: 11/06/2018-11/05/2019Important Note:
This Print View may not reflect all comments and contingencies for approval. Please check the
comments section of the online protocol.Questions that appear to not have been answered may not have been required for this submission.Please see the system application for more details.
----------------------------------------------------------------------------------------------------
;&OLQLFDO7ULDO7RUHJLVWHU\RXUWULDORQ&OLQLFDOWULDOVJRYSOHDVHFRQWDFW&DW%HQV&684XDOLW\$VVXUDQFH0DQDJHUDQG&OLQLFDO7UDLOV$GPLQLVWUDWRUDW
3URMHFWLVDVVRFLDWHGZLWKWKH&RORUDGR6FKRRORI3XEOLF+HDOWK&63+IDFXOW\DQGRUVWXGHQW&RRSHUDWLQJ&ROODERUDWLQJ,QVWLWXWLRQV,QVWLWXWLRQ
ZKHUHUHFUXLWPHQWZLOORFFXU25,QVWLWXWLRQZKHUH&ROODERUDWLQJ3,ZLOOFRQGXFWDVVRFLDWHGUHVHDUFK
,QWHUYLHZ
;4XHVWLRQQDLUH6XUYH\
;b6XEMHFWVZLOOEHFRPSHQVDWHGIRUSDUWLFLSDWLRQ
7KHVLVRU'LVVHUWDWLRQ3URMHFW
;Â…Â„b5DGLRLVRWRSHVUDGLDWLRQSURGXFLQJPDFKLQHVHYHQLIVWDQGDUGRIFDUH3OHDVHFRQWDFW-LP$EUDKDP5DGLDWLRQ6DIHW\2IILFHUIRUTXHVWLRQVUHODWHGWRXVHRIDOOUDGLDWLRQSURGXFLQJPDFKLQHMDPHVDEUDKDP#FRORVWDWHHGX8SORDG\RXUUDGLDWLRQXVHDSSURYDOLIDYDLODEOHRU\RXU5DGLDWLRQ6DIHW\7UDLQLQJFHUWLILFDWHLQWKHDWWDFKPHQWVHFWLRQ
;+XPDQEORRGFHOOVWLVVXHVRUERG\IOXLGV<RXZLOOQHHGWRREWDLQ,%&DSSURYDOLI\RXFKHFNWKLVER[)RULQIRUPDWLRQUHJDUGLQJ,%&DSSURYDOFRQWDFW&KULVWLQH-RKQVRQ,%&&RRUGLQDWRUFKULVWLQHMRKQVRQ#FRORVWDWHHGX
b7LVVXHVWREHVWRUHGIRUIXWXUHUHVHDUFKSURMHFWVb7LVVXHVWREHVHQWRXWRIWKLVLQVWLWXWLRQDVSDUWRIDUHVHDUFKDJUHHPHQW+XPDQ(PEU\RV<RXZLOOQHHGWRREWDLQ,%&DSSURYDOLI\RXFKHFNWKLVER[)RULQIRUPDWLRQUHJDUGLQJ,%&
DSSURYDOFRQWDFW&KULVWLQH-RKQVRQ,%&&RRUGLQDWRUFKULVWLQHMRKQVRQ#FRORVWDWHHGX
+XPDQ(PEU\RQLF&HOOV"3URYLGH1,+&RGH1XPEHUV
RUVWDWHWKDWQRIHGHUDOIXQGLQJZLOOEHXVHGWRVXSSRUWWKLVUHVHDUFK<RXPD\QHHGWRREWDLQ,%&DSSURYDOLI\RXFKHFNWKLVER[)RULQIRUPDWLRQUHJDUGLQJ,%&DSSURYDOFRQWDFW&KULVWLQH-RKQVRQ,%&&RRUGLQDWRUFKULVWLQHMRKQVRQ#FRORVWDWHHGX
b8VHRI3DWLHQWUHODWHGHTXLSPHQW",I<HVVSHFLI\ZKDWHTXLSPHQWLVEHLQJXVHG
0HGLFDOHTXLSPHQWXVHGIRUKXPDQSDWLHQWVVXEMHFWVDOVRXVHGRQDQLPDOV)RUTXHVWLRQVUHJDUGLQJDQLPDO
XVHDSSURYDOFRQWDFW(ODLQH.LP,$&8&6HQLRU&RRUGLQDWRU
3URWRFROLQYROYHVVWXG\LQJSRWHQWLDOO\DGGLFWLQJGUXJV)RUTXHVWLRQVUHJDUGLQJDSSURYDOIRUSRVVHVVLRQRI
FRQWUROOHGVXEVWDQFHVFRQWDFW&KULV*LJOLR'5&&RRUGLQDWRU&KULV*LJOLR#FRORVWDWHHGX
,QYHVWLJDWLRQDOGUXJVUHDJHQWVRUFKHPLFDOV,1'
;b&RPPHUFLDOO\DYDLODEOHGUXJVUHDJHQWVRURWKHUFKHPLFDOVDGPLQLVWHUHGWRVXEMHFWVHYHQLIWKH\DUHQRWEHLQJVWXGLHG
,QYHVWLJDWLRQDO'HYLFH,'(&DQFHU6XEMHFWVHJFOLQLFDOWULDOVEHKDYLRUSUHYHQWLRQRU&DQFHU7LVVXHVHJEORRGFHOOVERG\IOXLGV
<RXPD\QHHGWRREWDLQ,%&DSSURYDOLI\RXFKHFNWKLVER[)RULQIRUPDWLRQUHJDUGLQJ,%&DSSURYDOFRQWDFW&KULVWLQH-RKQVRQ,%&&RRUGLQDWRUFKULVWLQHMRKQVRQ#FRORVWDWHHGX
Page 8 of 47 8
PROTOCOL
BiomedicalProtocol # 14-5529H
 Date Printed: 01/30/2019
Protocol Title: Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
Clinical Research Protocol Title: Dapagliflozin  Augments The Favorable Adaptation ToEndurance Exercise Training
Protocol Type: Biomedical
Date Submitted: 11/01/2018
Approval Period: 11/06/2018-11/05/2019Important Note:
This Print View may not reflect all comments and contingencies for approval. Please check the
comments section of the online protocol.Questions that appear to not have been answered may not have been required for this submission.Please see the system application for more details.
----------------------------------------------------------------------------------------------------
&KULVWLQH-RKQVRQ,%&&RRUGLQDWRUFKULVWLQHMRKQVRQ#FRORVWDWHHGX
2WKHUFODULI\LQWH[WER[WRWKHULJKW
---------------------------------------------------------------------------------------------
* * * Funding * * *
 
Please complete this section if:  1. This protocol will be funded, 2. You have submitted or will submit a grant
application associated with this protocol.  Please be sure to input your PASS/SP1 number to assist SponsoredPrograms in setting up an account for your funds.
If this protocol is funded by [CONTACT_152625], or will lead to the regulatory involvement of the FDA or EPA, please
be certain you are cognizant of any specific regulatory requirements for data acquisition, storage, retention andsharing, as well as research expenditure allowability, with regard to this IRB protocol.
 Funding Checklist
121(
bb bb 127($SSOLFDEOH)HGHUDO*UDQW$SSOLFDWLRQLQFOXGLQJFRPSHWLQJUHQHZDOVPXVWEHDWWDFKHGLQWKH
$WWDFKPHQW6HFWLRQ$SSOLFDEOHLQYHVWLJDWRU
VEURFKXUHDQGVSRQVRU
VSURWRFROPXVWDOVREH
DWWDFKHGLQVHFWLRQIRUDOOLQGXVWU\VSRQVRUHGFOLQLFDOWULDOV
 
Funding - Grants/Contracts
)XQGLQJ$GPLQLVWHUHG%\
81,9(56,7<
&683$66 
6SRQVRU
V,',INQRZQ
)XQGHG%\ 2WKHU
b $VWUD=HQHFD
3ULQFLSDO,QYHVWLJDWRU %HOO
*UDQW&RQWUDFW7LWOHLIGLIIHUHQWIURP3URWRFRO7LWOH
)RU)HGHUDOSURMHFWVDUHFRQWHQWVRIWKLVSURWRFROWKHVDPHDVGHVFULEHGLQ)HGHUDOSURSRVDODSSOLFDWLRQ"
1 ,VWKLVDQ8PEUHOODSURWRFRO"
1 ,VWKLVSURWRFROXQGHUDQ8PEUHOODSURWRFRO"
Funding - Fellowships
Page 9 of 47 9
PROTOCOL
BiomedicalProtocol # 14-5529H
 Date Printed: 01/30/2019
Protocol Title: Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
Clinical Research Protocol Title: Dapagliflozin  Augments The Favorable Adaptation ToEndurance Exercise Training
Protocol Type: Biomedical
Date Submitted: 11/01/2018
Approval Period: 11/06/2018-11/05/2019Important Note:
This Print View may not reflect all comments and contingencies for approval. Please check the
comments section of the online protocol.Questions that appear to not have been answered may not have been required for this submission.Please see the system application for more details.
----------------------------------------------------------------------------------------------------
Funding - Other
 
Gift Funding
Dept. FundingOther Funding
---------------------------------------------------------------------------------------------
* * * Expedited Paragraphs * * *
 
PLEASE READ:  This online application is for projects that will be reviewed by [CONTACT_152626]-
board review process.  The criteria for expedited review are listed below. Review and check what expeditecriteria is/are appropriate for your project. NOTE:  If your research involves or may involve greater than minimalrisk, an element of deception, or is FDA-regulated research, do NOT check any of the expedited criteria listedbelow.  Your protocol will then be reviewed by [CONTACT_152627]-board at their next regularly scheduled meeting.  If yourproject meets the exempt criteria, please submit your exempt application via email to:[EMAIL_3134].  Information regarding exempt applications can be found here:http://ricro.colostate.edu/IRB/ExemptReview.html
 b([SHGLWH&ULWHULD 
 &OLQLFDOVWXGLHVRIGUXJVDQGPHGLFDOGHYLFHVRQO\ZKHQFRQGLWLRQDRUELVPHW
 
Db 5HVHDUFKRQGUXJVIRUZKLFKDQLQYHVWLJDWLRQDOQHZGUXJDSSOLFDWLRQ&)53DUWLV
QRWUHTXLUHG1RWH5HVHDUFKRQPDUNHWHGGUXJVWKDWVLJQLILFDQWO\LQFUHDVHVWKHULVNVRU
GHFUHDVHVWKHDFFHSWDELOLW\RIWKHULVNVDVVRFLDWHGZLWKWKHXVHRIWKHSURGXFWLVQRWHOLJLEOHIRUH[SHGLWHGUHYLHZ
 
Eb 5HVHDUFKRQPHGLFDOGHYLFHVIRUZKLFKbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbb
bbbbbbbbbbbbbbb
 
bbbbbbLb $QLQYHVWLJDWLRQDOGHYLFHH[HPSWLRQDSSOLFDWLRQ&)53DUWLVQRWUHTXLUHGRU
bbbbbbLLb 7KHPHGLFDOGHYLFHLVFOHDUHGDSSURYHGIRUPDUNHWLQJDQGWKHPHGLFDOGHYLFHLVEHLQJXVHGLQ
DFFRUGDQFHZLWKLWVFOHDUHGDSSURYHGODEHOLQJ
Page 10 of 47 10
PROTOCOL
BiomedicalProtocol # 14-5529H
 Date Printed: 01/30/2019
Protocol Title: Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
Clinical Research Protocol Title: Dapagliflozin  Augments The Favorable Adaptation ToEndurance Exercise Training
Protocol Type: Biomedical
Date Submitted: 11/01/2018
Approval Period: 11/06/2018-11/05/2019Important Note:
This Print View may not reflect all comments and contingencies for approval. Please check the
comments section of the online protocol.Questions that appear to not have been answered may not have been required for this submission.Please see the system application for more details.
----------------------------------------------------------------------------------------------------
 
 &ROOHFWLRQRIEORRGVDPSOHVE\ILQJHUVWLFNKHHOVWLFNHDUVWLFNRUYHQLSXQFWXUHDVIROORZV
 
Db )URPKHDOWK\QRQSUHJQDQWDGXOWVZKRZHLJKDWOHDVWSRXQGV)RUWKHVHVXEMHFWVWKH
DPRXQWVGUDZQPD\QRWH[FHHGPOLQDQZHHNSHULRGDQGFROOHFWLRQPD\QRWRFFXUPRUHIUHTXHQWO\WKDQWLPHVSHUZHHNRU
 
Eb )URPRWKHUDGXOWVDQGFKLOGUHQFRQVLGHULQJWKHDJHZHLJKWDQGKHDOWKRIWKHVXEMHFWVWKH
FROOHFWLRQSURFHGXUHWKHDPRXQWRIEORRGWREHFROOHFWHGDQGWKHIUHTXHQF\ZLWKZKLFKLWZLOOEHFROOHFWHG)RUWKHVHVXEMHFWVWKHDPRXQWGUDZQPD\QRWH[FHHGWKHOHVVHURIPORUPOSHUNJLQDQZHHNSHULRGDQGFROOHFWLRQPD\QRWRFFXUPRUHIUHTXHQWO\WKDQWLPHVSHUZHHN
 
 3URVSHFWLYHFROOHFWLRQRIELRORJLFDOVSHFLPHQVIRUUHVHDUFKSXUSRVHVE\QRQLQYDVLYHPHDQV
 
 &ROOHFWLRQRIGDWDWKURXJKQRQLQYDVLYHSURFHGXUHVQRWLQYROYLQJJHQHUDODQHVWKHVLDRUVHGDWLRQ
URXWLQHO\HPSOR\HGLQFOLQLFDOSUDFWLFHH[FOXGLQJSURFHGXUHVLQYROYLQJ[UD\VRUPLFURZDYHV:KHUHPHGLFDOGHYLFHVDUHHPSOR\HGWKH\PXVWEHFOHDUHGDSSURYHGIRUPDUNHWLQJ6WXGLHVLQWHQGHGWRHYDOXDWHWKHVDIHW\DQGHIIHFWLYHQHVVRIWKHPHGLFDOGHYLFHDUHQRWJHQHUDOO\HOLJLEOHIRUH[SHGLWHGUHYLHZLQFOXGLQJVWXGLHVRIFOHDUHGPHGLFDOGHYLFHVIRUQHZLQGLFDWLRQV
 
([DPSOHV
Db 3K\VLFDOVHQVRUVWKDWDUHDSSOLHGHLWKHUWRWKHVXUIDFHRIWKHERG\RUDWDGLVWDQFHDQGGRQRW
LQYROYHLQSXWRIVLJQLILFDQWDPRXQWVRIHQHUJ\LQWRWKHVXEMHFWRUDQLQYDVLRQRIWKHVXEMHFW
VSULYDF\
Eb :HLJKLQJRUWHVWLQJVHQVRU\DFXLW\bbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbb
bbbbbb
Fb 0DJQHWLFUHVRQDQFHLPDJLQJbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbb
bbb
Gb (OHFWURFDUGLRJUDSK\HOHFWURHQFHSKDORJUDSK\WKHUPRJUDSK\GHWHFWLRQRIQDWXUDOO\RFFXUULQJ
UDGLRDFWLYLW\HOHFWURUHWLQRJUDSK\XOWUDVRXQGGLDJQRVWLFLQIUDUHGLPDJLQJGRSSOHUEORRGIORZDQGHFKRFDUGLRJUDSK\
Hb 0RGHUDWHH[HUFLVHPXVFXODUVWUHQJWKWHVWLQJERG\FRPSRVLWLRQDVVHVVPHQWDQGIOH[LELOLW\
WHVWLQJZKHUHDSSURSULDWHJLYHQWKHDJHZHLJKWDQGKHDOWKRIWKHLQGLYLGXDO
 
 5HVHDUFKLQYROYLQJPDWHULDOVGDWDGRFXPHQWVUHFRUGVRUVSHFLPHQVWKDWKDYHEHHQFROOHFWHGRU
ZLOOEHFROOHFWHGVROHO\IRUQRQUHVHDUFKSXUSRVHVVXFKDVPHGLFDOWUHDWPHQWRUGLDJQRVLV127(6RPHUHVHDUFKLQWKLVSDUDJUDSKPD\EHH[HPSWIURPWKH++6UHJXODWLRQVIRUWKHSURWHFWLRQRIKXPDQVXEMHFWV&)5E7KLVOLVWLQJUHIHUVRQO\WRUHVHDUFKWKDWLVQRWH[HPSW
 
 &ROOHFWLRQRIGDWDIURPYRLFHYLGHRGLJLWDORULPDJHUHFRUGLQJVPDGHIRUUHVHDUFKSXUSRVHV
Page 11 of 47 11
PROTOCOL
BiomedicalProtocol # 14-5529H
 Date Printed: 01/30/2019
Protocol Title: Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
Clinical Research Protocol Title: Dapagliflozin  Augments The Favorable Adaptation ToEndurance Exercise Training
Protocol Type: Biomedical
Date Submitted: 11/01/2018
Approval Period: 11/06/2018-11/05/2019Important Note:
This Print View may not reflect all comments and contingencies for approval. Please check the
comments section of the online protocol.Questions that appear to not have been answered may not have been required for this submission.Please see the system application for more details.
----------------------------------------------------------------------------------------------------
 
 5HVHDUFKRQLQGLYLGXDORUJURXSFKDUDFWHULVWLFVRUEHKDYLRULQFOXGLQJEXWQRWOLPLWHGWRUHVHDUFKRQ
SHUFHSWLRQFRJQLWLRQPRWLYDWLRQLGHQWLW\ODQJXDJHFRPPXQLFDWLRQFXOWXUDOEHOLHIVRUSUDFWLFHVDQGVRFLDOEHKDYLRURUUHVHDUFKHPSOR\LQJVXUYH\LQWHUYLHZRUDOKLVWRU\IRFXVJURXSSURJUDPHYDOXDWLRQKXPDQIDFWRUVHYDOXDWLRQRUTXDOLW\DVVXUDQFHPHWKRGRORJLHV127(6RPHUHVHDUFKLQWKLVFDWHJRU\PD\EHH[HPSWIURPWKH++6UHJXODWLRQVIRUWKHSURWHFWLRQRIKXPDQVXEMHFWV&)5EDQGE7KLVOLVWLQJUHIHUVRQO\WRUHVHDUFKWKDWLVQRWH[HPSW
 
 
---------------------------------------------------------------------------------------------
* * * Purpose,Study Procedures,Background * * *
 
2ULJLQDO3URWRFRO1XPEHUHJ+
bbb 7LWOH3OHDVHLQGLFDWHLIWKHSURWRFROWLWOHLVGLIIHUHQWIURPWKHSURSRVDOWLWOH
'RHV'DSDJOLIOR]LQ$XJPHQW7KH)DYRUDEOH$GDSWDWLRQ7R(QGXUDQF H([HUFLVH7UDLQLQJ"
&OLQLFDO5HVHDUFK3URWRFRO7LWOH'DSDJOLIOR]LQ$XJPHQWV7KH)DYRUDEOH$GDSWDWLRQ7R(QGXUDQFH([HUFLVH7UDLQLQJ
 
bbbbbb&RPSOHWH6HFWLRQV6SHFLI\1$DVDSSURSULDWH'RQRWOHDYHDQ\UHTXLUHGVHFWLRQVEODQN3XUSRVHRIWKHVWXG\
D 3URYLGHDEULHIOD\VX[COMPANY_003]U\RIWKHSURMHFWLQZRUGV7KHOD\VX[COMPANY_003]U\VKRXOGEHUHDGLO\
XQGHUVWDQGDEOHWRWKHJHQHUDOSXEOLFDQGLVIRUH[DPSOHZKDWZRXOGEHUHOHDVHGWRDQHZVSDSHULI
UHTXHVWHG
([HUFLVHLVIUHTXHQWO\SUHVFULEHGDVDIDYRUDEOHOLIHVW\OHLQWH UYHQWLRQWRSUHYHQWUHYHUVHW\SHGLDEHWHV,W
LVDOVRSUHVFULEHGLQDGGLWLRQWRFRQFXUUHQWSKDUPDFRORJLFDOWUHDWPHQWVXFKDVPHWIRUPLQ5HFHQWGDWDDQLPDODQGKXPDQVXJJHVWWKDWPHWIRUPLQPD\DWWHQXDWHWKHIDYRUDEOHEHQHILWVRIH[HUFLVHWUDLQLQJ,QOLJKWRIWKHSK\VLRORJLFDOPHFKDQLVPRI'DSDJOLIOR]LQVRGLXPJOXFRVHFRWUDQVSRUWHU6*/7LQKLELWLRQRQHPLJKWVSHFXODWHWKDWUDWKHUWKDQLQKLELWLWZLOODXJPHQWW KHIDYRUDEOHDGDSWDWLRQVWRH[HUFLVHWUDLQLQJ
 
E :KDWGRHVWKH,QYHVWLJDWRUVKRSHWROHDUQIURPWKHVWXG\"
:HZLVKWROHDUQLI'DSDJOLIOR]LQDXJPHQWVWKHIDYRUDEOHDGDSWD WLRQWRHQGXUDQFHH[HUFLVHWUDLQLQJLQ
SUHYLRXVO\VHGHQWDU\RYHUZHLJKWREHVHDGXOWKXPDQV
 
F 3URSRVHG6WDUW'DWHPD\QRWSUHFHGH,5%DSSURYDOGDWH
2QUHFHLSWRI,5%DSSURYDODQG)'$DSSURYDORI,1'DSSOLFDWLRQ 
 
b
Page 12 of 4712
PROTOCOL
BiomedicalProtocol # 14-5529H
 Date Printed: 01/30/2019
Protocol Title: Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
Clinical Research Protocol Title: Dapagliflozin  Augments The Favorable Adaptation ToEndurance Exercise Training
Protocol Type: Biomedical
Date Submitted: 11/01/2018
Approval Period: 11/06/2018-11/05/2019Important Note:
This Print View may not reflect all comments and contingencies for approval. Please check the
comments section of the online protocol.Questions that appear to not have been answered may not have been required for this submission.Please see the system application for more details.
----------------------------------------------------------------------------------------------------
6WXG\3URFHGXUHV,IWKLVLVDVWXGHQWSURMHFWWKHPHWKRGVVHFWLRQRIWKHWKHVLVRUGLVVHUWDWLRQSURSRVDOPXVWEHDWWDFKHGLQVHFWLRQ$WWDFKPHQWVHFWLRQ
 
D ,QOD\ODQJXDJHGHVFULEHDOOWKHSURFHGXUHVIURPVFUHHQLQJWKURXJKHQGRIVWXG\WKDWWKHKXPDQVXEMHFW
PXVWXQGHUJRLQWKHUHVHDUFKSURMHFWLQFOXGLQJVWXG\YLVLWVGUXJWUHDWPHQWVUDQGRPL]DWLRQDQGWKH
SURFHGXUHVWKDWDUHSDUWRIVWDQGDUGRIFDUH3OHDVHQRWH'R127UHVSRQG6HH$WWDFKPHQW6HFWLRQ,I\RXZRXOGOLNHWRDGGWDEOHVFKDUWVHWFDWWDFKWKRVHILOHVLQWKH$WWDFKPHQWVHFWLRQ
29(59,(:7KLVLVDUDQGRPL]HGSODFHERFRQWUROOHGGRXEOHEOLQGUHSHDWH GPHDVXUHVVWXG\VHGHQWDU\DGXOWVZLOO
EHUHFUXLWHGIRUSDUWLFLSDWLRQDQGUDQGRPO\DVVLJQHGWRRQHRIWZRZHHNWUHDWPHQWVVXSHUYLVHGHQGXUDQFHH[HUFLVHWUDLQLQJGD\VSHUZHHNSOXVGDLO\RUDODGPLQLVWUDWLRQRI'DSDJOLIOR]LQVXSHUYLVHGHQGXUDQFHH[HUFLVHWUDLQLQJGD\VSHUZHHNSOXVGDLO\RUDODGP LQLVWUDWLRQRISODFHER3ULRUWRDQG
IROORZLQJFRPSOHWLRQRIWKHWUHDWPHQWWKHIROORZLQJGHSHQGHQWY DULDEOHVZLOOEHTXDQWLILHGDPD[LPDO
DHURELFFDSDFLW\EVXEVWUDWHXWLOL]DWLRQGXULQJVWDQGDUGL]HGORZPRGHUDWHLQWHQVLW\H[HUFLVHFVNHOHWDOPXVFOHDHURELFHQ]\PHDFWLYLW\GERG\FRPSRVLWLRQDQGHRUDOJOXFRVHWROHUDQFHIDVWLQJJOXFRVHDQGLQVXOLQUHVLVWDQFH
6WXG\SDUWLFLSDQWVZLOOUHSRUWWRWKH+XPDQ3HUIRUPDQFH&OLQLFD O5HVHDUFK/DERUDWRU\+3&5/RQ
VHSDUDWHRFFDVLRQV9LVLWVWXG\SDUWLFLSDQWVZLOOXQGHUJRVFUHHQLQJPHGLFDOKLVWRU\OHDGHOHFWURFDUGLRJUDPDQGEORRG
SUHVVXUHDVVHVVPHQWDWUHVWDQGGXULQJLQFUHPHQWDOH[HUFLVHWRYROLWLRQDOH[KDXVWLRQEORRGVDPSOLQJDQGPHDVXUHPHQWRIERG\FRPSRVLWLRQ
9LVLWPD[LPDOR[\JHQXSWDNHZLOOEHPHDVXUHG9LVLWWKHPHWDEROLFUHVSRQVHWRVWDQGDUGL]HGH[HUFLVHZLOOE HGHWHUPLQHG
9LVLWDQRUDOJOXFRVHWROHUDQFHWHVWZLOOEHSHUIRUPHGDQGWKHQVNHOHWDOPXVFOHZLOOEHVDPSOHG9LVLWVZHHNVRIVXSHUYLVHGH[HUFLVHWUDLQLQJ&RQFXUU HQWZLWKWKHVHYLVLWVUHVHDUFKSDUWLFLSDQWV
ZLOOLQJHVWRQDGDLO\EDVLVHLWKHU'DSDJOLIOR]LQRUSODFHER9LVLWPD[LPDOR[\JHQXSWDNHDQGERG\FRPSRVLWLRQZLOOEHPH DVXUHG
9LVLWWKHPHWDEROLFUHVSRQVHWRVWDQGDUGL]HGH[HUFLVHZLOO EHGHWHUPLQHG
9LVLWDQRUDOJOXFRVHWROHUDQFHWHVWZLOOEHSHUIRUPHGDQG WKHQVNHOHWDOPXVFOHZLOOEHVDPSOHG
'(7$,/(''(6&5,37,212)678'<352&('85(69LVLWVWXG\SDUWLFLSDQWVZLOOSURYLGHLQIRUPHGFRQVHQWDQGX QGHUJRVFUHHQLQJPHGLFDOKLVWRU\OHDG
HOHFWURFDUGLRJUDPDQGEORRGSUHVVXUHDVVHVVPHQWDWUHVWDQGGXULQJLQFUHPHQWDOH[HUFLVHWRYROLWLRQDO
H[KDXVWLRQEORRGVDPSOLQJDQGPHDVXUHPHQWRIERG\FRPSRVLWLRQ 
7KHVHVFUHHQLQJSURFHGXUHVDUHVWDQGDUGIRURXUODE(DFKRIW KHSURFHGXUHVLVFXUUHQWO\DFWLYHLQRWKHU
,5%DSSURYHGSURWRFROVHJ+++
Page 13 of 4713
PROTOCOL
BiomedicalProtocol # 14-5529H
 Date Printed: 01/30/2019
Protocol Title: Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
Clinical Research Protocol Title: Dapagliflozin  Augments The Favorable Adaptation ToEndurance Exercise Training
Protocol Type: Biomedical
Date Submitted: 11/01/2018
Approval Period: 11/06/2018-11/05/2019Important Note:
This Print View may not reflect all comments and contingencies for approval. Please check the
comments section of the online protocol.Questions that appear to not have been answered may not have been required for this submission.Please see the system application for more details.
----------------------------------------------------------------------------------------------------
+HDOWK+LVWRU\3RWHQWLDOSDUWLFLSDQWVZLOOFRPSOHWHDVWDQGDU GL]HGKHDOWKKLVWRU\TXHVWLRQQDLUHWKDWZLOO
DGGUHVVSDVWDQGSUHVHQWPHGLFDWLRQXVHDOOHUJLHVSDVWDQGSUHVHQWPHGLFDOFRQGLWLRQVDQGSK\VLFDOLQMXULHVDQGKDELWXDOXVHRIDOFRKRODQGWREDFFR
%RG\FRPSRVLWLRQ3HUFHQWERG\IDWIDWIUHHPDVVWRWDODQGU HJLRQDODGLSRVHWLVVXHPDVVDQGWRWDOERQH
PLQHUDOGHQVLW\ZLOOEHGHWHUPLQHGXVLQJDZKROHERG\GXDOHQHU J\[UD\DEVRUSWLRPHWU\VFDQ'(;$
0RGHO'3;,4/XQDU&RUS0DGLVRQ:,0D[LPDOJUDGHGH[HUFLVHVWUHVVWHVWLQJ$OHDG(&*DUWHULD OEORRGSUHVVXUHEUDFKLDO
VSK\JPRPDQRPHWHUZLOOEHREWDLQHGGXULQJTXLHWUHVWLQJFRQGLWLRQVLQWKHVXSLQHDQGXSULJKWVLWWLQJ
SRVLWLRQVDQGGXULQJLQFUHPHQWDOVWDWLRQDU\F\FOHHUJRPHWHURUWUHDGPLOOH[HUFLVHXQWLOYROLWLRQDOIDWLJXH'XULQJH[HUFLVHR[\JHQFRQVXPSWLRQFDUERQGLR[LGHSURGXFWLRQDQGYHQWLODWLRQPD\EHGHWHUPLQHGE\LQGLUHFWFDORULPHWU\$OOGDWDIURPWKHVHWHVWVZLOOEHZLOOEHUHYLHZHGE\DFDUGLRORJLVW2QO\WKRVHVXEMHFWVGHPRQVWUDWLQJQRVLJQVRUV\PSWRPVRIGLVHDVHZLOOEH LQYLWHGWRSDUWLFLSDWHLQWKHVWXG\
%ORRGVDPSOLQJà²¦%ORRGaPOZLOOEHVDPSOHGIURPDQDQWHFX ELWDORUKDQGYHLQIRUVXEVHTXHQWDQDO\VLV
RIFLUFXODWLQJIDFWRUVSHUWLQHQWWRLQFOXVLRQH[FOXVLRQFULWHULDLQFOXGLQJJOXFRVHDVSDUWDWHDPLQRWUDQVIHUDVHDODQLQHDPLQRWUDQVIHUDVHDQGWRWDOELOLUXELQ7KHVHEORRGDQDO\VHVZLOOEHSHUIRUPHGLQRQVLWH3LFFROR;SUHVV$ED[LV8QLRQ&LW\&$7HVWLQJIRU+HSDWLWLV%&ZLOOEHSHUIRUPHGDWDORFDOH[WHUQDOFOLQLFDOODEHJ8QLYHUVLW\RI&RORUDGR+HDOWK1RUWK 3HUWKH0HGLFDO0RQLWRUà²¬VGLVFUHWLRQIROORZ
XSEORRGGUDZVPD\EHUHTXHVWHG
9LVLW0D[LPDOR[\JHQXSWDNHZLOOEHPHDVXUHG7KLVSURFHGXUHVLVVWDQGDUGIRURXUODEDQGLVFXUUHQWO\DFWLYH LQRWKHU,5%DSSURYHGSURWRFROVHJ
++++0D[LPDOR[\JHQXSWDNH2[\JHQFRQVXPSWLRQFDUERQGLR[LGHSURGXFWLRQDQGYHQWLODWLRQZLOOEH
GHWHUPLQHGE\LQGLUHFWFDORULPHWU\GXULQJLQFUHPHQWDOVWDWLRQDU\F\FOHHUJRPHWHUH[HUFLVHXQWLOYROLWLRQDOIDWLJXH
9LVLW7KHPHWDEROLFUHVSRQVHWRVWDQGDUGL]HGH[HUFLVHZLOOE HGHWHUPLQHG
7KLVSURFHGXUHVLVVWDQGDUGIRURXUODEDQGLVFXUUHQWO\DFWLYH LQRWKHU,5%DSSURYHGSURWRFROVHJ
++6XEMHFWVZLOOSHUIRUPVWDWLRQDU\F\FOHHUJRPHWHUH[HUFLVH3DU WLFLSDQWVZLOOH[HUFLVHIRUFRQVHFXWLYH
PLQXWHSHULRGVDWDQH[WHUQDOZRUNUDWHRIDQG:DWWV5HVSLUDWRU\H[FKDQJHUDWLRKHDUWUDWH
DQGEORRGSUHVVXUHZLOOEHUHFRUGHGGXULQJWKHILQDOPLQXWHV RIHDFKPLQXWHSHULRG'XULQJWKHILQDO
VHFRQGVRIHDFKPLQXWHSHULRGUDWLQJVRISHUFHLYHGH[HUW LRQZLOOEHUHFRUGHG'XULQJWKHILQDO
VHFRQGVRIHDFKPLQXWHSHULRGYHQRXVEORRGZLOOEHVDPSOHGIRUVXEVHTXHQWGHWHUPLQDWLRQRIFLUFXODWLQJFRQFHQWUDWLRQVRIJOXFRVHODFWDWHQRQHVWHULILHG IDWW\DFLGVJO\FHURODQGLQVXOLQ
9LVLW$QRUDOJOXFRVHWROHUDQFHWHVWZLOOEHSHUIRUPHGIROO RZHGE\PXVFOHVDPSOLQJ
7KHVHSURFHGXUHVDUHVWDQGDUGIRURXUODE(DFKRIWKHSURFHGXUHVLVFXUUHQWO\DFWLYHLQRWKHU,5%DSSURYHGSURWRFROVHJ+++
3DUWLFLSDQWVZLOOUHSRUWWRWKHODERUDWRU\HDUO\LQWKHPRUQLQJIROORZLQJDKRXUIDVWDQGKRXU
Page 14 of 4714
PROTOCOL
BiomedicalProtocol # 14-5529H
 Date Printed: 01/30/2019
Protocol Title: Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
Clinical Research Protocol Title: Dapagliflozin  Augments The Favorable Adaptation ToEndurance Exercise Training
Protocol Type: Biomedical
Date Submitted: 11/01/2018
Approval Period: 11/06/2018-11/05/2019Important Note:
This Print View may not reflect all comments and contingencies for approval. Please check the
comments section of the online protocol.Questions that appear to not have been answered may not have been required for this submission.Please see the system application for more details.
----------------------------------------------------------------------------------------------------
DEVWHQWLRQIURPH[HUFLVH$QLQWUDYHQRXVFDWKHWHUZLOOEHLQVHUWHGLQWRDQDQWHFXELWDORUKDQGYHLQDQGNHSWSDWHQWZLWKDVDOLQHGULS)ROORZLQJEDVHOLQHEORRGVDPSOLQJIRUIDVWLQJJOXFRVHDQGLQVXOLQSDUWLFLSDQWVZLOOLQJHVWJRIGH[WURVHGLVVROYHGLQPORIZDWHURYHUPLQXWHV9HQRXVEORRGaPOZLOOEHVDPSOHGDWWLPHEDVHOLQHDQGDQGPLQXWHVIRUGHWHUPLQDWLRQRIFRQFHQWUDWLRQRIEORRGJOXFRVHDQGLQVXOLQFRPPHUFLDOO\DYDLOD EOHDVVD\
2QFRPSOHWLRQRIWKHRUDOJOXFRVHWROHUDQFHWHVWVNHOHWDOPXVFOHaPJRIYDVWXVODWHUDOLVZLOOEHVDPSOHGXVLQJVWDQGDUGWHFKQLTXHV%HUJVWUÂ¸PQHHGOHDQGDQDO\] HGIRUSURWHLQFRQWHQWDQGPD[LPDO
HQ]\PDWLFDFWLYLWLHV
9LVLWVZHHNVRIVXSHUYLVHGH[HUFLVHWUDLQLQJ&RQFXUU HQWZLWKWKHVHYLVLWVUHVHDUFKSDUWLFLSDQWV
ZLOOLQJHVWRQDGDLO\EDVLVHLWKHU'DSDJOLIOR]LQRUSODFHER$OOSDUWLFLSDQWVZLOOFRPSOHWHDZHHNSURJUDPRIVXSHUYLVHGH[HUFLVHWUDLQLQJ([HUFLVHZLOOEHJLQZLWK
WUDLQLQJVHVVLRQVSHUZHHNRIPLQXWHVDQGSURJUHVVDIWHU ZHHNVWRVHVVLRQVSHUZHHNRI
PLQXWHV3DUWLFLSDQWVZLOOUHSRUWWKHLUUDWHRISHUFHLYHGH[HUWLRQ53(WKHWDUJHWZLOOEHWRVRPHZKDWKDUGWRKDUG,IDQ53(LQGLFDWLYHRIPRGHUDWHWRKH DY\H[HUFLVHLVQRWDFKLHYHGE\DKHDUW
UDWHHTXLYDOHQWWRRIKHDUWUDWHUHVHUYHWKHH[WHUQDOZRUNUDWHZLOOEHDGMXVWHGWRDFKLHYHDQDSSURSULDWHWUDLQLQJVWLPXOXV6XEMHFWVZLOOQRWEHSHUPLWWHGWRH[HUFLVHZLWKLQEHDWVSHUPLQXWHRIWKHLUPD[LPXPKHDUWUDWH7KHH[HUFLVHPRGDOLWLHVZLOOEHWUHDGPLOOZDONLQJUXQQLQJVWDWLRQDU\F\FOHHUJRPHWHUH[HUFLVHDQGHOOLSWLFDOHUJRPHWHUH[HUFLVH7KHPRGDOLWLHVZLOOEHYDULHGEHWZHHQEXWQRWZLWKLQVHVVLRQVWRDYRLGERUHGRPDQGSRWHQWLDORYHUXVHLQMXULHV,QWRWDOHDF KSDUWLFLSDQWZLOOEHVFKHGXOHGWRFRPSOHWH
H[HUFLVHVHVVLRQV(YHU\VHVVLRQZLOOEHJLQDQGHQGZLWKDPL QXWHVHOISDFHGZDUPXSFRROGRZQ
7KHVHPLQXWHSHULRGVZLOOQRWEHLQFOXGHGLQWKHWUDLQLQJGXU DWLRQIRUH[DPSOHDPLQXWHVHVVLRQZLOO
FRQVLVWRIDPLQXWHZDUPXSPLQXWHVRIH[HUFLVHWUDLQLQJ DQGPLQXWHVRIFRROGRZQ
7KHGRVHRI'DSDJOLIOR]LQZLOOEHJLQDVPJGD\IRUWKHILUVWGD\V,QWKHDEVHQFHRIFRPSOLFDWLRQVVLGHHIIHFWVRUXQIDYRUDEOHUHDFWLRQVWKHGRVHZLOOWKHQLQFUHDVHWRPJGD\IRUWKHUHPDLQGHURIWKHVWXG\
9LVLW0D[LPDOR[\JHQXSWDNHZLOOEHPHDVXUHG%RG\FRPSRVL WLRQZLOOEHPHDVXUHG
6HHGHVFULSWLRQIRU9LVLW9LVLW7KHPHWDEROLFUHVSRQVHWRVWDQGDUGL]HGH[HUFLVHZLOO EHGHWHUPLQHG
6HHGHVFULSWLRQIRU9LVLW9LVLW$QRUDOJOXFRVHWROHUDQFHWHVWZLOOEHSHUIRUPHGIRO ORZHGE\PXVFOHVDPSOLQJ
6HHGHVFULSWLRQIRU9LVLW
 
E ([SODLQZK\KXPDQVXEMHFWVPXVWEHXVHGIRUWKLVSURMHFW
'DSDJOLIOR]LQLVDSSURYHGIRUKXPDQXVH:HZLVKWRLQYHVWLJDWHDSRWHQWLDOIDYRUDEOHVLGHHIIHFWWKDW
PD\RFFXULQKXPDQVZKRXVH'DSDJOLIOR]LQDQGH[HUFLVH'XHWR SRWHQWLDOVSHFLHVGLIIHUHQFHVLWZRXOG
QRWEHDSSURSULDWHWRSHUIRUPWKHVHVWXGLHVRQH[SHULPHQWDODQL PDOV
Page 15 of 4715
PROTOCOL
BiomedicalProtocol # 14-5529H
 Date Printed: 01/30/2019
Protocol Title: Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
Clinical Research Protocol Title: Dapagliflozin  Augments The Favorable Adaptation ToEndurance Exercise Training
Protocol Type: Biomedical
Date Submitted: 11/01/2018
Approval Period: 11/06/2018-11/05/2019Important Note:
This Print View may not reflect all comments and contingencies for approval. Please check the
comments section of the online protocol.Questions that appear to not have been answered may not have been required for this submission.Please see the system application for more details.
----------------------------------------------------------------------------------------------------
 
F $OWHUQDWLYH3URFHGXUHV,IWKHSURSRVHGVWXG\LVDFOLQLFDOWULDORIDGUXJYDFFLQHGHYLFHRUWUHDWPHQW
GHVFULEHDOWHUQDWLYHSURFHGXUHVLIDQ\WKDWPLJKWEHDGYDQWDJHRXVWRWKHVXEMHFW'HVFULEHWKHLPSRUWDQW
SRWHQWLDOULVNVDQGEHQHILWVDVVRFLDWHGZLWKWKHDOWHUQDWLYHSURFHGXUHVRUFRXUVHVRIWUHDWPHQW$Q\VWDQGDUGWUHDWPHQWWKDWLVEHLQJZLWKKHOGPXVWEHGLVFORVHG7KLVLQIRUPDWLRQPXVWEHLQFOXGHGLQWKHFRQVHQWIRUP
7KHUHDUHQRDSSURSULDWHDOWHUQDWLYHSURFHGXUHV
 
G ,IWKHSURSRVHGVWXG\LVDFOLQLFDOWULDORIDGUXJYDFFLQHGHYLFHRUWUHDWPHQWZLOOLWEHSRVVLEOHWRFRQWLQXH
WKHPRUHPRVWDSSURSULDWHWKHUDS\IRUWKHVXEMHFWVDIWHUWKHFRQFOXVLRQRIWKHVWXG\"
1RWDSSOLFDEOH
 
H 6WXG\(QGSRLQW,IWKHSURSRVHGVWXG\LVDFOLQLFDOWULDORIDGUXJYDFFLQHGHYLFHRUWUHDWPHQWZKDWDUHWKH
JXLGHOLQHVRUHQGSRLQWVE\ZKLFK\RXFDQHYDOXDWHWKHDOWHUQDWLYHWUHDWPHQWVGXULQJWKHVWXG\",IRQH
WUHDWPHQWSURYHVWREHFOHDUO\PRUHHIIHFWLYHWKDQDQRWKHURURWKHUVZLOOWKHVWXG\EHWHUPLQDWHGEHIRUHWKHSURMHFWHGWRWDOVXEMHFWSRSXODWLRQKDVEHHQHQUROOHG":KHQZLOOWKHVWXG\HQGLIQRLPSRUWDQWGLIIHUHQFHVDUHGHWHFWHG"
1RWDSSOLFDEOH
 
I 6WDWHLIGHFHSWLRQZLOOEHXVHG,IVRSURYLGHDUDWLRQDOHDQGGHVFULEHGHEULHILQJSURFHGXUHV6XEPLWD
GHEULHILQJVFULSWLQWKH$WWDFKPHQW6HFWLRQ
7KHUHZLOOEHQRGHFHSWLRQ6XEMHFWVPD\UHFHLYH'DSDJOLIOR]LQ RUDSODFHERWKH\ZLOOQRWNQRZZKLFK
WUHDWPHQW'DSDJOLIOR]LQRUSODFHERWKH\UHFHLYHXQWLOVWXG\F RPSOHWLRQ
 
%DFNJURXQG
D 'HVFULEHSDVWH[SHULPHQWDODQGRUFOLQLFDOILQGLQJVOHDGLQJWRWKHIRUPXODWLRQRIWKHVWXG\LIDSSOLFDEOH
$GXOWVGLDJQRVHGZLWKLPSDLUHGJOXFRVHWROHUDQFHSUHGLDEHWHVPDQLIHVWDSSUHFLDEO\GHFUHDVHGLQVXOLQVHQVLWLYLW\DUHKLJKO\OLNHO\WRGHYHORSGLDEHWHVDQGFRQVHTX HQWO\IDFHWKHSRWHQWLDORIDOLIHORQJEXUGHQ
RILQFUHDVHGPHWDEROLFDQGFDUGLRYDVFXODUFRPSOLFDWLRQV7RSUHYHQWWKHWUDQVLWLRQIURPLPSDLUHGJOXFRVHWROHUDQFHWRGLDEHWHVSKDUPDFHXWLFDOLQWHUYHQWLRQVVXFKDVPH WIRUPLQDUHFRPPRQO\SUHVFULEHGRIWHQLQ
FRPELQDWLRQZLWKIDYRUDEOHOLIHVW\OHLQWHUYHQWLRQVLQFOXGLQJKDELWXDODHURELFH[HUFLVH+RZHYHUUHFHQWHYLGHQFHIURPERWKDQLPDODQGKXPDQVWXGLHVVXJJHVWVWKDWPHW IRUPLQPD\DWWHQXDWHWKHIDYRUDEOH
EHQHILWVRIH[HUFLVHWUDLQLQJ6SHFLILFDOO\ZLWKLQWKHPLWRFKRQGULDPHWIRUPLQLVWKRXJKWWRLPSDLUWKHIXQFWLRQRIFRPSOH[,LQWKHHOHFWURQWUDQVSRUWFKDLQWKXVLQK LELWLQJR[LGDWLYHSKRVSKRU\ODWLRQDQG
SRWHQWLDOO\OLPLWLQJJDLQVLQDHURELFFDSDFLW\IROORZLQJH[HUFLVHWUDLQLQJ2ZHQHWDO%UXQPDLUHWDO,QKXPDQVZKHQPHWIRUPLQWUHDWPHQWZDVFRPELQHGZLWKDVLQJOHERXWRIH[HUFLVHWKHH[HUFLVHPHGLDWHGLPSURYHPHQWLQLQVXOLQVHQVLWLYLW\ZDVDEROLVKHG6KDURIIHWDO)XUWKHUZHHNVRIDHURELFH[HUFLVHWUDLQLQJGHFUHDVHGEORRGSUHVVXUHDQGKLJKVHQ VLWLYLW\&UHDFWLYHSURWHLQLQDGXOWVZLWK
LPSDLUHGJOXFRVHWROHUDQFHZKHQPHWIRUPLQZDVDGGHGWRH[HUFLVHWUDLQLQJWKHVHIDYRUDEOHDGDSWDWLRQVZHUHDEURJDWHG0DOLQHWDO0RUHUHFHQWO\LQDUDWPRGHORIQRQDOFRKROLFIDWW\OLYHUGLVHDVHWKHEHQHILFLDOHIIHFWVRIH[HUFLVHRQKHSDWLFPLWRFKRQGULDOIXQFWLRQZHUHEOXQWHGZLWKWKHDGGLWLRQRIPHWIRUPLQ
Page 16 of 4716
PROTOCOL
BiomedicalProtocol # 14-5529H
 Date Printed: 01/30/2019
Protocol Title: Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
Clinical Research Protocol Title: Dapagliflozin  Augments The Favorable Adaptation ToEndurance Exercise Training
Protocol Type: Biomedical
Date Submitted: 11/01/2018
Approval Period: 11/06/2018-11/05/2019Important Note:
This Print View may not reflect all comments and contingencies for approval. Please check the
comments section of the online protocol.Questions that appear to not have been answered may not have been required for this submission.Please see the system application for more details.
----------------------------------------------------------------------------------------------------
/LQGHQHWDO&ROOHFWLYHO\WKHVHGDWDUDLVHVHULRXV FRQFHUQVDQGLPSOLFDWLRQVIRUWKHFRPELQDWLRQ
WUHDWPHQWVRIPHWIRUPLQDQGH[HUFLVHWUDLQLQJLQDGXOWVZLWKLPSDLUHGJOXFRVHWROHUDQFH,QFRQWUDVWJLYHQWKHSK\VLRORJLFDOPHFKDQLVPRI'DSDJOLIOR]LQVRGLXPJOXFRVHFR WUDQVSRUWHU6*/7LQKLELWLRQRQH
PLJKWVSHFXODWHWKDWUDWKHUWKDQLQKLELW'DSDJOLIOR]LQZLOODXJPHQWWKHIDYRUDEOHDGDSWDWLRQVWRH[HUFLVHWUDLQLQJ,QDGGLWLRQWRLPSURYHGJOXFRVHFRQWURO6*/7LQKLELWLRQKDVEHHQVKRZQWRSURPRWHZHLJKWORVV,GULV	'RQQHOO\.LORYHWDO2SLH5HFHQWHYLGHQFHVXJJHVWVWKDWWKHPDJQLWXGHRILPSURYHPHQWLQSK\VLRORJLFDOIXQFWLRQIROORZLQJLQLWLDWLRQRIUHJXODUH[HUFLVHPD\EHDWWHQXDWHGZLWKREHVLW\DQGRUPHWDEROLFV\QGURPHDQGDXJPHQWHGZLWKSULRUZHLJ KWORVV)RUH[DPSOHFRPSDUHGZLWK
OHDQPLFHPLFHZLWKGLHWLQGXFHGREHVLW\GHPRQVWUDWHGDVPDOOHUGHJUHHRIVNHOHWDOPXVFOHK\SHUWURSK\LQUHVSRQVHWRH[WHUQDOORDGLQJLHUHVLVWDQFHWUDLQLQJ6LWQLF NHWDO,QDQRWKHUVWXG\PLFHZLWK
VWUHSWR]RWRFLQLQGXFHGGLDEHWHVH[KLELWHGDVPDOOHUDQJLRJHQLFUHVSRQVHWRWUHDGPLOOUXQQLQJWKDQWKHUHVSRQVHTXDQWLILHGLQKHDOWK\PLFH.LYHODHWDO3H[LOCATION_006]DSVPRUHFRPSHOOLQJLQDGXOWKXPDQVZLWKPHWDEROLFV\QGURPHWKHUHZDVQRGHWHFWDEOHLPSURYHPHQWLQLQVXOLQVHQVLWLYLW\IROORZLQJZHHNVRIH[HUFLVHWUDLQLQJFRPSDUHGZLWKWKHDSSUHFLDEOHLQFUHDVHREVHUYHGLQKHDOWK\EXWSUHYLRXVO\VHGHQWDU\DGXOWV/D\QHHWDO)XUWKHULQWKHDGXOWVZLWKPHWDE ROLFV\QGURPHPXVFOHJOXFRVHWUDQVSRUWHU
LQFUHDVHGE\RQO\FRPSDUHGZLWKDLQFUHDVHLQWKHSUHYL RXVO\VHGHQWDU\FRQWUROV)LQDOO\GDWD
IURPDODUJHUHFHQWO\SXEOLVKHGVWXG\RIRYHUZHLJKWREHVHDGXO WVQHZO\GLDJQRVHGZLWKW\SHGLDEHWHV
VKRZHGWKDWDPRQWKH[HUFLVHSOXVGLHWDU\LQWHUYHQWLRQZDVQ RPRUHHIIHFWLYHWKDQDGLHWDU\
LQWHUYHQWLRQDORQHLQLPSURYLQJEORRGJOXFRVHFRQWUROJO\FDWHGKHPRJORELQ$FFRQFHQWUDWLRQ$QGUHZVHWDO7KHVHREVHUYDWLRQVKDYHOHGVRPHWRVSHFXODWHDVWRWKHH[LVWHQFHRIà²¯FURVVWDONà²°EHWZHHQDGLSRVHWLVVXHDQGVNHOHWDOPXVFOHWKDWOLPLWVWKHDGDSWDWLRQV RIVNHOHWDOPXVFOHWRH[HUFLVH3HGHUVHQ
%HOO7KDWLVDGLSRF\WHGHULYHGVLJQDOVVXFKDVFLUFXODWLQJLQIOD[COMPANY_003]WRU\IDFWRUVPD\LQWHUIHUHZLWKWKHPROHFXODUVLJQDOLQJLQVNHOHWDOPXVFOHWKDWQRUPDOO\UHVXOWVLQIDYRUDEOHDGDSWLRQVWRH[HUFLVH:HLJKWORVVPHGLDWHGE\'DSDJOLIOR]LQLVDVVRFLDWH GZLWKGHFUHDVHGLQIOD[COMPANY_003]WLRQDQG
SRWHQWLDOO\DXJPHQWHGH[HUFLVHWUDLQLQJUHVSRQVHV
,QDGGLWLRQWRWKHEHQHILWVGHULYHGIURPZHLJKWORVVDQGLQFRQWUDVWWRPHWIRUPLQ6*/7LQKLELWLRQLV
XQOLNHO\WRKDYHGLUHFWHIIHFWVRQPLWRFKRQGULDOIXQFWLRQDQG WKXVVKRXOGQRWLPSDLUVNHOHWDOPXVFOH
UHVSRQVHVWRH[HUFLVHWUDLQLQJ)XUWKHUWKHZHLJKWORVVDVVRF LDWHGZLWK'DSDJOLIOR]LQXVHPD\SURPRWH
IDWLJXHUHVLVWDQFHGXULQJZHLJKWEHDULQJDFWLYLWLHVVXFKDVZDONLQJDQGMRJJLQJLQSUHYLRXVO\VHGHQWDU\DGXOWV
5()(5(1&(66RPHRIZKLFKKDYHEHHQSURYLGHGDVDWWDFKPHQWV$QGUHZV5&&RRSHU$50RQWJRPHU\$$1RUFURVV$-3HWHUV7-6KDUS'--DFNVRQ1)LW]VLPRQV.
%ULJKW-&RXOPDQ.(QJODQG&<*RUWRQ-0F/HQDJKDQ$3D[WRQ (3ROHW$7KRPSVRQ&	'D\DQ
&0'LHWRUGLHWSOXVSK\VLFDODFWLYLW\YHUVXVXVXDOFDUHLQSDWLHQWVZLWKQHZO\GLDJQRVHGW\SHGLDEHWHVWKH(DUO\$&7,'UDQGRPLVHGFRQWUROOHGWULDO/DQFHW
%HOO&3LJPHQW(SLWKHOLXP'HULYHG)DFWRU$1RW6R6\P SDWKHWLF5HJXODWRURI,QVXOLQ5HVLVWDQFH"
([HUF6SRUW6FL5HY%RUJ*$3V\FKRSK\VLFDOEDVHVRISHUFHLYHGH[HUWLRQ0HG6FL6SRUWV([HUF%UXQPDLU%6WDQLHN.*UDV)6FKDUI1$OWKD\P$&ODUD55R GHQ0*QDLJHU(1RKO+:DOGKDXVO:
	)XUQVLQQ&7KLD]ROLGLQHGLRQHVOLNHPHWIRUPLQLQKLELWUHVSLUDWRU\FRPSOH[,DFRPPRQ
PHFKDQLVPFRQWULEXWLQJWRWKHLUDQWLGLDEHWLFDFWLRQV"'LDEHWHV 
'DXVVLQ)13RQVRW('XIRXU63/RQVGRUIHU:ROI('RXWUHOHDX6*HQ\%3LTXDUG)	5LFKDUG5
Page 17 of 4717
PROTOCOL
BiomedicalProtocol # 14-5529H
 Date Printed: 01/30/2019
Protocol Title: Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
Clinical Research Protocol Title: Dapagliflozin  Augments The Favorable Adaptation ToEndurance Exercise Training
Protocol Type: Biomedical
Date Submitted: 11/01/2018
Approval Period: 11/06/2018-11/05/2019Important Note:
This Print View may not reflect all comments and contingencies for approval. Please check the
comments section of the online protocol.Questions that appear to not have been answered may not have been required for this submission.Please see the system application for more details.
----------------------------------------------------------------------------------------------------
,PSURYHPHQWRI92PD[E\FDUGLDFRXWSXWDQGR[\JHQH[WU DFWLRQDGDSWDWLRQGXULQJLQWHUPLWWHQW
YHUVXVFRQWLQXRXVHQGXUDQFHWUDLQLQJ(XU-$SSO3K\VLRO 
,GULV,	'RQQHOO\56RGLXPJOXFRVHFRWUDQVSRUWHUL QKLELWRUVDQHPHUJLQJQHZFODVVRIRUDO
DQWLGLDEHWLFGUXJ'LDEHWHV2EHV0HWDE
.LORY*/HRZ6	7KRPDV06*/7LQKLELWLRQZLWKGDSDJOLIOR]LQDQRYHODSSURDFKIRUWKH
PDQDJHPHQWRIW\SHGLDEHWHV$XVW)DP3K\VLFLDQ
.LYHOD56LOYHQQRLQHQ0/HKWL0-DODYD69LKNR9	.DLQXODL QHQ+([HUFLVHLQGXFHG
H[SUHVVLRQRIDQJLRJHQLFJURZWKIDFWRUVLQVNHOHWDOPXVFOHDQGLQFDSLOODULHVRIKHDOWK\DQGGLDEHWLFPLFH
&DUGLRYDVF'LDEHWRO
/D\QH$61DVUDOODK66RXWK0$+RZHOO0(0F&XUU\035DPVH\ 0:6WRQH0+	6WXDUW&$
,PSDLUHGPXVFOH$03.DFWLYDWLRQLQWKHPHWDEROLFV\QGURPHPD\DWWHQXDWHLPSURYHGLQVXOLQDFWLRQDIWHU
H[HUFLVHWUDLQLQJ-&OLQ(QGRFULQRO0HWDE
/LQGHQ0$)OHWFKHU-$0RUULV(00HHUV*0.HDUQH\0/&ULVVH\-0/DXJKOLQ0+%RRWK):6RZHUV
-5,EGDK-$7K\IDXOW-3	5HFWRU56&RPELQLQJPHWIRU PLQDQGDHURELFH[HUFLVHWUDLQLQJLQWKH
WUHDWPHQWRIW\SHGLDEHWHVDQG1$)/'LQ2/(7)UDWV$P-3K\V LRO(QGRFULQRO0HWDE(
0DOLQ6.1LJKWLQJDOH-&KRL6(&KLSNLQ65	%UDXQ%0HWIRUPLQPRGLILHVWKHH[HUFLVHWUDLQLQJHIIHFWVRQULVNIDFWRUVIRUFDUGLRYDVFXODUGLVHDVHLQLPSDLUHG JOXFRVHWROHUDQWDGXOWV2EHVLW\6LOYHU
6SULQJ
0DWVXGD0	'H)URQ]R5$,QVXOLQVHQVLWLYLW\LQGLFHVRE WDLQHGIURPRUDOJOXFRVHWROHUDQFHWHVWLQJ
FRPSDULVRQZLWKWKHHXJO\FHPLFLQVXOLQFODPS'LDEHWHV&DUH 
0L\D]DNL+2KLVKL62RNDZDUD7.L]DNL77RVKLQDL.+D6+DJD6-L//	2KQR+
6WUHQXRXVHQGXUDQFHWUDLQLQJLQKXPDQVUHGXFHVR[LGDWLYHVWUHVVIROORZLQJH[KDXVWLQJH[HUFLVH(XU-$SSO3K\VLRO
0XOOHU.(/D9DQJH/05DPH\6/	5DPH\&73RZHUFDOFX ODWLRQVIRUJHQHUDOOLQHDU
PXOWLYDULDWHPRGHOVLQFOXGLQJUHSHDWHGPHDVXUHVDSSOLFDWLRQV- $P6WDW$VVRF
2SLH/+6RGLXP*OXFRVH&RWUDQVSRUWHU6*/7,QKLELWRUV1HZDPRQJ$QWLGLDEHWLF'UXJV
&DUGLRYDVF'UXJV7KHU
2ZHQ05'RUDQ(	+DOHVWUDS$3(YLGHQFHWKDWPHWIRUPLQH[HUWVLWVDQWLGLDEHWLFHIIHFWV
WKURXJKLQKLELWLRQRIFRPSOH[RIWKHPLWRFKRQGULDOUHVSLUDWRU \FKDLQ%LRFKHP-3W
3HGHUVHQ%.0XVFOHWRIDWLQWHUDFWLRQDWZRZD\VWUHHW"-3K\VLRO
6KDURII&*+DJRELDQ7$0DOLQ6.&KLSNLQ65<X++LUVKPDQ0)*RRG\HDU/-	%UDXQ%
&RPELQLQJVKRUWWHUPPHWIRUPLQWUHDWPHQWDQGRQHERXWRIH[HUFL VHGRHVQRWLQFUHDVHLQVXOLQDFWLRQLQ
LQVXOLQUHVLVWDQWLQGLYLGXDOV$P-3K\VLRO(QGRFULQRO0HWDE (
6LWQLFN0%RGLQH6&	5XWOHGJH-&&KURQLFKLJKIDWIH HGLQJDWWHQXDWHVORDGLQGXFHGK\SHUWURSK\
LQPLFH-3K\VLRO
Page 18 of 4718
PROTOCOL
BiomedicalProtocol # 14-5529H
 Date Printed: 01/30/2019
Protocol Title: Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
Clinical Research Protocol Title: Dapagliflozin  Augments The Favorable Adaptation ToEndurance Exercise Training
Protocol Type: Biomedical
Date Submitted: 11/01/2018
Approval Period: 11/06/2018-11/05/2019Important Note:
This Print View may not reflect all comments and contingencies for approval. Please check the
comments section of the online protocol.Questions that appear to not have been answered may not have been required for this submission.Please see the system application for more details.
----------------------------------------------------------------------------------------------------
6PLWK'$	2
'RQQHOO797KHWLPHFRXUVHGXULQJZHHNV
HQGXUDQFHWUDLQLQJRIFKDQJHVLQ9RPD[DQGDQDHURELFWKUHVKROGDVGHWHUPLQHGZLWKDQHZFRPSXWHUL ]HGPHWKRG&OLQ6FL/RQG

 
E 'HVFULEHDQ\DQLPDOH[SHULPHQWDWLRQDQGILQGLQJVOHDGLQJWRWKHIRUPXODWLRQRIWKHVWXG\LIDSSOLFDEOH
6HHSUHYLRXVVHFWLRQD
---------------------------------------------------------------------------------------------
* * * Radioisotopes or Radiation Machines * * *
 
 <RXVHOHFWHG12IRU5DGLRLVRWRSHVLQWKH*HQHUDO&KHFNOLVW,I\RXZRXOGOLNHWRDGG5DGLRLVRWRSHVFKDQJHWKH
VHOHFWLRQWR<(6LQJHQHUDO&KHFNOLVW
 
b
5DGLRLVRWRSHVRU5DGLDWLRQ0DFKLQHV3OHDVHQRWH)RUSURMHFWVU HTXLULQJUDGLDWLRQSURFHGXUHVSOHDVH
FRQWDFWWKH&685DGLDWLRQ&RQWURO2IILFH5&2)RUPRUHLQIRUP DWLRQVHH
KWWSZZZHKVFRORVWDWHHGX:5DG+RPHDVS[
 
b Db ,IDSSOLFDEOHVX[COMPANY_003]UL]HLQOD\ODQJXDJHWKHUDGLRJUDSKLFGLDJQRVWLFDQGWKHUDSHXWLFSURFHGXUHV
DVVRFLDWHGZLWKWKLVSURWRFRO
%RG\FRPSRVLWLRQZLOOEHPHDVXUHGE\GXDOHQHUJ\[UD\DEVRUSWLRPHWU\'(;$RQYLVLWDQGYLVLW
bbEb
$UHWKHUDGLDWLRQSURFHGXUHVEHLQJSHUIRUPHGDQRUPDOSDUWRIW KHFOLQLFDOPDQDJHPHQWIRUWKHPHGLFDO
FRQGLWLRQWKDWLVXQGHUVWXG\6WDQGDUGRI&DUHRUDUHWKHSURFHGXUHVEHLQJSHUIRUPHGEHFDXVHWKHUHVHDUFKVXEMHFWLVSDUWLFLSDWLQJLQWKLVSURMHFWH[WUD&7VFD QVPRUHIOXRURVFRS\WLPHDGGLWLRQDO1XFOHDU
0HGLFLQH6WXGLHVHWF1RW6WDQGDUGRI&DUH",IVRPHSURFHGXUHVDUH6WDQGDUGRI&DUHDQGVRPHDUH1RW6WDQGDUGRI&DUHFKHFNERWKER[HV
 
bb 12767$1'$5'2)&$5( ;67$1'$5'2)&$5(
bb ,ILWLVQRWVWDQGDUGRIFDUHFRPSOHWHWKHUHVWRI
WKLVVHFWLRQ3URYLGHWKH&685&2DSSURYDOLQIRUPDWLRQ,ILWLVRQO\VWDQGDUGRIFDUHVNLSWKHUHVWRIWKLVVHFWLRQ
 
b &685DGLDWLRQ&RQWURO2IILFHDSSURYHGSURWRFROQXPEHU
 
Page 19 of 4719
PROTOCOL
BiomedicalProtocol # 14-5529H
 Date Printed: 01/30/2019
Protocol Title: Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
Clinical Research Protocol Title: Dapagliflozin  Augments The Favorable Adaptation ToEndurance Exercise Training
Protocol Type: Biomedical
Date Submitted: 11/01/2018
Approval Period: 11/06/2018-11/05/2019Important Note:
This Print View may not reflect all comments and contingencies for approval. Please check the
comments section of the online protocol.Questions that appear to not have been answered may not have been required for this submission.Please see the system application for more details.
----------------------------------------------------------------------------------------------------
b &685DGLDWLRQ&RQWURO2IILFHSURWRFRODSSURYDOGDWH
b
)RUPRUHLQIRUPDWLRQVHHWKH5&2ZHEVLWHDWKWWSZZZHKVFRORVWDWHHGX:UDGKRPHDVS[RU&RQWDFW-DPHV$EUDKDP5DGLDWLRQ6DIHW\2IILFHUDW
---------------------------------------------------------------------------------------------
* * * Medical Equipment for Human Subjects and Laboratory Animals; Investigatiional Devices * * *
 
 0HGLFDO(TXLSPHQWIRU+XPDQ6XEMHFWV
 
bb ,IPHGLFDOHTXLSPHQWLVEHLQJXVHGIRUKXPDQVXEMHFWVSDWLHQWVGHVFULEHWKLVHTXLSPHQWDQGLQGLFDWHLIWKH
XVHLVQRUPDOSUDFWLFHIRUWKHSRSXODWLRQXQGHUVWXG\<RXPD\KDYHDOUHDG\GHVFULEHGWKLVHTXLSPHQWLQ
WKH6WXG\3URFHGXUHVVHFWLRQ,I\RXKDYHDOUHDG\OLVWHGWKLVLQIRUPDWLRQLQWKH6WXG\3URFHGXUHV6HFWLRQSOHDVHGRQRWGXSOLFDWHWKLVLQIRUPDWLRQKHUH,QWKHVSDFHEHORZLQSXW1$LIQRWDSSOLFDEOHLQGLFDWHLIWKLVLVDOUHDG\OLVWHGLQWKH6WXG\3URFHGXUHV6HFWLRQRUGHVFULEHWKHHTXLSPHQW
1$
 
 ,QYHVWLJDWLRQDO'HYLFHV
bbbbbbbbb3OHDVHOLVWLQWKHVSDFHEHORZDOO,QYHVWLJDWLRQDO'HYLFHVWREHXVHGRQ6XEMHFWV
Investigational Devices
---------------------------------------------------------------------------------------------
* * * Drugs, Reagents, or Chemicals * * *
 
 'UXJV5HDJHQWVRU&KHPLFDOV
bD 3OHDVHOLVWLQWKHVSDFHEHORZDOOLQYHVWLJDWLRQDOGUXJVUHDJHQWVRUFKHPLFDOVWREHDGPLQLVWHUHGWR
VXEMHFWVGXULQJWKLVVWXG\
 
bE 3OHDVHOLVWLQWKHVSDFHEHORZDOOFRPPHUFLDOGUXJVUHDJHQWVRUFKHPLFDOVWREHDGPLQLVWHUHGWRVXEMHFWV
GXULQJWKLVVWXG\
 
Page 20 of 4720
PROTOCOL
BiomedicalProtocol # 14-5529H
 Date Printed: 01/30/2019
Protocol Title: Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
Clinical Research Protocol Title: Dapagliflozin  Augments The Favorable Adaptation ToEndurance Exercise Training
Protocol Type: Biomedical
Date Submitted: 11/01/2018
Approval Period: 11/06/2018-11/05/2019Important Note:
This Print View may not reflect all comments and contingencies for approval. Please check the
comments section of the online protocol.Questions that appear to not have been answered may not have been required for this submission.Please see the system application for more details.
----------------------------------------------------------------------------------------------------
'UXJ1DPH 'DSDJOLIOR]LQFRPPHUFLDOO\NQRZQDV)DU[LJD
6RXUFHHJ3KDUPDF\6SRQVRUHWF $VWUD=HQHFD3KDUPDFHXWLFDOV/3
,IQRWSUHPL[HGZKHUHZLOOWKHPDWHULDOEHPL[HGDQGE\ZKRP 3UHPL[HGE\%ULVWRO0\HUV6TXLEE&RPSDQ\
0DQXIDFWXUHU %ULVWRO0\HUV6TXLEE&RPSDQ\
,1'LIDYDLODEOH 7REHVXEPLWWHG
'RVDJH PJGD\RI'DSDJOLIOR]LQIRUWKHILUVWGD\VDQGWKHQDGRVHLQFUHDVHWRPJGD\RI'DSDJOLIOR]LQIRUUHPDLQLQJZHHNV
$GPLQLVWUDWLRQ5RXWH 2UDO
< $UHWKHVHQHZRUGLIIHUHQWXVHVRIWKHVH
FRPPHUFLDOO\DYDLODEOHGUXJVUHDJHQWVRUFKHPLFDOV"
< ,1'5HJXODWLRQV
 
3OHDVHUHDGWKH,1'6WDWHPHQWV
---------------------------------------------------------------------------------------------
* * * Subject Population (a-g) * * *
 
 b
6XEMHFW3RSXODWLRQ,QWKHVSDFHEHORZSOHDVHGHWDLOWKHSDUWLFLSDQWVWKDW\RXDUHUHTXHVWLQJWRUHFUXLWLQFOXGHUHTXHVWHGSDUWLFLSDQWQXPEHUDQGGHVFULSWLRQRIHDFKJ URXSUHTXHVWHG,QSXW1$LIQRW
DSSOLFDEOH
D 5HTXHVWHG3DUWLFLSDQW'HVFULSWLRQ,QFOXGHQXPEHURISDUWLFLSDQWVWKDW\RXSODQWRVWXG\DQGGHVFULSWLRQRI
HDFKJURXSUHTXHVWHGLIDSSOLFDEOH
:HSODQRQHQUROOLQJSDUWLFLSDQWVZLWKHVWLPDWLRQWKDWZLOOVFUHHQRXWRUQRWFRPSOHWHWKHVWXG\:HSODQWRFRPSOHWHWKHVWXG\LQRYHUZHLJKWREHVHDGXOWYROXQWH HUVPHQDQGZRPHQ
 
E :KDWLVWKHUDWLRQDOHIRUVWXG\LQJWKHUHTXHVWHGJURXSVRISDUWLFLSDQWV"
$GXOWVZKRDUHRYHUZHLJKWREHVHDUHDWWKHJUHDWHVWULVNRIGHYHORSLQJW\SHGLDEHWHVWKXVRYHUZHLJKWREHVHDGXOWVSRWHQWLDOO\KDYHWKHPRVWWRJDLQVKRXOGWKHRXWFRPHRIWKHVWXG\SURYH
Page 21 of 4721
PROTOCOL
BiomedicalProtocol # 14-5529H
 Date Printed: 01/30/2019
Protocol Title: Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
Clinical Research Protocol Title: Dapagliflozin  Augments The Favorable Adaptation ToEndurance Exercise Training
Protocol Type: Biomedical
Date Submitted: 11/01/2018
Approval Period: 11/06/2018-11/05/2019Important Note:
This Print View may not reflect all comments and contingencies for approval. Please check the
comments section of the online protocol.Questions that appear to not have been answered may not have been required for this submission.Please see the system application for more details.
----------------------------------------------------------------------------------------------------
IDYRUDEOH,QFOXVLRQRIDGXOWVDOUHDG\GLDJQRVHGZLWKGLDEHWHV PLJKWFRPSOLFDWHWKHLQWHUSUHWDWLRQRIWKH
GDWDWKDWLVDVDFRQVHTXHQFHRIWKHSDWKRSK\VLRORJ\DVVRFLDWHGZLWKGLDEHWHVWKHUHVSRQVHWRH[HUFLVHWUDLQLQJZLWKRUZLWKRXW'DSDJOLIOR]LQPD\GLIIHULQDGXOWVZLWKGLDEHWHVFRPSDUHGZLWKDGXOWVZKRDUHGLDEHWHVIUHH
 
F ,IDSSOLFDEOHVWDWHWKHUDWLRQDOHIRULQYROYHPHQWRISRWHQWLDOO\YXOQHUDEOHVXEMHFWVWREHHQWHUHGLQWRWKH
VWXG\LQFOXGLQJPLQRUVSUHJQDQWZRPHQHFRQRPLFDOO\DQGHGXFDWLRQDOO\GLVDGYDQWDJHGRUGHFLVLRQDOO\
LPSDLUHGVXEMHFWV6SHFLI\WKHPHDVXUHVEHLQJWDNHQWRPLQLPL]HWKHULVNVDQGWKHFKDQFHRIKDUPWRWKHSRWHQWLDOO\YXOQHUDEOHVXEMHFWV
3RWHQWLDOO\YXOQHUDEOHVXEMHFWVZLOOQRWEHVWXGLHG
 
G ,IZRPHQPLQRULWLHVRUPLQRUVDUHQRWLQFOXGHGDFOHDUFRPSHOOLQJUDWLRQDOHPXVWEHSURYLGHG([DPSOHV
IRUQRWLQFOXGLQJPLQRUVGLVHDVHGRHVQRWRFFXULQFKLOGUHQGUXJRUGHYLFHZRXOGLQWHUIHUHZLWKQRUPDO
JURZWKDQGGHYHORSPHQWHWF
:RPHQDQGPLQRULWLHVZLOOEHLQYLWHGWRSDUWLFLSDWH0LQRUVZLOOEHH[FOXGHG7KHSUHYDOHQFHRIW\SHGLDEHWHVLVJUHDWHULQDGXOWVWKDQPLQRUV6DIHW\DQGHIIHFWLY HQHVVRI'DSDJOLIOR]LQLQSHGLDWULFSDWLHQWV
XQGHU\HDUVRIDJHKDYHQRWEHHQHVWDEOLVKHG
 
H 6WDWHLIDQ\RIWKHVXEMHFWVDUHVWXGHQWVHPSOR\HHVRUODERUDWRU\SHUVRQQHO7KH\VKRXOGEHSUHVHQWHG
ZLWKWKHVDPHZULWWHQLQIRUPHGFRQVHQW,IFRPSHQVDWLRQLVDOORZHGWKH\VKRXOGDOVRUHFHLYHLW
,IDQ\RIWKHVXEMHFWVDUHVWXGHQWVHPSOR\HHVRUODERUDWRU\SHUVRQQHOWKH\ZLOOEHSUHVHQWHGZLWKWKHVDPHZULWWHQLQIRUPHGFRQVHQWFRPSHQVDWLRQLVDOORZHGWKH\ZL OODOVRUHFHLYHLW
 
Ib 'HVFULEHKRZSRWHQWLDOVXEMHFWVZLOOEHLGHQWLILHGIRUUHFUXLWPHQWHJFKDUWUHYLHZUHIHUUDOIURPLQGLYLGXDO
V
WUHDWLQJSK\VLFLDQWKRVHLQGLYLGXDOVDQVZHULQJDQDG+RZZLOOSRWHQWLDOSDUWLFLSDQWVOHDUQDERXWWKH
UHVHDUFKDQGKRZZLOOWKH\EHUHFUXLWHGHJIO\HUHPDLOZHESRVWLQJWHOHSKRQHHWF"$WWDFKUHFUXLWPHQWPDWHULDOVLQWKH$WWDFKPHQW6HFWLRQ,PSRUWDQWWRUHPHPEHUSRWHQWLDOVXEMHFWVPD\QRWEHFRQWDFWHGEHIRUH,5%DSSURYDO
3OHDVHVHHH[DPSOHVRIUHFUXLWPHQWPDWHULDOVLQWKHDWWDFKPHQW VHFWLRQ
3RWHQWLDOVXEMHFWVZLOOEHUHFUXLWHGYLDHOHFWURQLFDGYHUWLVHPH QWHJ7KH6RXUFHDQGHPDLOOLVWVHJ&68
JHQIDF,IQHFHVVDU\SRWHQWLDOVXEMHFWVPD\DOVREHUHFUXLWHGYLDQHZVSDSHUDGYHUWLVHPHQWHJ7KH&RORUDGRDQFOLQLFDOWULDOVZHEVLWHVHJFOLQLFDOWULDOVJRYDQGRUIO\HUVSRVWHUVSODFHGLQSXEOLFSODFHVHJFRIIHHVKRSVLQDQGDURXQGWKH)RUW&ROOLQVDUHD
 
Jb ,IDSSOLFDEOHSURYLGHUDWLRQDOHIRUWKHLQFOXVLRQRIKHDOWK\YROXQWHHUVLQWKLVVWXG\6SHFLI\DQ\ULVNVWR
ZKLFKWKHVHKHDOWK\YROXQWHHUVPD\SRVVLEO\EHH[SRVHG6SHFLI\WKHPHDVXUHVEHLQJWDNHQWRPLQLPL]H
WKHULVNVDQGWKHFKDQFHRIKDUPWRWKHVHYROXQWHHUV
$GXOWVZKRDUHRYHUZHLJKWREHVHEXWRWKHUZLVHKHDOWK\ZLOOEHLQYLWHGWRSDUWLFLSDWH,QFOXVLRQRIDGXOWVDOUHDG\GLDJQRVHGZLWKGLDEHWHVPLJKWFRPSOLFDWHWKHLQWHUSUHWD WLRQRIWKHGDWDWKDWLVDVDFRQVHTXHQFH
RIWKHSDWKRSK\VLRORJ\DVVRFLDWHGZLWKGLDEHWHVWKHUHVSRQVH WRH[HUFLVHWUDLQLQJZLWKRUZLWKRXW
Page 22 of 4722
PROTOCOL
BiomedicalProtocol # 14-5529H
 Date Printed: 01/30/2019
Protocol Title: Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
Clinical Research Protocol Title: Dapagliflozin  Augments The Favorable Adaptation ToEndurance Exercise Training
Protocol Type: Biomedical
Date Submitted: 11/01/2018
Approval Period: 11/06/2018-11/05/2019Important Note:
This Print View may not reflect all comments and contingencies for approval. Please check the
comments section of the online protocol.Questions that appear to not have been answered may not have been required for this submission.Please see the system application for more details.
----------------------------------------------------------------------------------------------------
'DSDJOLIOR]LQPD\GLIIHULQDGXOWVZLWKGLDEHWHVFRPSDUHGZLWKDGXOWVZKRDUHGLDEHWHVIUHH
,WLVQRWSRVVLEOHWRLGHQWLI\DOOSRWHQWLDOULVNVLQUHVHDUFKSURFHGXUHVEXWWKHUHVHDUFKHUVKDYHWDNHQ
UHDVRQDEOHVDIHJXDUGVWRPLQLPL]HDQ\NQRZQDQGSRWHQWLDOEXWXQNQRZQULVNV7KH+XPDQ3HUIRUPDQFH&OLQLFDO5HVHDUFK/DERUDWRU\KDVHPHUJHQF\VXSSOLHV LQFOXGLQJDPHGLFLQHWUROOH\HTXLSSHG
ZLWKKHDUWPDFKLQHVDQGVXSSOHPHQWDOR[\JHQ7KHUHVHDUFKWHDP KDVDJUHDWGHDORIH[SHULHQFHZLWKDOO
RIWKHSURFHGXUHV6RPHRIWKHSURFHGXUHVIRUZKLFK\RXDUHEHLQJDVNHGWRYROXQWHHUKDYHDQXPEHURIDVVRFLDWHGULVNV
%RG\&RPSRVLWLRQ
7KHULVNVDVVRFLDWHGZLWKWKH'(;$DUHYHU\ORZ7KHPD[LPXPU DGLDWLRQGRVH\RXZLOOUHFHLYHLQWKLV
VWXG\LVOHVVWKDQWKRIWKHIHGHUDODQGVWDWHRFFXSDWLRQ DOZKROHERG\GRVHOLPLWDOORZHGWRUDGLDWLRQ
ZRUNHUVPUHP3XWDQRWKHUZD\WKHPD[LPXPGRVHIURPDQ\VFDQZHXWLOL]HZLWKWKLV'(;$UDQJHVIURPPUHP:KROHERG\VFDQWRPUHPIRUVHYHUDORIWKHUHJLRQDOVFDQVVXFKDVOXPEDUIHPXUDQGIRUHDUPVFDQV7KHDYHUDJHDQQXDOEDFNJURXQGUDGLD WLRQ\RXDOUHDG\UHFHLYHLVDWOHDVW
PUHP\HDU7KHPRUHUDGLDWLRQ\RXUHFHLYHRYHUWKHFRXUVHRI\RXUOLIHWKHPRUHWKHULVNLQFUHDVHVRIGHYHORSLQJDIDWDOFDQFHURULQGXFLQJFKDQJHVLQJHQHV7KHUD GLDWLRQLQWKLVVFDQLVQRWH[SHFWHGWR
VLJQLILFDQWO\LQFUHDVHWKHVHULVNVEXWWKHH[DFWLQFUHDVHLQVXFKULVNVLVQRWNQRZQ7KHUHDUHQRGLVFRPI[INVESTIGATOR_81622]DVVRFLDWHGZLWKWKLVSURFHGXUH:RPHQZKRDUHRUFR XOGEHSUHJQDQWVKRXOGUHFHLYHQR
XQQHFHVVDU\UDGLDWLRQDQGVKRXOGQRWSDUWLFLSDWHLQWKLVVWXG\
:RPHQZLOOFRPSOHWHDSUHJQDQF\WHVWEHIRUHSDUWLFLSDWLQJLQD'(;$VFDQ([HUFLVH7HVWVDQG([HUFLVH7UDLQLQJ
7KHUHLVDYHU\VPDOOFKDQFHRIDQLUUHJXODUKHDUWEHDWGXULQJH [HUFLVHRIDOOVXEMHFWV2WKHUUDUH
ULVNVRIDVWUHVVWHVWDUHKHDUWDWWDFNLQDQGGHDWKLQ:HDULQJDPRXWKSLHFHDQGQRVHFOLSFDQVRPHWLPHVFDXVHGU\QHVVLQWKHPRXWKDQGPLOGGLV FRPI[INVESTIGATOR_13318]'LIILFXOWH[HUFLVHPD\PDNH\RX
IHHOYHU\WLUHGOLJKWKHDGHGDQGQDXVHRXV([KDXVWLQJH[HUFLVHZLOOE\GHILQLWLRQPDNH\RXIHHOYHU\WLUHG$IWHUDQ\H[HUFLVH\RXUPXVFOHVPLJKWDFKH
$&60JXLGHOLQHVSHUWLQHQWWRWKHUHTXLUHPHQWRISK\VLFLDQVXSHU YLVHGH[HUFLVHVWUHVVWHVWLQJZLOOEH
IROORZHG%ORRG&ROOHFWLRQ
:KHQWKHQHHGOHJRHVLQWRDYHLQLWPD\KXUWIRUDVKRUWSHULRGRIWLPHDIHZVHFRQGV$OVRWKHUHPD\EHPLQRUGLVFRPI[INVESTIGATOR_13318]RIKDYLQJWKHQHHGOHSODVWLFWXEHWDSHGWR\RXUDUP,QDERXWLQFDVHVDVPDOODPRXQWRIEOHHGLQJZLOORFFXUXQGHUWKHVNLQWKDWZLOOFDXVHDEUXLVH7KHULVNRIIRUPLQJDEORRGFORWLQWKHYHLQLVDERXWLQDQGWKHULVNRIVLJQLILFDQWEORRGORVVLVLQ$GGLWLRQDOO\WKHUHLVDULVNWKDW\RXPD\IDLQWZKLOHKDYLQJEORRGFROOHFWHGRUKDYLQJWKHFDWKHWHULQVHUWHGLQ\RXUYHLQ
2QO\WUDLQHGUHVHDUFKSHUVRQQHOZLOOEHSHUPLWWHGWRSHUIRUPSK OHERWRP\
0XVFOH%LRSV\
'XULQJWKHSURFHGXUH\RXPD\IHHOGLVFRPI[INVESTIGATOR_13318]DVVRFLDWHGZLWKWKHLQMHFWLRQRIWKHQXPELQJGUXJWKHDQHVWKHWLFEXWGXULQJWKHDFWXDOPXVFOHUHPRYDOWKHGLVFRPI[INVESTIGATOR_13318] VKRXOGEHPLQLPDO7KHUHLVDULVNWKDW\RX
PD\IDLQWGXULQJWKHSURFHGXUH7KHUHLVDOVRDULVNRIPXVFOHFUDPSEOHHGLQJRIORVVRIIHHOLQJLQ\RXUOHJDQGRIGDPDJHWRDVNLQFXWDQHRXVQHUYH7KHULVNRILQ IHFWLRQDQGEUXLVLQJLVH[WUHPHO\VPDOOLI\RX
IROORZWKHLQVWUXFWLRQVIRUFDULQJIRUWKHLQFLVLRQ$YHU\VPDOODQGPLQRUVFDUZLOOUHPDLQDVDUHVXOWRIWKHLQFLVLRQEXWPD\QRWEHQRWLFHDEOH7KHVHSURFHGXUHVZLOOEHS HUIRUPHGXQGHUVXUJLFDOO\FOHDQFRQGLWLRQV
Page 23 of 4723
PROTOCOL
BiomedicalProtocol # 14-5529H
 Date Printed: 01/30/2019
Protocol Title: Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
Clinical Research Protocol Title: Dapagliflozin  Augments The Favorable Adaptation ToEndurance Exercise Training
Protocol Type: Biomedical
Date Submitted: 11/01/2018
Approval Period: 11/06/2018-11/05/2019Important Note:
This Print View may not reflect all comments and contingencies for approval. Please check the
comments section of the online protocol.Questions that appear to not have been answered may not have been required for this submission.Please see the system application for more details.
----------------------------------------------------------------------------------------------------
(PHUJHQF\PHGLFDOHTXLSPHQWZLOOEHDYDLODEOH<RXZLOOEHVFU HHQHGSULRUWRWKHSURFHGXUHIRUKLVWRU\RI
DOOHUJLFUHDFWLRQVWR1RYRFDLQ/LGRFDLQH
2QO\WUDLQHGUHVHDUFKSHUVRQQHOZLOOEHSHUPLWWHGWRSHUIRUPPX VFOHELRSVLHV
---------------------------------------------------------------------------------------------
* * * Subject Population (h-m) * * *
 
 6XEMHFW3RSXODWLRQ,QSXW1$LIQRWDSSOLFDEOH
K ,QFOXVLRQDQG([FOXVLRQ&ULWHULDHJ3DUWLFLSDQWVPXVWKDYHYLVLRQ3DUWLFLSDQWVPXVWEH
\HDUVRIDJHHWF
 
b bb bbb ,GHQWLI\LQFOXVLRQFULWHULD
)RULQFOXVLRQLQWKHVWXG\VXEMHFWVVKRXOGIXOILOOWKHIROORZLQ JFULWHULD
3URYLVLRQRILQIRUPHGFRQVHQWSULRUWRDQ\VWXG\VSHFLILFSUR FHGXUHV
$JHG\HDUV
1RNQRZQ7\SH'LDEHWHV%RG\PDVVLQGH[NJPALQFOXVLYH6HGHQWDU\PD[LPXPRIZHHNUHJXODUO\VFKHGXOHGDFWLYLW\VHV VLRQVRIPLQXWHVGXULQJ
WKHSUHYLRXV\HDUV&RPSOHWLRQRIDVFUHHQLQJYLVLWFRQVLVWLQJRIPHGLFDOKLVWRU\SK\VLFDOH[DPLQDWLRQDQGOHDGHOHFWURFDUGLRJUDPDQGEORRGSUHVVXUHDVVHVVPHQWDWUHVWDQGGXULQJLQFUHPHQWDOH[HUFLVHWRYROLWLRQDOH[KDXVWLRQ1RWH6XEMHFWVZLWKDEQRUPDOVFUHHQLQ JYDOXHVPD\EHHOLJLEOHLIWKH
UHVXOWVDUHQRWFOLQLFDOO\VLJQLILFDQWDVMXGJHGE\WKHLQYHVWLJDWRURUPHGLFDOPRQLWRU$JUHHWRDELGHE\WKHVWXG\VFKHGXOHDQGGLHWDU\UHVWULFWLRQVDQGWRUHWXUQIRUWKHUHTXLUHGDVVHVVPHQWV%HZLOOLQJDQGDEOHWRUHSHDWHGO\SHUIRUPH[HUFLVH:RPHQRIFKLOGEHDULQJSRWHQWLDOPXVWKDYHQHJDWLYHSUHJQDQF\ WHVWDQGEHXVLQJDFFHSWDEOH
FRQWUDFHSWLRQ
 
b bb bbb ,GHQWLI\H[FOXVLRQFULWHULD
6XEMHFWVVKRXOGQRWHQWHUWKHVWXG\LIDQ\RIWKHIROORZLQJH[F OXVLRQFULWHULDDUHIXOILOOHG
(YLGHQFHRIFOLQLFDOO\VLJQLILFDQWFDUGLRYDVFXODUUHVSLUDWRU\UHQDOKHSDWLFSXOPRQDU\JDVWURLQWHVWLQDOKDHPDWRORJLFDOQHXURORJLFDOSV\FKLDWULFRU RWKHUGLVHDVHWKDWPD\LQWHUIHUH
ZLWKWKHREMHFWLYHVRIWKHVWXG\RUWKHVDIHW\RIWKHVXEMHFWDVMXGJHGE\WKHLQYHVWLJDWRULQDJUHHPHQWZLWKWKHVSRQVRURUPHGLFDOPRQLWRUKDYHEHHQKRVSLW DOL]HGLQWKHSDVW\HDUVDVD
UHVXOWRIWKHVHFRQGLWLRQVRUDUHUHFHLYLQJSKDUPDFRORJLFDOWU HDWPHQWIRUWKHVHFRQGLWLRQV
8VHRISUHVFULSWLRQGUXJVVHHH[FHSWLRQVOLVWHGEHORZRUKHUEDOSUHSDUDWLRQVLQWKHZHHNVEHIRUHVWXG\FRPPHQFHPHQW33HUPLWWHG3UHVFULSWLRQ'UXJVà²µ%LUWK&RQWUROà²µ/HVVWKDQGD\VVKRUWFRXUVHDQWLELRWLFV1RWH5LIDPSLQLVQRWSHUPLWWHG
Page 24 of 4724
PROTOCOL
BiomedicalProtocol # 14-5529H
 Date Printed: 01/30/2019
Protocol Title: Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
Clinical Research Protocol Title: Dapagliflozin  Augments The Favorable Adaptation ToEndurance Exercise Training
Protocol Type: Biomedical
Date Submitted: 11/01/2018
Approval Period: 11/06/2018-11/05/2019Important Note:
This Print View may not reflect all comments and contingencies for approval. Please check the
comments section of the online protocol.Questions that appear to not have been answered may not have been required for this submission.Please see the system application for more details.
----------------------------------------------------------------------------------------------------
à²µ/HVVWKDQGD\VVKRUWFRXUVHDQWLELRWLFV1RWH5LIDPSLQLVQRWSHUPLWWHGà²µ2WKHUPHGLFLQHVIRU*(5'GHSUHVVLRQVHDVRQDODOOHUJLHVDQG 27&DQDOJHVLFVPD\EH
DOORZHGEXWZLOOEHDSSURYHGRQDFDVHE\FDVHEDVLV,VFXUUHQWO\HQUROOHGLQDQRWKHUFOLQLFDOVWXG\IRUDQRWKHUL QYHVWLJDWLRQDOGUXJRUKDVWDNHQDQ\
RWKHULQYHVWLJDWLRQDOGUXJZLWKLQGD\VEHIRUHWKHVFUHHQLQJYLVLW+DELWXDODQGRUUHFHQWXVHZLWKLQ\HDUVRIWREDFFR%HLQJFRQVLGHUHGXQVXLWDEOHIRUSDUWLFLSDWLRQLQWKLVWULDOIRUDQ\UHDVRQDVMXGJHGE\WKHLQYHVWLJDWRURUPHGLFDOPRQLWRU+LVWRU\RIVHULRXVK\SHUVHQVLWLYLW\UHDFWLRQWR'DSDJOLIOR]LQ 
6HYHUHUHQDOLPSDLUPHQWHQGVWDJHUHQDOGLVHDVHRUGLDO\VLV 
3UHJQDQWRUEUHDVWIHHGLQJSDWLHQWV6HYHUHKHSDWLFLQVXIILFLHQF\DQGRUVLJQLILFDQWDEQRUPDOOLYH UIXQFWLRQGHILQHGDVDVSDUWDWH
DPLQRWUDQVIHUDVH$67![XSSHUOLPLWRIQRUPDODQGRUDODQLQHDPLQRWUDQVIHUDVH$/7![XSSHUOLPLWRIQRUPDO7RWDOELOLUXELQ!PJG/XPRO/3RVLWLYHVHURORJLFHYLGHQFHRIFXUUHQWLQIHFWLRXVOLYHUGLVHDVHLQFOXGLQJ+HSDWLWLV%YLUDODQWLERG\,*0+HSDWLWLV%VXUIDFHDQWLJHQDQG+HSDWLWLV&YLUXV DQWLERG\
(VWLPDWHG*ORPHUXODU)LOWUDWLRQ5DWHP/PLQPAFD OFXODWHGE\&RFNFURIW*DXOW
IRUPXOD+LVWRU\RIEODGGHUFDQFHU5HFHQWFDUGLRYDVFXODUHYHQWVLQDSDWLHQWLQFOXGLQJDQ\RIWKHIROORZLQJDFXWHFRURQDU\V\QGURPHZLWKLQPRQWKVSULRUWRHQUROPHQWKRVSLWDOL]DWLRQIR UXQVWDEOHDQJLQDRUDFXWH
P\RFDUGLDOLQIDUFWLRQZLWKLQPRQWKVSULRUWRHQUROPHQWDFXWHVWURNHRUWUDQVLVFKHPLFDWWDFNZLWKLQWZRPRQWKVSULRUWRHQUROPHQWOHVVWKDQWZRPRQWKVSRVW FRURQDU\DUWHU\
UHYDVFXODUL]DWLRQFRQJHVWLYHKHDUWIDLOXUHGHILQHGDV1HZ<RUN +HDUW$VVRFLDWLRQFODVV,9
XQVWDEOHRUDFXWHFRQJHVWLYHKHDUWIDLOXUH1RWHHOLJLEOHSDWLHQWVZLWKFRQJHVWLYHKHDUWIDLOXUHHVSHFLDOO\WKRVHZKRDUHRQGLXUHWLFWKHUDS\VKRXOGKDYHFDUHIXOPRQLWRULQJRIWKHLUYROXPHVWDWXVWKURXJKRXWWKHVWXG\%ORRGSUHVVXUHDWHQUROPHQW6\VWROLFEORRGSUHVVXUHà¸¸PP +JDQGRUGLDVWROLFEORRG
SUHVVXUHà¸¸PP+J%ORRGSUHVVXUHDWUDQGRPL]DWLRQ6\VWROLFEORRGSUHVVXUHà¸¸PP+JDQGRUGLDVWROLFEORRGSUHVVXUHà¸¸PP+J3DWLHQWVZKRLQWKHMXGJPHQWRIWKHPHGLFDOPRQLWRUPD\EHDWULVNIRUGHK\GUDWLRQ
 
L 'HVFULEH\RXUVFUHHQLQJSURFHGXUHV$WWDFK\RXUVFUHHQLQJGRFXPHQWVHJKHDOWKKLVWRU\
TXHVWLRQQDLUHLQWKH$WWDFKPHQW6HFWLRQ
3OHDVHVHHDWWDFKHGVFUHHQLQJGRFXPHQW6XEMHFWVZLOOEHSURYLGHGZLWKWKHRSWLRQRIUHFHLYLQJDQHOHFWURQLFYHUVLRQRIWKHVFUHHQLQJGRFXPHQWLQDGYDQFHRIYLVL W
 
M 'HVFULEHKRZ\RXZLOOEHFRJQL]DQWRIRWKHUSURWRFROVLQZKLFKVXEMHFWVPLJKWEHSDUWLFLSDWLQJ3OHDVH
H[SODLQLIVXEMHFWVZLOOEHSDUWLFLSDWLQJLQPRUHWKDQRQHVWXG\
6XEMHFWVZLOODVNHGLIWKH\DUHSDUWLFLSDWLQJLQDQRWKHUVWXG\RULIWKH\LQWHQGWRHQUROOLQDQRWKHUVWXG\6XEMHFWVZLOOEHSHUPLWWHGWRSDUWLFLSDWHLQRWKHUVWXGLHVZKHQSDUWLFLSDWLRQGRHVQRWLQWHUIHUHZLWKWKHFXUUHQWVWXG\WKDWLVQRSRVVLEOHLQWHUDFWLRQZLWK'DSDJOLIO R]LQRUH[HUFLVHQRLQFUHDVHULVNWRVXEMHFW
VDIHW\HWF
Page 25 of 4725
PROTOCOL
BiomedicalProtocol # 14-5529H
 Date Printed: 01/30/2019
Protocol Title: Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
Clinical Research Protocol Title: Dapagliflozin  Augments The Favorable Adaptation ToEndurance Exercise Training
Protocol Type: Biomedical
Date Submitted: 11/01/2018
Approval Period: 11/06/2018-11/05/2019Important Note:
This Print View may not reflect all comments and contingencies for approval. Please check the
comments section of the online protocol.Questions that appear to not have been answered may not have been required for this submission.Please see the system application for more details.
----------------------------------------------------------------------------------------------------
 
N &RPSHQVDWLRQ([SODLQWKHDPRXQWDQGVFKHGXOHRIFRPSHQVDWLRQLIDQ\WKDWZLOOEHSDLGIRUSDUWLFLSDWLRQ
LQWKHVWXG\&RPSHQVDWLRQLQFOXGHVIRRGJLIWFDUGVPRQH\WRNHQVHWF,QFOXGHSURYLVLRQVIRUSURUDWLQJ
SD\PHQWLIDSSOLFDEOH&RPSHQVDWLRQVKRXOGEHSURUDWHGLIVHYHUDODFWLYLWLHVDUHLQYROYHGIRUGLIIHUHQWWLPHSHULRGVHJIRUVHVVLRQDQGIRUVHVVLRQ
6XEMHFWVDUHSURYLGHGZLWKWKHIROORZLQJLQIRUPDWLRQ,I\RXFRPSOHWHDOORIWKHYLVLWVDQGDOORIWKHSURFHGXUHVDVGHVFULEHG\RXPD\UHFHLYHLQWRWDO7KLVSD\PHQWZLOOEHSDLGLQLQVWDOOPHQWVDQGSURUDWHGDVIROORZV\RXZLOOQRWUHFHLYHFRPSHQVDWLRQIRUYLVL WWKHVFUHHQLQJYLVLW<RXZLOOUHFHLYH
RQFRPSOHWLRQRIYLVLWVDQG<RXZLOOQRWUHFHLYHFRPSHQVDWLRQIRUYLVLWVQRUZLOO\RXEHFKDUJHGIRUWKLVVXSHUYLVHGH[HUFLVHWUDLQLQJ<RXZLOOUHFHLY HIRUFRPSOHWLRQRIYLVLW<RXZLOO
UHFHLYHIRUFRPSOHWLRQRIYLVLW<RXZLOOUHFHLYHIRUFRPSOHWLRQRIYLVLW,I\RXDWWHQGRI\RXUVFKHGXOHGYLVLWVDQGDUULYHQRODWHUWKDQPLQXWHVDIWHUWKHVFKHGXOHGDSSRLQWPHQWWLPHIRUDOODSSRLQWPHQWV\RXZLOOUHFHLYHDERQXVRI
 
O &RVWV3OHDVHH[SODLQDQ\FRVWVWKDWZLOOEHFKDUJHGWRWKHVXEMHFW
6XEMHFWVDUHSURYLGHGZLWKWKHIROORZLQJLQIRUPDWLRQ2WKHUWKDQWUDQVSRUWWRDQGIURPWKHODE\RXUSDUWLFLSDWLRQVKRXOGLQFXUQRFRVWV<RXZLOOQRWEHFKDUJHGI RU\RXUVXSHUYLVHGH[HUFLVHWUDLQLQJ7KH
FRPPHUFLDOFRVWIRUZHHNVRIVXSHUYLVHGH[HUFLVHWUDLQLQJLVDSSUR[LPDWHO\
 
P (VWLPDWHWKHSUREDEOHGXUDWLRQRIWKHHQWLUHVWXG\7KLVHVWLPDWHVKRXOGLQFOXGHWKHWRWDOWLPHHDFKVXEMHFW
LVWREHLQYROYHGDQGWKHGXUDWLRQWKHGDWDDERXWWKHVXEMHFWLVWREHFROOHFWHGHJ7KLVLVD\HDUVWXG\
3DUWLFLSDQWVZLOOEHLQWHUYLHZHGWLPHVSHU\HDUHDFKLQWHUYLHZZLOOODVWDSSUR[LPDWHO\KRXUV7RWDODSSUR[LPDWHWLPHFRPPLWPHQWIRUSDUWLFLSDQWVLVKRXUV7KHVHWLPHVVKRXOGEHFRQVLVWHQWZLWKWKHWLPHFRPPLWPHQWOLVWHGRQWKHFRQVHQWGRFXPHQW
7KHVWXG\ZLOOWDNHSODFHRYHUDSSUR[LPDWHO\\HDUV6XEMHFWV ZLOOEHLQYROYHGIRUDSSUR[LPDWHO\PRQWKV
DQGZLOOEHDVNHGWRYLVLWWKH+XPDQ3HUIRUPDQFH&OLQLFDO5HVHD UFK/DERUDWRU\RQGLIIHUHQWGD\V
9LVLWVZLOOODVWEHWZHHQPLQXWHVDQGKRXUV
---------------------------------------------------------------------------------------------
* * * Risks * * *
 
 5LVNV,QSXW1$LIQRWDSSOLFDEOH
bbbbb
86'HSDUWPHQWRI+HDOWK	+XPDQ6HUYLFHV++65HJXODWLRQVGHILQHDVXEMHFWDWULVNDVIROORZVDQ\LQGLYLGXDOZKRPD\EHH[SRVHGWRWKHSRVVLELOLW\RILQMXU\LQF OXGLQJSK\VLFDOSV\FKRORJLFDORUVRFLDOLQMXU\
DVDFRQVHTXHQFHRISDUWLFLSDWLRQDVDVXEMHFWLQDQ\UHVHDUFK GHYHORSPHQWRUUHODWHGDFWLYLW\ZKLFK
GHSDUWVIURPWKHDSSOLFDWLRQRIWKRVHDFFHSWHGPHWKRGVQHFHVVDU\WRPHHWKLVQHHGVRUZKLFKLQFUHDVHVWKHRUGLQDU\ULVNVRIGDLO\OLIHLQFOXGLQJWKHUHFRJQL]HGULVNVLQKHUHQWLQDFKRVHQRFFXSDWLRQRUILHOGRIVHUYLFH
 
Page 26 of 4726
PROTOCOL
BiomedicalProtocol # 14-5529H
 Date Printed: 01/30/2019
Protocol Title: Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
Clinical Research Protocol Title: Dapagliflozin  Augments The Favorable Adaptation ToEndurance Exercise Training
Protocol Type: Biomedical
Date Submitted: 11/01/2018
Approval Period: 11/06/2018-11/05/2019Important Note:
This Print View may not reflect all comments and contingencies for approval. Please check the
comments section of the online protocol.Questions that appear to not have been answered may not have been required for this submission.Please see the system application for more details.
----------------------------------------------------------------------------------------------------
bDb 3,
VHYDOXDWLRQRIWKHRYHUDOOOHYHORI5LVN3OHDVHFKHFNRQHPLQLPDORU!PLQLPDO
0LQLPDOHYHU\GD\OLYLQJ
<!0LQLPDOJUHDWHUWKDQHYHU\GD\OLYLQJ
 
bEbbb
)RUWKHIROORZLQJFDWHJRULHVLQFOXGHDVFLHQWLILFHVWLPDWHRIWKHIUHTXHQF\VHYHULW\DQGUHYHUVLELOLW\RISRWHQWLDOULVNV:KHUHYHUSRVVLEOHLQFOXGHVWDWLVWLFDOLQFLGHQ FHRIFRPSOLFDWLRQVDQGWKHPRUWDOLW\UDWHRI
SURSRVHGSURFHGXUHV:KHUHWKHUHKDVEHHQLQVXIILFLHQWWLPHWRDFFXPXODWHVLJQLILFDQWGDWD21ULVNDVWDWHPHQWWRWKLVHIIHFWVKRXOGEHLQFOXGHG,QGHVFULELQJWKHVHULVNVLQWKHFRQVHQWIRUPWRWKHVXEMHFWLWLVKHOSIXOWRXVHFRPSDULVRQVZKLFKDUHPHDQLQJIXOWRSHUVRQVXQIDPLOLDUZLWKPHGLFDOWHUPLQRORJ\$GGUHVVDQ\ULVNVUHODWHGWR
 
 bbb bbb bbb 8VHRILQYHVWLJDWLRQDOGHYLFHV3OHDVHLQFOXGHWKHFOLQLFDODGYHUVHHYHQWV$(VDVVRFLDWHGZLWK
HDFKRIWKHGHYLFHVZLWKDQLQGLFDWLRQRIIUHTXHQF\VHYHULW\DQGUHYHUVLELOLW\7KLVLQIRUPDWLRQ
FDQRIWHQEHIRXQGLQWKH,QYHVWLJDWRUVEURFKXUH
1$
 
 bbb bbb bbb 8VHRILQYHVWLJDWLRQDOGUXJV3OHDVHLQFOXGHWKHFOLQLFDO$(VDVVRFLDWHGZLWKHDFKRIWKHGUXJV
ZLWKDQLQGLFDWLRQRIIUHTXHQF\VHYHULW\DQGUHYHUVLELOLW\7KLVLQIRUPDWLRQFDQRIWHQEHIRXQGLQ
WKH,QYHVWLJDWRUVEURFKXUH
1$
 
 bbb bbb bbb 8VHRIFRPPHUFLDOO\DYDLODEOHGUXJVUHDJHQWVRUFKHPLFDOV3OHDVHLQFOXGHWKHFOLQLFDO$(V
DVVRFLDWHGZLWKHDFKRIWKHGUXJVZLWKDQLQGLFDWLRQRIIUHTXHQF\VHYHULW\DQGUHYHUVLELOLW\7KLV
LQIRUPDWLRQFDQRIWHQEHIRXQGLQWKHSDFNDJHLQVHUWSURYLGHGE\WKHPDQXIDFWXUHU
3OHDVHVHHWKHSDFNDJHLQVHUWSURYLGHGE\WKHPDQXIDFWXUHUIRUIXUWKHULQIRUPDWLRQ
$GYHUVHUHDFWLRQVLQSODFHERFRQWUROOHGVWXGLHVUHSRUWHGLQPRUHWKDQEXWOHVVWKDQ
RISDWLHQWVWUHDWHGZLWK'DSDJOLIOR]LQLQFOXGH
à²µ)HPDOHJHQLWDOP\FRWLFLQIHFWLRQVVXFKDVOLVWHGLQRUGHURI IUHTXHQF\UHSRUWHGYXOYRYDJLQDO
P\FRWLFLQIHFWLRQYDJLQDOLQIHFWLRQYXOYRYDJLQDOFDQGLGLDVLVYXOYRYDJLQLWLVJHQLWDOLQIHFWLRQ
JHQLWDOFDQGLGLDVLVIXQJDOJHQLWDOLQIHFWLRQYXOYLWLVJHQLWR XULQDU\WUDFWLQIHFWLRQYXOYDODEVFHVV
DQGYDJLQLWLVEDFWHULDO
à²µ1DVRSKDU\QJLWLVFROGOLNHV\PSWRPV
Page 27 of 4727
PROTOCOL
BiomedicalProtocol # 14-5529H
 Date Printed: 01/30/2019
Protocol Title: Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
Clinical Research Protocol Title: Dapagliflozin  Augments The Favorable Adaptation ToEndurance Exercise Training
Protocol Type: Biomedical
Date Submitted: 11/01/2018
Approval Period: 11/06/2018-11/05/2019Important Note:
This Print View may not reflect all comments and contingencies for approval. Please check the
comments section of the online protocol.Questions that appear to not have been answered may not have been required for this submission.Please see the system application for more details.
----------------------------------------------------------------------------------------------------
à²µ8ULQDU\WUDFWLQIHFWLRQVVXFKDVOLVWHGLQRUGHURIIUHTXHQF\UHSRUWHGXULQDU\WUDFWLQIHFWLRQF\VWLWLV(VFKHULFKLDXULQDU\WUDFWLQIHFWLRQJHQLWRXULQDU\WUDFWLQIHFWLRQS\HORQHSKULWLVWULJRQLWLVXUHWKULWLVNLGQH\LQIHFWLRQDQGSURVWDWLWLV
à²µ%DFNSDLQà²µ,QFUHDVHGXULQDWLRQà²µ0DOHJHQLWDOP\FRWLFLQIHFWLRQVVXFKDVOLVWHGLQRUGHURII UHTXHQF\UHSRUWHGEDODQLWLVIXQJDO
JHQLWDOLQIHFWLRQEDODQLWLVFDQGLGDJHQLWDOFDQGLGLDVLVJHQL WDOLQIHFWLRQPDOHSHQLOHLQIHFWLRQ
EDODQRSRVWKLWLVEDODQRSRVWKLWLVLQIHFWLYHJHQLWDOLQIHFWLRQ DQGSRVWKLWLV
à²µ,QIOXHQ]Dà²µ1DXVHDà²µ'\VOLSLGHPLDà²µ&RQVWLSDWLRQà²µ'LVFRPI[INVESTIGATOR_13318]ZLWKXULQDWLRQà²µ3DLQLQH[WUHPLW\,QDGGLWLRQXVHRI'DSDJOLIOR]LQLVDOVRDVVRFLDWHGZLWKDULVNRIZHLJKWORVVXSWROEVRYHU
ZHHNV
 
 bbb bbb bbb :KHQSHUIRUPLQJSURFHGXUHVSOHDVHLQFOXGHDOOLQYHVWLJDWLRQDOQRQLQYHVWLJDWLRQDODQGQRQ
LQYDVLYHSURFHGXUHVHJVXUJHU\EORRGGUDZVWUHDGPLOOWHVWV
6XEMHFWVDUHSURYLGHGZLWKWKHIROORZLQJLQIRUPDWLRQSHUWDLQLQJ WRULVNV
%RG\&RPSRVLWLRQ7KHULVNVDVVRFLDWHGZLWKWKH'(;$DUHYHU\ORZ7KHPD[LPXPU DGLDWLRQGRVH\RXZLOOUHFHLYH
LQWKLVVWXG\LVOHVVWKDQWKRIWKHIHGHUDODQGVWDWHRF FXSDWLRQDOZKROHERG\GRVHOLPLW
DOORZHGWRUDGLDWLRQZRUNHUVPUHP3XWDQRWKHUZD\WKHPD[LPXPGRVHIURPDQ\VFDQZHXWLOL]HZLWKWKLV'(;$UDQJHVIURPPUHP:KROHERG\VFDQWRPUHPIRUVHYHUDORIWKHUHJLRQDOVFDQVVXFKDVOXPEDUIHPXUDQGIRUHDUPVFDQV 7KHDYHUDJHDQQXDO
EDFNJURXQGUDGLDWLRQ\RXDOUHDG\UHFHLYHLVDWOHDVWPUHP\ HDU7KHPRUHUDGLDWLRQ\RX
UHFHLYHRYHUWKHFRXUVHRI\RXUOLIHWKHPRUHWKHULVNLQFUHDVHVRIGHYHORSLQJDIDWDOFDQFHURULQGXFLQJFKDQJHVLQJHQHV7KHUDGLDWLRQLQWKLVVFDQLVQRWH [SHFWHGWRVLJQLILFDQWO\LQFUHDVH
WKHVHULVNVEXWWKHH[DFWLQFUHDVHLQVXFKULVNVLVQRWNQRZQ7KHUHDUHQRGLVFRPI[INVESTIGATOR_438842]ZLWKWKLVSURFHGXUH:RPHQZKRDUHRUFRXOGEHSUHJQDQWVKRXOGUHFHLYHQRXQQHFHVVDU\UDGLDWLRQDQGVKRXOGQRWSDUWLFLSDWHLQWKLVVWXG\
([HUFLVH7HVWVDQG([HUFLVH7UDLQLQJ
7KHUHLVDYHU\VPDOOFKDQFHRIDQLUUHJXODUKHDUWEHDWGXULQJH [HUFLVHRIDOOVXEMHFWV
Page 28 of 4728
PROTOCOL
BiomedicalProtocol # 14-5529H
 Date Printed: 01/30/2019
Protocol Title: Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
Clinical Research Protocol Title: Dapagliflozin  Augments The Favorable Adaptation ToEndurance Exercise Training
Protocol Type: Biomedical
Date Submitted: 11/01/2018
Approval Period: 11/06/2018-11/05/2019Important Note:
This Print View may not reflect all comments and contingencies for approval. Please check the
comments section of the online protocol.Questions that appear to not have been answered may not have been required for this submission.Please see the system application for more details.
----------------------------------------------------------------------------------------------------
2WKHUUDUHULVNVRIDVWUHVVWHVWDUHKHDUWDWWDFNLQDQGGHDWKLQ:HDULQJDPRXWKSLHFHDQGQRVHFOLSFDQVRPHWLPHVFDXVHGU\QHVVLQWKHPRXWKDQGPLOGGLVFRPI[INVESTIGATOR_13318]'LIILFXOWH[HUFLVHPD\PDNH\RXIHHOYHU\WLUHGOL JKWKHDGHGDQGQDXVHRXV
([KDXVWLQJH[HUFLVHZLOOE\GHILQLWLRQPDNH\RXIHHOYHU\WLUHG$IWHUDQ\H[HUFLVH\RXUPXVFOHVPLJKWDFKH
%ORRG&ROOHFWLRQ
:KHQWKHQHHGOHJRHVLQWRDYHLQLWPD\KXUWIRUDVKRUWSHULRGRIWLPHDIHZVHFRQGV$OVRWKHUHPD\EHPLQRUGLVFRPI[INVESTIGATOR_13318]RIKDYLQJWKHQHHGOHSODVWLFWXEH WDSHGWR\RXUDUP,QDERXW
LQFDVHVDVPDOODPRXQWRIEOHHGLQJZLOORFFXUXQGHUWKHVNLQWKDWZLOOFDXVHDEUXLVH7KHULVNRIIRUPLQJDEORRGFORWLQWKHYHLQLVDERXWLQDQGWKHULVNRIVLJQLILFDQWEORRGORVVLVLQ$GGLWLRQDOO\WKHUHLVDULVNWKDW\RXPD\IDLQWZKL OHKDYLQJEORRGFROOHFWHGRUKDYLQJ
WKHFDWKHWHULQVHUWHGLQ\RXUYHLQ
0XVFOH%LRSV\
'XULQJWKHSURFHGXUH\RXPD\IHHOGLVFRPI[INVESTIGATOR_13318]DVVRFLDWHGZLWKWKHLQMHFWLRQRIWKHQXPELQJGUXJWKHDQHVWKHWLFEXWGXULQJWKHDFWXDOPXVFOHUHPRYDOWKHGLVFRPI[INVESTIGATOR_13318]VKRXOGEHPLQLPDO7KHUHLVDULVNWKDW\RXPD\IDLQWGXULQJWKHSURFHGXUH7KHUHLVDOVRDULVNRIPXVFOHFUDPSEOHHGLQJRIORVVRIIHHOLQJLQ\RXUOHJDQGRIGDPDJHWRDVNLQFXWDQHRXVQHUYH7KHULVNRILQIHFWLRQDQGEUXLVLQJLVH[WUHPHO\VPDOOLI\RXIROORZWKHLQVWUXFWLRQV IRUFDULQJIRUWKHLQFLVLRQ$YHU\
VPDOODQGPLQRUVFDUZLOOUHPDLQDVDUHVXOWRIWKHLQFLVLRQEXWPD\QRWEHQRWLFHDEOH7KHVHSURFHGXUHVZLOOEHSHUIRUPHGXQGHUVXUJLFDOO\FOHDQFRQGLWLRQV (PHUJHQF\PHGLFDOHTXLSPHQW
ZLOOEHDYDLODEOH<RXZLOOEHVFUHHQHGSULRUWRWKHSURFHGXUH IRUKLVWRU\RIDOOHUJLFUHDFWLRQVWR
1RYRFDLQ/LGRFDLQH
 
 bbb bbb bb 5DGLRLVRWRSHVUDGLDWLRQSURGXFLQJPDFKLQHVHJ;UD\V&7VFDQVIOXRURVFRS\
%RG\&RPSRVLWLRQ7KHULVNVDVVRFLDWHGZLWKWKH'(;$DUHYHU\ORZ7KHPD[LPXPU DGLDWLRQGRVH\RXZLOOUHFHLYH
LQWKLVVWXG\LVOHVVWKDQWKRIWKHIHGHUDODQGVWDWHRF FXSDWLRQDOZKROHERG\GRVHOLPLW
DOORZHGWRUDGLDWLRQZRUNHUVPUHP3XWDQRWKHUZD\WKHPD[LPXPGRVHIURPDQ\VFDQZHXWLOL]HZLWKWKLV'(;$UDQJHVIURPPUHP:KROHERG\VFDQWRPUHPIRUVHYHUDORIWKHUHJLRQDOVFDQVVXFKDVOXPEDUIHPXUDQGIRUHDUPVFDQV 7KHDYHUDJHDQQXDO
EDFNJURXQGUDGLDWLRQ\RXDOUHDG\UHFHLYHLVDWOHDVWPUHP\ HDU7KHPRUHUDGLDWLRQ\RX
UHFHLYHRYHUWKHFRXUVHRI\RXUOLIHWKHPRUHWKHULVNLQFUHDVHVRIGHYHORSLQJDIDWDOFDQFHURULQGXFLQJFKDQJHVLQJHQHV7KHUDGLDWLRQLQWKLVVFDQLVQRWH [SHFWHGWRVLJQLILFDQWO\LQFUHDVH
WKHVHULVNVEXWWKHH[DFWLQFUHDVHLQVXFKULVNVLVQRWNQRZQ7KHUHDUHQRGLVFRPI[INVESTIGATOR_438842]ZLWKWKLVSURFHGXUH:RPHQZKRDUHRUFRXOGEHSUHJQDQWVKRXOGUHFHLYHQRXQQHFHVVDU\UDGLDWLRQDQGVKRXOGQRWSDUWLFLSDWHLQWKLVVWXG\
 
 Fbbbbbb
)RUWKHIROORZLQJFDWHJRULHVLQFOXGHDQHVWLPDWHRIWKHSRWHQW LDOULVNLIDSSOLFDEOH
 
Page 29 of 4729
PROTOCOL
BiomedicalProtocol # 14-5529H
 Date Printed: 01/30/2019
Protocol Title: Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
Clinical Research Protocol Title: Dapagliflozin  Augments The Favorable Adaptation ToEndurance Exercise Training
Protocol Type: Biomedical
Date Submitted: 11/01/2018
Approval Period: 11/06/2018-11/05/2019Important Note:
This Print View may not reflect all comments and contingencies for approval. Please check the
comments section of the online protocol.Questions that appear to not have been answered may not have been required for this submission.Please see the system application for more details.
----------------------------------------------------------------------------------------------------
 
bbb bbb bbb 3K\VLFDOZHOOEHLQJ
6XEMHFWVDUHSURYLGHGZLWKWKHIROORZLQJLQIRUPDWLRQSHUWDLQLQJWRULVNVWRSK\VLFDOZHOOEHLQJ
%RG\&RPSRVLWLRQ
7KHULVNVDVVRFLDWHGZLWKWKH'(;$DUHYHU\ORZ7KHPD[LPXPU DGLDWLRQGRVH\RXZLOOUHFHLYH
LQWKLVVWXG\LVOHVVWKDQWKRIWKHIHGHUDODQGVWDWHRF FXSDWLRQDOZKROHERG\GRVHOLPLW
DOORZHGWRUDGLDWLRQZRUNHUVPUHP3XWDQRWKHUZD\WKHPD[LPXPGRVHIURPDQ\VFDQZHXWLOL]HZLWKWKLV'(;$UDQJHVIURPPUHP:KROHERG\VFDQWRPUHPIRUVHYHUDORIWKHUHJLRQDOVFDQVVXFKDVOXPEDUIHPXUDQGIRUHDUPVFDQV 7KHDYHUDJHDQQXDO
EDFNJURXQGUDGLDWLRQ\RXDOUHDG\UHFHLYHLVDWOHDVWPUHP\ HDU7KHPRUHUDGLDWLRQ\RX
UHFHLYHRYHUWKHFRXUVHRI\RXUOLIHWKHPRUHWKHULVNLQFUHDVHVRIGHYHORSLQJDIDWDOFDQFHURULQGXFLQJFKDQJHVLQJHQHV7KHUDGLDWLRQLQWKLVVFDQLVQRWH [SHFWHGWRVLJQLILFDQWO\LQFUHDVH
WKHVHULVNVEXWWKHH[DFWLQFUHDVHLQVXFKULVNVLVQRWNQRZQ7KHUHDUHQRGLVFRPI[INVESTIGATOR_438842]ZLWKWKLVSURFHGXUH:RPHQZKRDUHRUFRXOGEHSUHJQDQWVKRXOGUHFHLYHQRXQQHFHVVDU\UDGLDWLRQDQGVKRXOGQRWSDUWLFLSDWHLQWKLVVWXG\
([HUFLVH7HVWVDQG([HUFLVH7UDLQLQJ
7KHUHLVDYHU\VPDOOFKDQFHRIDQLUUHJXODUKHDUWEHDWGXULQJH [HUFLVHRIDOOVXEMHFWV
2WKHUUDUHULVNVRIDVWUHVVWHVWDUHKHDUWDWWDFNLQDQGGHDWKLQ:HDULQJDPRXWKSLHFHDQGQRVHFOLSFDQVRPHWLPHVFDXVHGU\QHVVLQWKHPRXWKDQGPLOGGLVFRPI[INVESTIGATOR_13318]'LIILFXOWH[HUFLVHPD\PDNH\RXIHHOYHU\WLUHGOL JKWKHDGHGDQGQDXVHRXV
([KDXVWLQJH[HUFLVHZLOOE\GHILQLWLRQPDNH\RXIHHOYHU\WLUHG$IWHUDQ\H[HUFLVH\RXUPXVFOHVPLJKWDFKH
%ORRG&ROOHFWLRQ
:KHQWKHQHHGOHJRHVLQWRDYHLQLWPD\KXUWIRUDVKRUWSHULRGRIWLPHDIHZVHFRQGV$OVRWKHUHPD\EHPLQRUGLVFRPI[INVESTIGATOR_13318]RIKDYLQJWKHQHHGOHSODVWLFWXEH WDSHGWR\RXUDUP,QDERXW
LQFDVHVDVPDOODPRXQWRIEOHHGLQJZLOORFFXUXQGHUWKHVNLQWKDWZLOOFDXVHDEUXLVH7KHULVNRIIRUPLQJDEORRGFORWLQWKHYHLQLVDERXWLQDQGWKHULVNRIVLJQLILFDQWEORRGORVVLVLQ$GGLWLRQDOO\WKHUHLVDULVNWKDW\RXPD\IDLQWZKL OHKDYLQJEORRGFROOHFWHGRUKDYLQJ
WKHFDWKHWHULQVHUWHGLQ\RXUYHLQ
0XVFOH%LRSV\
'XULQJWKHSURFHGXUH\RXPD\IHHOGLVFRPI[INVESTIGATOR_13318]DVVRFLDWHGZLWKWKHLQMHFWLRQRIWKHQXPELQJGUXJWKHDQHVWKHWLFEXWGXULQJWKHDFWXDOPXVFOHUHPRYDOWKHGLVFRPI[INVESTIGATOR_13318]VKRXOGEHPLQLPDO7KHUHLVDULVNWKDW\RXPD\IDLQWGXULQJWKHSURFHGXUH7KHUHLVDOVRDULVNRIPXVFOHFUDPSEOHHGLQJRIORVVRIIHHOLQJLQ\RXUOHJDQGRIGDPDJHWRDVNLQFXWDQHRXVQHUYH7KHULVNRILQIHFWLRQDQGEUXLVLQJLVH[WUHPHO\VPDOOLI\RXIROORZWKHLQVWUXFWLRQV IRUFDULQJIRUWKHLQFLVLRQ$YHU\
VPDOODQGPLQRUVFDUZLOOUHPDLQDVDUHVXOWRIWKHLQFLVLRQEXWPD\QRWEHQRWLFHDEOH7KHVHSURFHGXUHVZLOOEHSHUIRUPHGXQGHUVXUJLFDOO\FOHDQFRQGLWLRQV (PHUJHQF\PHGLFDOHTXLSPHQW
ZLOOEHDYDLODEOH<RXZLOOEHVFUHHQHGSULRUWRWKHSURFHGXUH IRUKLVWRU\RIDOOHUJLFUHDFWLRQVWR
1RYRFDLQ/LGRFDLQH
 
 bbb bbb bbb 3V\FKRORJLFDOZHOOEHLQJ
Page 30 of 4730
PROTOCOL
BiomedicalProtocol # 14-5529H
 Date Printed: 01/30/2019
Protocol Title: Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
Clinical Research Protocol Title: Dapagliflozin  Augments The Favorable Adaptation ToEndurance Exercise Training
Protocol Type: Biomedical
Date Submitted: 11/01/2018
Approval Period: 11/06/2018-11/05/2019Important Note:
This Print View may not reflect all comments and contingencies for approval. Please check the
comments section of the online protocol.Questions that appear to not have been answered may not have been required for this submission.Please see the system application for more details.
----------------------------------------------------------------------------------------------------
1$
 
 bbb bbb bbb (FRQRPLFZHOOEHLQJ
1$
 
 bbb bbb bbb 6RFLDOZHOOEHLQJ
1$
 
bGb ,QFDVHRIRYHUVHDVUHVHDUFKRUZRUNLQJZLWKDVSHFLILFUDFHHWKQLFLW\LQWKH8QLWHG6WDWHVSURYLGH
EDFNJURXQGRQZKDWH[SHULHQFHWKH,QYHVWLJDWRUVKDYHZLWKWKHSURSRVHGSRSXODWLRQ'HVFULEH
TXDOLILFDWLRQVSUHSDUDWLRQVWKDWHQDEOHWKH,QYHVWLJDWRUVWRHYDOXDWHFXOWXUDODSSURSULDWHQHVVDQGHVWLPDWHPLQLPL]HULVNVWRVXEMHFWV
1$
 
bHb 6SHFLDO3UHFDXWLRQV'HVFULEHWKHSODQQHGSURFHGXUHVIRUSURWHFWLQJDJDLQVWRUPLQLPL]LQJSRWHQWLDOULVNV,I
DSSURSULDWHLQFOXGHWKHVWDQGDUGVIRUWHUPLQDWLRQRIWKHSDUWLFLSDWLRQRIWKHLQGLYLGXDOVXEMHFW'LVFXVV
SODQVIRUHQVXULQJQHFHVVDU\PHGLFDORUSURIHVVLRQDOLQWHUYHQWLRQLQWKHHYHQWRIDGYHUVHHIIHFWVWRWKHVXEMHFWV
1$
 
bIb
'DWD6DIHW\0RQLWRULQJbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbb bbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbb
bbbb 1 ,VWKHUHD'DWD6DIHW\0RQLWRULQJ%RDUG'60%"
 
 bbb bbb bbb ,I\HVGHVFULEHLWVUROHDQGLQGLFDWHZKRVHWXSWKH'DWD6DIHW\0RQLWRULQJ%RDUGHJVSRQVRU
RU3URWRFRO'LUHFWRU
  bbb bbb bbb 'HVFULEHWKHGDWDDQGVDIHW\PRQLWRULQJSODQGHYHORSHGWRHQVXUHWKHVDIHW\RISDUWLFLSDQWVDQG
WKHYDOLGLW\DQGLQWHJULW\RIUHVHDUFKGDWD0RQLWRULQJVKRXOGEHFRPPHQVXUDWHZLWKULVNVDQG
ZLWKWKHVL]HDQGFRPSOH[LW\RIWKHWULDOV
Page 31 of 4731
PROTOCOL
BiomedicalProtocol # 14-5529H
 Date Printed: 01/30/2019
Protocol Title: Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
Clinical Research Protocol Title: Dapagliflozin  Augments The Favorable Adaptation ToEndurance Exercise Training
Protocol Type: Biomedical
Date Submitted: 11/01/2018
Approval Period: 11/06/2018-11/05/2019Important Note:
This Print View may not reflect all comments and contingencies for approval. Please check the
comments section of the online protocol.Questions that appear to not have been answered may not have been required for this submission.Please see the system application for more details.
----------------------------------------------------------------------------------------------------
---------------------------------------------------------------------------------------------
* * * Benefits, Procedures to Maintain Confidentiality * * *
 
 %HQHILWV,QSXW1$LIQRWDSSOLFDEOH
D 'HVFULEHWKHSRWHQWLDOEHQHILWVWREHJDLQHGE\WKHVXEMHFWV,IWKHUHLVQRGLUHFWEHQHILWWRWKHVXEMHFWV
GHVFULEHKRZWKHUHVXOWVRIWKHVWXG\PD\EHQHILWVRFLHW\RUDSDUWLFXODUJURXS
7KHEHQHILWVRISDUWLFLSDWLRQLQWKLVVWXG\PD\LQFOXGHEHQHILWVIURPQXWULWLRQDQGH[HUFLVHWUDLQLQJWKHSDWLHQWSRSXODWLRQLQJHQHUDOPD\EHQHILWIURPWKHNQRZOHGJHSURYLGHGE\WKHUHVXOWVRIWKLVVWXG\
 
3URFHGXUHVWR0DLQWDLQ&RQILGHQWLDOLW\
D 'HVFULEHWKHSURFHGXUHVWKDWSURWHFWWKHSULYDF\RIWKHVXEMHFWVDQGPDLQWDLQWKHFRQILGHQWLDOLW\RIWKHGDWD
,IDOLQNHGOLVWLVXVHGH[SODLQZKHQWKHOLQNHGOLVWZLOOEHGHVWUR\HG3URYLGHDVDPSOHRIWKHFRGHWKDWZLOO
EHXVHGLIDSSOLFDEOH
3DUWLFLSDQWVZLOOEHLGHQWLILHGRQO\RQDVLJQHGFRQVHQWIRUPDQGLQLWLDOVFUHHQLQJIRUPWKDWZLOOEHNHSWORFNHGDQGVHSDUDWHIURPRWKHUUHVHDUFKGDWD(DFKVXEMHFWZLOO EHDVVLJQHGDUDQGRPO\JHQHUDWHGFRGH
HJDIGWKDWZLOOEHXVHGWRLGHQWLI\WKHPLQDVVRFLDWLRQZLWKDOORWKHUUHVHDUFKGDWDDQGEORRGRUWLVVXHVDPSOHV5HFRUGVLGHQWLI\LQJLQGLYLGXDOVZLOOEHNHSWLQ 'U%HOOà²¬VRIILFHODERUDWRU\LQDORFNHGFDELQHW
DQGZLOOEHGHVWUR\HGVKUHGGHGIROORZLQJFRPSOHWLRQSXEOLFDWL RQRIWKHSURMHFW'DWDZLOORQO\EHUHOHDVHG
WRUHJXODWRU\JRYHUQPHQWDOHQWLWLHVDXWKRUL]HGWRLQVSHFWUHVHD UFKUHFRUGVVXFKDVWKH)'$
 
E ,ILQIRUPDWLRQGHULYHGIURPWKHVWXG\ZLOOEHSURYLGHGWRWKHVXEMHFW
VSHUVRQDOSK\VLFLDQDJRYHUQPHQW
DJHQF\RUDQ\RWKHUSHUVRQRUJURXSRWKHUWKDQWKHUHVHDUFKWHDPGHVFULEHWRZKRPWKHLQIRUPDWLRQZLOO
EHJLYHQDQGWKHQDWXUHRIWKHLQIRUPDWLRQLIDSSOLFDEOH
8QOHVVRUGHUHGE\DQDJHQWRIWKHODZQRLQIRUPDWLRQZLOOEHVKDUHGVSHFLILFWRDVXEMHFWZLWKRXWWKDWVXEMHFW
VZULWWHQSHUPLVVLRQ$QRQ\PRXVGDWDZLOORQO\EHUHOHDVHGWRUHJXODWRU\JRYHUQPHQWDOHQWLWLHVDXWKRUL]HGWRLQVSHFWUHVHDUFKUHFRUGVVXFKDVWKH)'$
 
F 6SHFLI\ZKHUHDQGXQGHUZKDWFRQGLWLRQVVWXG\GDWDZLOOEHNHSWKRZVDPSOHVZLOOEHODEHOHGZKRKDV
DFFHVVWRWKHGDWDDQGZKDWZLOOEHDYDLODEOHDQGWRZKRP)HGHUDOUHJXODWLRQVUHTXLUHWKDWVWXG\GDWD
DQGFRQVHQWGRFXPHQWVEHNHSWIRUDPLQLPXPRIWKUHH\HDUVDIWHUWKHFRPSOHWLRQRIWKHVWXG\E\WKH3,)RUORQJLWXGLQDOSURMHFWVDQGIHGHUDOO\UHJXODWHGVWXGLHVWKH3,PD\EHUHTXLUHGWRNHHSWKHGDWDDQGGRFXPHQWVIRUDORQJHUWLPHSHULRG
5HVHDUFKUHFRUGVDQGGDWDZLOOEHVWRUHGRQILOHLQORFNHGFDEL QHWVLQ'U%HOOà²¬VRIILFHODERUDWRU\RUGLJLWDOO\
RQDSDVVZRUGSURWHFWHGFHQWUDOVHUYHU2QO\PHPEHUVRIWKHUHVHDUFKWHDPZLOOKDYHDFFHVVWRWKHVHUHFRUGV7KHPDWHULDOVZLOOEHDUFKLYHGIRUDPLQLPXPRIWKUHH\HDUVDIWHUFRPSOHWLRQRIWKHSURMHFW
---------------------------------------------------------------------------------------------
* * * Potential Conflict of Interest * * *
Page 32 of 4732
PROTOCOL
BiomedicalProtocol # 14-5529H
 Date Printed: 01/30/2019
Protocol Title: Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
Clinical Research Protocol Title: Dapagliflozin  Augments The Favorable Adaptation ToEndurance Exercise Training
Protocol Type: Biomedical
Date Submitted: 11/01/2018
Approval Period: 11/06/2018-11/05/2019Important Note:
This Print View may not reflect all comments and contingencies for approval. Please check the
comments section of the online protocol.Questions that appear to not have been answered may not have been required for this submission.Please see the system application for more details.
----------------------------------------------------------------------------------------------------
 
 3RWHQWLDO&RQIOLFWRI,QWHUHVW
$OWKRXJK\RXKDYHDOUHDG\VXEPLWWHG&68
VRIILFLDO&RQIOLFWRI ,QWHUHVWIRUP)&2,&2,&2&WRWKH
8QLYHUVLW\LWLVWKH,5%
VUHVSRQVLELOLW\WRHQVXUHWKDWFRQIOLFWLQJLQWHUHVWVUHODWHGWRVXEPLWWHGSURWRFROVGRQRWDGYHUVHO\DIIHFWWKHSURWHFWLRQRISDUWLFLSDQWVRUWKHFUHG LELOLW\RIWKHKXPDQUHVHDUFKSURWHFWLRQSURJUDP
DW&683OHDVHDQVZHUTXHVWLRQVDGEHORZ3OHDVHQRWHWKDWLI\RXLQGLFDWHWKDW\RXKDYHDSRWHQWLDOILQDQFLDORUSURIHVVLRQDOFRQIOLFWRILQWHUHVWLQUHODWLRQWRWKLVSURWRFRO\RXU&68)&2,&2,&2&5HSRUWLQJ)RUPPXVWUHIOHFWWKLVSRWHQWLDOFRQIOLFW/LQNWR&68
V&RQIOLFWRI,QWHUHVWSROLF\KWWSZZZIDFXOW\FRXQFLOFRORVWDWHHGXILOHVPDQXDOVHFWLRQGKWP'
D 1 ,QFRQQHFWLRQZLWKWKLVSURWRFROGR\RXRUDQ\RIWKHSURWRFROLQYHVWLJDWRUVRUWKHLULPPHGLDWHIDPLO\PHPEHUVLHVSRXVHDQGOHJDOGHSHQGHQWVDVGHWHUPLQHGE\WKH,56KDYHDSRWHQWLDOILQDQFLDORUSURIHVVLRQDOFRQIOLFWRILQWHUHVW"
E
1$ ,I\RXGRKDYHDSRWHQWLDOFRQIOLFWRILQWHUHVWLVWKLVUHSRUWHGLQ\RXUFXUUHQW)&2,&2,&2&"
F
1$ ,I\RXGRKDYHDSRWHQWLDOFRQIOLFWRILQWHUHVWLVWKHUHDPDQDJHPHQWSODQLQSODFHWRPDQDJHWKLVSRWHQWLDOFRQIOLFW"
G
1$ ,I\RXGRKDYHDSRWHQWLDOFRQIOLFWRILQWHUHVWLVWKLVSRWHQWLDOFRQIOLFWRILQWHUHVWLQFOXGHGLQ\RXUFRQVHQWGRFXPHQWDVUHTXLUHGLQWKH0DQDJHPHQW3ODQ"
 
If you have reported a possible conflict of interest, the IRB will forward the title of this protocol to your Research
Associate Dean to complete your COI file. 
 
)RUPRUHLQIRUPDWLRQRQ&68
VSROLF\RQ&RQIOLFWRI,QWHUHVWSOHDVHVHHWKH&RORUDGR6WDWH8QLYHUVLW\$FDGHPLF)DFXOW\DQG$GPLQLVWUDWLYH3URIHVVLRQDO0DQXDO6HFWLRQ V'	'
KWWSZZZIDFXOW\FRXQFLOFRORVWDWHHGXILOHVPDQXDOVHFWLRQGKWP'
 
/LQNWR&68
V&RQIOLFWRI,QWHUHVW3ROLF\KWWSZZZSURYRVWF RORVWDWHHGXLQGH[DVS"XUO IDFXOW\BDIIDLUV
---------------------------------------------------------------------------------------------
* * * Informed Consent * * *
 
 ,QIRUPHG&RQVHQW
127(,QRUGHUWRFRPSOHWHWKLVSURWRFRO\RXPXVWXSORDGHLWKHUD&RQVHQW)RUPRUDQ$OWHUDWLRQRI&RQVHQW)RUPLH&RYHU/HWWHURU9HUEDO6FULSW25LIQHLWKHURIWKRVHDSSO\WR\RXUSURMHFW\RXPXVWFRPSOHWHWKH:DLYHURI&RQVHQWLQIRUPDWLRQ
Page 33 of 4733
PROTOCOL
BiomedicalProtocol # 14-5529H
 Date Printed: 01/30/2019
Protocol Title: Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
Clinical Research Protocol Title: Dapagliflozin  Augments The Favorable Adaptation ToEndurance Exercise Training
Protocol Type: Biomedical
Date Submitted: 11/01/2018
Approval Period: 11/06/2018-11/05/2019Important Note:
This Print View may not reflect all comments and contingencies for approval. Please check the
comments section of the online protocol.Questions that appear to not have been answered may not have been required for this submission.Please see the system application for more details.
----------------------------------------------------------------------------------------------------
,QWKHVSDFHEHORZSOHDVHSURYLGHFRQVHQWSURFHVVEDFNJURXQGL QIRUPDWLRQIRUHDFK&RQVHQW)RUPV
$OWHUDWLRQRI&RQVHQW)RUPVRU:DLYHUV
Informed Consent
bb7LWOH +%HOO&RQVHQW-XO\
bb&RQVHQW,QIRUPDWLRQ7\SH &RQVHQW
bb6SRQVRU
V&RQVHQW9HUVLRQ1XPEHULIDQ\
&RQVHQW)RUP7HPSODWH ; $WWDFKPHQW b +%HOO&RQVHQW
-XO\,5%
DKUHI 
KWWSULFURFRORVWDWHHGX,5%&RQVHQW$VVHQW7HPSODWHVKWPO
WDUJHW BEODQN&RQVHQW)RUP
6DPSOHV
:KRLVREWDLQLQJFRQVHQW"7KHSHUVRQREWDLQLQJFRQVHQWPXVWEH NQRZOHGJHDEOHDERXWWKHVWXG\DQG
DXWKRUL]HGE\WKH3,WRFRQVHQWKXPDQVXEMHFWV+RZLVFRQVHQWEHLQJREWDLQHG":KDWVWHSVDUH\RXWDNLQJWRGHWHUPLQHWKDWSRWHQWLDOVXEMHFWVDUHFRPSHWHQWWRSDUWLFLSDWHLQWKHGHFLVLRQ
PDNLQJSURFHVV"
---------------------------------------------------------------------------------------------
* * * Assent Background * * *
 
 $VVHQW%DFNJURXQG&RPSOHWHLIDSSOLFDEOH
$OOPLQRUVPXVWSURYLGHDQDIILUPDWLYHFRQVHQWWRSDUWLFLSDWHE\VLJQLQJDVLPSOLILHGDVVHQWIRUPXQOHVVWKH,QYHVWLJDWRUVSURYLGHVHYLGHQFHWRWKH,5%WKDWWKHPLQRUVXEMHFWVDUHQRWFDSDEOHRIDVVHQWLQJEHFDXVHRIDJHPDWXULW\SV\FKRORJLFDOVWDWHRURWKHUIDFWRUV
6HHVDPSOHFRQVHQWDVVHQWIRUPVDWKWWSULFURFRORVWDWHHGX,5%&RQVHQW$VVHQW7HPSODWHVKWPO3URYLGHDVVHQWSURFHVVEDFNJURXQGLQIRUPDWLRQLQWKHVSDFHEHO RZIRUHDFK$VVHQW)RUP$OWHUDWLRQ)RUP
LH&RYHU/HWWHURU9HUEDO6FULSWDQG:DLYHU
Assent  Background
---------------------------------------------------------------------------------------------
Page 34 of 4734
PROTOCOL
BiomedicalProtocol # 14-5529H
 Date Printed: 01/30/2019
Protocol Title: Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
Clinical Research Protocol Title: Dapagliflozin  Augments The Favorable Adaptation ToEndurance Exercise Training
Protocol Type: Biomedical
Date Submitted: 11/01/2018
Approval Period: 11/06/2018-11/05/2019Important Note:
This Print View may not reflect all comments and contingencies for approval. Please check the
comments section of the online protocol.Questions that appear to not have been answered may not have been required for this submission.Please see the system application for more details.
----------------------------------------------------------------------------------------------------
* * * HIPAA * * *
 
 +,3$$
$UH\RXXVLQJ3+,
"6HHGHILQLWLRQEHORZ
[ADDRESS_556147] a research-related HIPAA policy. If you will beworking with a HIPAA covered entity (e.g., Poudre Valley Health System), you will need to follow their HIPAAguidelines. If your project will involve a HIPAA-regulated entity, in the Attachment section (#16) please attach thatentity's required HIPAA consent and/or each waiver of authorization or alteration of authorization requested (e.g.,waiver of authorization for access to medical records). Include HIPAA authorization language in the consentdocument(s) as appropriate (e.g., when enrolling subjects).  

3URWHFWHG+HDOWK,QIRUPDWLRQ3+,LVKHDOWKLQIRUPDWLRQZLWKRQHRUPRUHRIWKHIROORZLQJLGHQWLILHUV)RUPRUHLQIRUPDWLRQVHHKWWSZZZKKVJRYRFUKLSDD
bb 1DPHV
bb 6RFLDO6HFXULW\QXPEHUV
bb 7HOHSKRQHQXPEHUV
bb $OOJHRJUDSKLFVXEGLYLVLRQVVPDOOHUWKDQD6WDWHLQFOXGLQJ VWUHHWDGGUHVVFLW\FRXQW\SUHFLQFW
]LSFRGHDQGWKHLUHTXLYDOHQWJHRFRGHVH[FHSWIRUWKHLQLWLDOWKUHHGLJLWVRID]LSFRGHLIDFFRUGLQJWRWKHFXUUHQWSXEOLFO\DYDLODEOHGDWDIURPWKH%XUHDXRIWKH&HQVXV7KHJHRJUDSKLFXQLWIRUPHGE\FRPELQLQJDOO]LSFRGHVZLWKWKHVDPH WKUHHLQLWLDOGLJLWVFRQWDLQV
PRUHWKDQSHRSOHDQG7KHLQLWLDOWKUHHGLJLWVRID ]LSFRGHIRUDOOVXFKJHRJUDSKLF
XQLWVFRQWDLQLQJRUIHZHUSHRSOHLVFKDQJHGWR
bb $OOHOHPHQWVRIGDWHVH[FHSW\HDUIRUGDWHVGLUHFWO\UHODWHGWRDQLQGLYLGXDOLQFOXGLQJELUWKGDWH
DGPLVVLRQGDWHGLVFKDUJHGDWHGDWHRIGHDWKDQGDOODJHVRYHUDQGDOOHOHPHQWVRIGDWHVLQFOXGLQJ\HDULQGLFDWLYHRIVXFKDJHH[FHSWWKDWVXFKDJHVDQGHOHPHQWVPD\EHDJJUHJDWHGLQWRDVLQJOHFDWHJRU\RIDJHRUROGHU
bb )D[QXPEHUV
bb (OHFWURQLFPDLODGGUHVVHV
bb 0HGLFDOUHFRUGQXPEHUV
bb +HDOWKSODQEHQHILFLDU\QXPEHUV
 $FFRXQWQXPEHUV
 &HUWLILFDWHOLFHQVHQXPEHUV
 9HKLFOHLGHQWLILHUVDQGVHULDOQXPEHUVLQFOXGLQJOLFHQVHSODWHQXPEHUV
 'HYLFHLGHQWLILHUVDQGVHULDOQXPEHUV
 :HE8QLYHUVDO5HVRXUFH/RFDWLRQV85/V
 ,QWHUQHW3URWRFRO,3DGGUHVVQXPEHUV
 %LRPHWULFLGHQWLILHUVLQFOXGLQJILQJHUDQGYRLFHSULQWV
Page 35 of 4735
PROTOCOL
BiomedicalProtocol # 14-5529H
 Date Printed: 01/30/2019
Protocol Title: Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
Clinical Research Protocol Title: Dapagliflozin  Augments The Favorable Adaptation ToEndurance Exercise Training
Protocol Type: Biomedical
Date Submitted: 11/01/2018
Approval Period: 11/06/2018-11/05/2019Important Note:
This Print View may not reflect all comments and contingencies for approval. Please check the
comments section of the online protocol.Questions that appear to not have been answered may not have been required for this submission.Please see the system application for more details.
----------------------------------------------------------------------------------------------------
 )XOOIDFHSKRWRJUDSKLFLPDJHVDQGDQ\FRPSDUDEOHLPDJHVDQG
 $Q\RWKHUXQLTXHLGHQWLI\LQJQXPEHUFKDUDFWHURUFRGHQRW HWKLVGRHVQRWPHDQWKHXQLTXH
FRGHDVVLJQHGE\WKH,QYHVWLJDWRUVWRFRGHWKHUHVHDUFKGDWD
---------------------------------------------------------------------------------------------
* * * Attachments * * *
 
$WWDFKPHQWV
$WWDFKUHOHYDQWGRFXPHQWVKHUH7KHVHFRXOGLQFOXGH&ROODERUDW LQJ,QYHVWLJDWRU
V,5%DSSURYDODQG
DSSURYHGGRFXPHQWV&RQIOLFWRI,QWHUHVWLQIRUPDWLRQ'HEULHILQ J6FULSW*UDQW6XEFRQWUDFW+,3$$
$XWKRUL]DWLRQ)RUPIURP+,3$$FRYHUHGHQWLW\,QWHUYLHZ)RFXV*URXS4XHVWLRQV,QYHVWLJDWRU
V%URFKXUH/HWWHUVRI$JUHHPHQW&RRSHUDWLRQIURPRUJDQL]DWLRQVZKRZLOOKHOSZLWKUHFUXLWPHQW0HWKRGRORJ\VHFWLRQRIDVVRFLDWHG7KHVLVRU'LVVHUWDWLRQSURMHFW4XHVWLRQQDLUHV5DGL DWLRQ&RQWURO2IILFHDSSURYDOPDWHULDO
5HFUXLWPHQW0DWHULDOHJIO\HUVHPDLOWH[WYHUEDOVFULSWV6SRQVRU
V3URWRFRO6XUYH\V2WKHUILOHVDVVRFLDWHGZLWKWKHSURWRFRO\RXFDQXSORDGPRVWVWDQGDUGILOH IRUPDWV[OVSGIMSJWLIHWF3OHDVHEH
VXUHWRDWWDFKDOOGRFXPHQWVDVVRFLDWHGZLWK\RXUSURWRFRO)DLOXUHWRDWWDFKWKHILOHVDVVRFLDWHGZLWKWKHSURWRFROPD\UHVXOWLQWKLVSURWRFROEHLQJUHWXUQHGWR\RXIRU FRPSOHWLRQSULRUWREHLQJUHYLHZHG6WXGHQWV
%HVXUHWRDWWDFKWKH0HWKRGVVHFWLRQRI\RXUWKHVLVRUGLVVHUWDWLRQSURSRVDO,IWKLVSURWRFROLVDVVRFLDWHGZLWKDJUDQWSURSRVDOSOHDVHUHPHPEHUWRDWWDFK\RXUJUDQW
To update or revise any attachments, please delete the existing attachment and upload the revised document toreplace it. 
'RFXPHQW7\SH ,QYHVWLJDWRU
V%URFKXUH
$WWDFKPHQW
,QYHVWLJDWRU
V%URFKXUH'DSDJOLIOR]LQ(GLWLRQ
'RFXPHQW1DPH ,QYHVWLJDWRU
V%URFKXUH'DSDJOLIOR]LQ(GLWLRQ
'RFXPHQW7\SH 2WKHU3URWRFRO0DWHULDO
$WWDFKPHQW )DU[LJD'DSDJOLIOR]LQ
'RFXPHQW1DPH )DU[LJD'DSDJOLIOR]LQ
'RFXPHQW7\SH 2WKHU3URWRFRO0DWHULDO
$WWDFKPHQW 6*/7'DSDJOLIOR]LQ
'RFXPHQW1DPH 6*/7'DSDJOLIOR]LQ
'RFXPHQW7\SH 2WKHU3URWRFRO0DWHULDO
$WWDFKPHQW 6*/7,QKLELWRUV7'LDEHWHV
'RFXPHQW1DPH 6*/7,QKLELWRUV7'LDEHWHV
Page 36 of 4736
PROTOCOL
BiomedicalProtocol # 14-5529H
 Date Printed: 01/30/2019
Protocol Title: Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
Clinical Research Protocol Title: Dapagliflozin  Augments The Favorable Adaptation ToEndurance Exercise Training
Protocol Type: Biomedical
Date Submitted: 11/01/2018
Approval Period: 11/06/2018-11/05/2019Important Note:
This Print View may not reflect all comments and contingencies for approval. Please check the
comments section of the online protocol.Questions that appear to not have been answered may not have been required for this submission.Please see the system application for more details.
----------------------------------------------------------------------------------------------------
'RFXPHQW7\SH 2WKHU3URWRFRO0DWHULDO
$WWDFKPHQW 6*/7,QKLELWRUV'LDEHWHV
'RFXPHQW1DPH 6*/7,QKLELWRUV'LDEHWHV
'RFXPHQW7\SH 2WKHU3URWRFRO0DWHULDO
$WWDFKPHQW 6*/7,QKLELWRUV1HZ'LDEHWHV'UXJ
'RFXPHQW1DPH 6*/7,QKLELWRUV1HZ'LDEHWHV'UXJ
'RFXPHQW7\SH 623
$WWDFKPHQW +355HSRUWLQJ$(V623
'RFXPHQW1DPH +355HSRUWLQJ$(V623
'RFXPHQW7\SH 5HFUXLWPHQW0DWHULDOHJIO\HUVHPDLOWH[WYHUEDOVFULSWV
$WWDFKPHQW
+5HFUXLWPHQW([DPSOHV
'RFXPHQW1DPH +5HFUXLWPHQW([DPSOHV
'RFXPHQW7\SH 2WKHU3URWRFRO0DWHULDO
$WWDFKPHQW ,GFDUGVIRUVXEMHFWV
'RFXPHQW1DPH ,GFDUGVIRUVXEMHFWV
'RFXPHQW7\SH 6SRQVRU
V3URWRFRO
$WWDFKPHQW 3URWRFRO,66'$3
'RFXPHQW1DPH 3URWRFRO,66'$3
'RFXPHQW7\SH 2WKHU3URWRFRO0DWHULDO
$WWDFKPHQW )'$BB-XQH
'RFXPHQW1DPH )'$BB-XQH
Page 37 of 4737
PROTOCOL
BiomedicalProtocol # 14-5529H
 Date Printed: 01/30/2019
Protocol Title: Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
Clinical Research Protocol Title: Dapagliflozin  Augments The Favorable Adaptation ToEndurance Exercise Training
Protocol Type: Biomedical
Date Submitted: 11/01/2018
Approval Period: 11/06/2018-11/05/2019Important Note:
This Print View may not reflect all comments and contingencies for approval. Please check the
comments section of the online protocol.Questions that appear to not have been answered may not have been required for this submission.Please see the system application for more details.
----------------------------------------------------------------------------------------------------
'RFXPHQW7\SH 6SRQVRU
V3URWRFRO
$WWDFKPHQW %HOO,,65),1$/
'RFXPHQW1DPH %HOO,,65),1$/
'RFXPHQW7\SH 2WKHU3URWRFRO0DWHULDO
$WWDFKPHQW ,PSRUWDQW&RPPXQLFDWLRQIURP$=UHJDUGLQJ'.$RWKHU7'VWXGLHV-XO\
'RFXPHQW1DPH ,PSRUWDQW&RPPXQLFDWLRQIURP$=UHJDUGLQJ'.$RWKHU7'VWXGLHV-XO\
'RFXPHQW7\SH 2WKHU3URWRFRO0DWHULDO
$WWDFKPHQW $=(PDLO
'RFXPHQW1DPH $=(PDLO
'RFXPHQW7\SH 4XHVWLRQQDLUH6XUYH\
$WWDFKPHQW 6FUHHQLQJ0HG+LVWRU\
'RFXPHQW1DPH 6FUHHQLQJ0HG+LVWRU\
'RFXPHQW7\SH 2WKHU3URWRFRO0DWHULDO
$WWDFKPHQW )'$VDIHW\ZDUQLQJ'HF
'RFXPHQW1DPH )'$VDIHW\ZDUQLQJ'HF
'RFXPHQW7\SH 2WKHU3URWRFRO0DWHULDO
$WWDFKPHQW &'&+HSDWLWLV%)DFW6KHHW
'RFXPHQW1DPH &'&+HSDWLWLV%)DFW6KHHW
'RFXPHQW7\SH 5HFUXLWPHQW0DWHULDOHJIO\HUVHPDLOWH[WYHUEDOVFULSWV
$WWDFKPHQW
5HFUXLWPHQWB$=B([HUFLVH
'RFXPHQW1DPH 5HFUXLWPHQWB$=B([HUFLVH
Page 38 of 4738
PROTOCOL
BiomedicalProtocol # 14-5529H
 Date Printed: 01/30/2019
Protocol Title: Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
Clinical Research Protocol Title: Dapagliflozin  Augments The Favorable Adaptation ToEndurance Exercise Training
Protocol Type: Biomedical
Date Submitted: 11/01/2018
Approval Period: 11/06/2018-11/05/2019Important Note:
This Print View may not reflect all comments and contingencies for approval. Please check the
comments section of the online protocol.Questions that appear to not have been answered may not have been required for this submission.Please see the system application for more details.
----------------------------------------------------------------------------------------------------
'RFXPHQW7\SH 2WKHU3URWRFRO0DWHULDO
$WWDFKPHQW GHOHJDWLRQRIDXWKRULW\ORJ$SULO
'RFXPHQW1DPH GHOHJDWLRQRIDXWKRULW\ORJ$SULO
'RFXPHQW7\SH 2WKHU3URWRFRO0DWHULDO
$WWDFKPHQW 17),QWHUSUHWDWLRQRI+HS%UHVXOWVJMORFW
'RFXPHQW1DPH 17),QWHUSUHWDWLRQRI+HS%UHVXOWVJMORFW
'RFXPHQW7\SH 2WKHU3URWRFRO0DWHULDO
$WWDFKPHQW +%6(;$(KHDGDFKH
'RFXPHQW1DPH +%6(;$(KHDGDFKH
'RFXPHQW7\SH 2WKHU3URWRFRO0DWHULDO
$WWDFKPHQW +%6(;$(NLFNHGIRRW
'RFXPHQW1DPH +%6(;$(NLFNHGIRRW
'RFXPHQW7\SH 2WKHU3URWRFRO0DWHULDO
$WWDFKPHQW +%6(;FRQPHGV
'RFXPHQW1DPH +%6(;FRQPHGV
'RFXPHQW7\SH 623
$WWDFKPHQW 4$,5+GUXJGLVSHQVLQJ)HE
'RFXPHQW1DPH 4$,5+GUXJGLVSHQVLQJ)HE
'RFXPHQW7\SH (PDLO&RUUHVSRQGHQFH
$WWDFKPHQW ):B,66'$3$DQG,66'$3$$OOHUJ\0HGV
'RFXPHQW1DPH ):B,66'$3$DQG,66'$3$$OOHUJ\0HGV
'RFXPHQW7\SH 4XHVWLRQQDLUH6XUYH\
Page 39 of 4739
PROTOCOL
BiomedicalProtocol # 14-5529H
 Date Printed: 01/30/2019
Protocol Title: Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
Clinical Research Protocol Title: Dapagliflozin  Augments The Favorable Adaptation ToEndurance Exercise Training
Protocol Type: Biomedical
Date Submitted: 11/01/2018
Approval Period: 11/06/2018-11/05/2019Important Note:
This Print View may not reflect all comments and contingencies for approval. Please check the
comments section of the online protocol.Questions that appear to not have been answered may not have been required for this submission.Please see the system application for more details.
----------------------------------------------------------------------------------------------------
$WWDFKPHQW +0HGLFDO6FUHHQLQJ)RUP-XO\
'RFXPHQW1DPH +0HGLFDO6FUHHQLQJ)RUP-XO\
'RFXPHQW7\SH ,QYHVWLJDWRU
V%URFKXUH
$WWDFKPHQW ,QYHVWLJDWRU
V%URFKXUH'DSDJOLIOR]LQ(GLWLRQ
'RFXPHQW1DPH ,QYHVWLJDWRU
V%URFKXUH'DSDJOLIOR]LQ(GLWLRQ
'RFXPHQW7\SH 2WKHU3URWRFRO0DWHULDO
$WWDFKPHQW 3URWRFROGHYLDWLRQ,QFRUUHFWLQWHUYHQWLRQGRVDJH-XO\
'RFXPHQW1DPH 3URWRFROGHYLDWLRQ,QFRUUHFWLQWHUYHQWLRQGRVDJH-XO\
'RFXPHQW7\SH 2WKHU3URWRFRO0DWHULDO
$WWDFKPHQW 'HYLDWLRQ3UHVFULEHG,URQ6XSSOHPHQW-DQ
'RFXPHQW1DPH 'HYLDWLRQ3UHVFULEHG,URQ6XSSOHPHQW-DQ
'RFXPHQW7\SH 2WKHU3URWRFRO0DWHULDO
$WWDFKPHQW (YHQW/RJFRQWUHYLHZBB
'RFXPHQW1DPH (YHQW/RJFRQWUHYLHZBB
'RFXPHQW7\SH ,QYHVWLJDWRU
V%URFKXUH
$WWDFKPHQW ,QYHVWLJDWRU
V%URFKXUH'DSDJOLIOR]LQ(GLWLRQ
'RFXPHQW1DPH ,QYHVWLJDWRU
V%URFKXUH'DSDJOLIOR]LQ(GLWLRQ
'RFXPHQW7\SH 2WKHU3URWRFRO0DWHULDO
$WWDFKPHQW &RQWLQXDWLRQ)RUPBB
'RFXPHQW1DPH &RQWLQXDWLRQ)RUPBB
Page 40 of 4740
PROTOCOL
BiomedicalProtocol # 14-5529H
 Date Printed: 01/30/2019
Protocol Title: Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
Clinical Research Protocol Title: Dapagliflozin  Augments The Favorable Adaptation ToEndurance Exercise Training
Protocol Type: Biomedical
Date Submitted: 11/01/2018
Approval Period: 11/06/2018-11/05/2019Important Note:
This Print View may not reflect all comments and contingencies for approval. Please check the
comments section of the online protocol.Questions that appear to not have been answered may not have been required for this submission.Please see the system application for more details.
----------------------------------------------------------------------------------------------------
'RFXPHQW7\SH 2WKHU3URWRFRO0DWHULDO
$WWDFKPHQW (YHQW/RJY(79HULILHG
'RFXPHQW1DPH (YHQW/RJY(79HULILHG
'RFXPHQW7\SH 2WKHU3URWRFRO0DWHULDO
$WWDFKPHQW 3URWRFRO'HYLDWLRQ2*77DQG0(7(;5+(;BB
'RFXPHQW1DPH 3URWRFRO'HYLDWLRQ2*77DQG0(7(;5+(;BB
'RFXPHQW7\SH 2WKHU3URWRFRO0DWHULDO
$WWDFKPHQW (YHQW/RJY(79HULILHGFRQWUHYLHZB
'RFXPHQW1DPH (YHQW/RJY(79HULILHGFRQWUHYLHZB
---------------------------------------------------------------------------------------------
* * * Obligations * * *
 
 Obligations (Researcher's Responsibilities) 7KH3ULQFLSDO,QYHVWLJDWRULVXOWLPDWHO\UHVSRQVLEOHIRUWKHFRQGXFWRIWKHSURMHFW2EOLJDWLRQVRIWKH3ULQFLSDO
,QYHVWLJDWRUDUH
 
&RQGXFWWKHUHVHDUFKLQYROYLQJKXPDQVXEMHFWVDVSUHVHQWHGLQWKHSURWRFROLQFOXGLQJPRGLILFDWLRQVDV
DSSURYHGE\WKH'HSDUWPHQWDQG,QVWLWXWLRQDO5HYLHZ%RDUG&KDQJHVLQDQ\DVSHFWRIWKHVWXG\IRUH[DPSOHSURMHFWGHVLJQSURFHGXUHVFRQVHQWIRUPVDGYHUWLVLQJPDWHULDOVDGGLWLRQDONH\SHUVRQQHORUVXEMHFWSRSXODWLRQVZLOOEHVXEPLWWHGWRWKH,5%IRUDSSURYDOEHIRUHLQVWLWXWLQJWKHFKDQJHV3,ZLOOVXEPLWWKH$PHQGPHQW5HYLVLRQIRUP
 
3URYLGHDOOVXEMHFWVDFRS\RIWKHVLJQHGFRQVHQWIRUPLIDSSOLFDEOH,QYHVWLJDWRUVZLOOEHUHTXLUHGWRUHWDLQVLJQHG
FRQVHQWGRFXPHQWVIRUWKUHH\HDUVDIWHUFORVHRIWKHVWXG\
 
Page 41 of 4741
PROTOCOL
BiomedicalProtocol # 14-5529H
 Date Printed: 01/30/2019
Protocol Title: Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
Clinical Research Protocol Title: Dapagliflozin  Augments The Favorable Adaptation ToEndurance Exercise Training
Protocol Type: Biomedical
Date Submitted: 11/01/2018
Approval Period: 11/06/2018-11/05/2019Important Note:
This Print View may not reflect all comments and contingencies for approval. Please check the
comments section of the online protocol.Questions that appear to not have been answered may not have been required for this submission.Please see the system application for more details.
----------------------------------------------------------------------------------------------------
0DLQWDLQDQDSSURYHGVWDWXVIRU+XPDQ6XEMHFWV3URWHFWLRQWUDLQLQJ7UDLQLQJPXVWEHXSGDWHGHYHU\WKUHH\HDUV&RQWDFW5,&52WRFKHFN\RXUFXUUHQWDSSURYDOUHQHZDOGDWHV)RUPRUHLQIRUPDWLRQ+XPDQ6XEMHFWV7UDLQLQJ&RPSOHWHG"
 
6XEPLWHLWKHUWKH3URWRFRO'HYLDWLRQ)RUPRUWKH5HSRUW)RUPWRUHSRUWSURWRFRO'HYLDWLRQV9LRODWLRQV
8QDQWLFLSDWHG3UREOHPV83VDQGRU$GYHUVH(YHQWV$(VWKDWRFFXULQWKHFRXUVHRIWKHSURWRFRO$Q\RIWKHVHHYHQWVPXVWEHUHSRUWHGWRWKH,5%DVVRRQDVSRVVLEOHEXWQRWODWHUWKDQILYHZRUNLQJGD\V1RWHWKDWLIDQHYHQWUHVXOWHGLQOLIHWKUHDWHQLQJLQMXU\RUGHDWK25DQHYHQWUHVXOWHGLQVXEVWDQWLYHKDUPWRWKHVDIHW\ULJKWVRUZHOIDUHWRKXPDQVXEMHFWVWKLVPXVWEHUHSRUWHGWRWKH,5%ZLWKLQKRXUV
 
6XEPLWWKH&RQWLQXLQJ5HYLHZ)RUPLQRUGHUWRPDLQWDLQDFWLYHVWDWXVRIWKHDSSURYHGSURWRFRO7KLVIRUPPXVW
EHVXEPLWWHGDQQXDOO\DWOHDVWIRXUZHHNVSULRUWRH[SLUDWLRQILYHZHHNVIRUSURWRFROVWKDWUHTXLUHIXOOUHYLHZ,IWKHSURWRFROLVQRWUHQHZHGEHIRUHH[SLUDWLRQDOODFWLYLWLHVPXVWFHDVHXQWLOWKHSURWRFROKDVEHHQUHUHYLHZHG
 
1RWLI\WKH,5%WKDWWKHVWXG\LVFRPSOHWHE\VXEPLWWLQJWKH)LQDO5HSRUWIRUP
 
bb bb
; 7KH3ULQFLSDO,QYHVWLJDWRUKDVUHDGDQGDJUHHVWRDELGHE\WKHDERYHREOLJDWLRQV
---------------------------------------------------------------------------------------------
* * * Event History * * *
Event History
Date Status View Attachments Letters
 1(:)250&5($7('
 1(:)250
68%0,77('<
 1(:)2503$1(/
$66,*1('
 1(:)250
5(9,(:(56
$66,*1('
 1(:)250
5(9,(:(56$66,*1('
Page 42 of 4742
PROTOCOL
BiomedicalProtocol # 14-5529H
 Date Printed: 01/30/2019
Protocol Title: Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
Clinical Research Protocol Title: Dapagliflozin  Augments The Favorable Adaptation ToEndurance Exercise Training
Protocol Type: Biomedical
Date Submitted: 11/01/2018
Approval Period: 11/06/2018-11/05/2019Important Note:
This Print View may not reflect all comments and contingencies for approval. Please check the
comments section of the online protocol.Questions that appear to not have been answered may not have been required for this submission.Please see the system application for more details.
----------------------------------------------------------------------------------------------------
 1(:)250
68%0,77('&<&/(<
 1(:)250
5(9,(:(56$66,*1('
 1(:)250
68%0,77('&<&/(<
 1(:)250$[ZIP_CODE](' < <
 1(:)25081'2
$[ZIP_CODE]('
 1(:)250029('
 1(:)250$[ZIP_CODE](' < <
 $0(1'0(17)250
&5($7('
 $0(1'0(17)250
68%0,77('<
 $0(1'0(17)250
5(9,(:(56
$66,*1('
 $0(1'0(17)250
029('
 $0(1'0(17)250
$[ZIP_CODE]('<<
 $0(1'0(17)250
&5($7('
 $0(1'0(17)250
68%0,77('<
 $0(1'0(17)250
5(9,(:(56$66,*1('
 $0(1'0(17)250
$[ZIP_CODE]('<<
 $0(1'0(17)250
81'2$[ZIP_CODE]('
 $0(1'0(17)250
029('
 $0(1'0(17)250
$[ZIP_CODE]('<<
 $0(1'0(17)250
&5($7('
Page 43 of 4743
PROTOCOL
BiomedicalProtocol # 14-5529H
 Date Printed: 01/30/2019
Protocol Title: Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
Clinical Research Protocol Title: Dapagliflozin  Augments The Favorable Adaptation ToEndurance Exercise Training
Protocol Type: Biomedical
Date Submitted: 11/01/2018
Approval Period: 11/06/2018-11/05/2019Important Note:
This Print View may not reflect all comments and contingencies for approval. Please check the
comments section of the online protocol.Questions that appear to not have been answered may not have been required for this submission.Please see the system application for more details.
----------------------------------------------------------------------------------------------------
 $0(1'0(17)250
68%0,77('<
 $0(1'0(17)250
5(9,(:(56$66,*1('
 $0(1'0(17)250
$[ZIP_CODE]('<<
 &217,18,1*5(9,(:
)250&5($7('
 &217,18,1*5(9,(:
)25068%0,77('<
 &217,18,1*5(9,(:
)2505(9,(:(56$66,*1('
 &217,18,1*5(9,(:
)250$[ZIP_CODE]('<<
 &217,18,1*5(9,(:
)25081'2$[ZIP_CODE]('
 &217,18,1*5(9,(:
)250$[ZIP_CODE]('<<
 '(9,$7,21)250
&5($7('
 '(9,$7,21)250
68%0,77('<
 $0(1'0(17)250
&5($7('
 $0(1'0(17)250
68%0,77('<
 $0(1'0(17)250
5(9,(:(56$66,*1('
 '(9,$7,21)250
5(9,(:(56$66,*1('
 '(9,$7,21)250
$[ZIP_CODE]('<1
 $0(1'0(17)250
$[ZIP_CODE]('<<
 '(9,$7,21)250
&5($7('
Page 44 of 4744
PROTOCOL
BiomedicalProtocol # 14-5529H
 Date Printed: 01/30/2019
Protocol Title: Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
Clinical Research Protocol Title: Dapagliflozin  Augments The Favorable Adaptation ToEndurance Exercise Training
Protocol Type: Biomedical
Date Submitted: 11/01/2018
Approval Period: 11/06/2018-11/05/2019Important Note:
This Print View may not reflect all comments and contingencies for approval. Please check the
comments section of the online protocol.Questions that appear to not have been answered may not have been required for this submission.Please see the system application for more details.
----------------------------------------------------------------------------------------------------
 '(9,$7,21)250
68%0,77('<
 '(9,$7,21)250
&5($7('
 '(9,$7,21)250
68%0,77('<
 $0(1'0(17)250
&5($7('
 $0(1'0(17)250
68%0,77('<
 $0(1'0(17)250
5(9,(:(56$66,*1('
 '(9,$7,21)250
5(9,(:(56$66,*1('
 $0(1'0(17)250
$[ZIP_CODE]('<<
 $0(1'0(17)250
&5($7('
 $0(1'0(17)250
68%0,77('<
 $0(1'0(17)250
5(9,(:(56$66,*1('
 5(3257)250
&5($7('
 5(3257)250
68%0,77('<
 5(3257)250
5(9,(:(56$66,*1('
 5(3257)250
5(9,(:(56$66,*1('
 $0(1'0(17)250
5(9,(:(56$66,*1('
 5(3257)250
5(9,(:(56$66,*1('
Page 45 of 4745
PROTOCOL
BiomedicalProtocol # 14-5529H
 Date Printed: 01/30/2019
Protocol Title: Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
Clinical Research Protocol Title: Dapagliflozin  Augments The Favorable Adaptation ToEndurance Exercise Training
Protocol Type: Biomedical
Date Submitted: 11/01/2018
Approval Period: 11/06/2018-11/05/2019Important Note:
This Print View may not reflect all comments and contingencies for approval. Please check the
comments section of the online protocol.Questions that appear to not have been answered may not have been required for this submission.Please see the system application for more details.
----------------------------------------------------------------------------------------------------
 '(9,$7,21)250
5(9,(:(56$66,*1('
 '(9,$7,21)250
5(9,(:(56$66,*1('
 $0(1'0(17)250
68%0,77('&<&/(<
 $0(1'0(17)250
5(9,(:(56$66,*1('
 '(9,$7,21)250
&5($7('
 '(9,$7,21)250
68%0,77('<
 '(9,$7,21)250
029('
 $0(1'0(17)250
029('
 $0(1'0(17)250
$[ZIP_CODE]('<<
 '(9,$7,21)250
$[ZIP_CODE]('<1
 '(9,$7,21)250
5(9,(:(56$66,*1('
 '(9,$7,21)250
$[ZIP_CODE]('<1
 5(3257)250
$[ZIP_CODE]('<1
 $0(1'0(17)250
&5($7('
 $0(1'0(17)250
68%0,77('<
 $0(1'0(17)250
$[ZIP_CODE]('<<
 $0(1'0(17)250
&5($7('
 $0(1'0(17)250
68%0,77('<
Page 46 of 4746
PROTOCOL
BiomedicalProtocol # 14-5529H
 Date Printed: 01/30/2019
Protocol Title: Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
Clinical Research Protocol Title: Dapagliflozin  Augments The Favorable Adaptation ToEndurance Exercise Training
Protocol Type: Biomedical
Date Submitted: 11/01/2018
Approval Period: 11/06/2018-11/05/2019Important Note:
This Print View may not reflect all comments and contingencies for approval. Please check the
comments section of the online protocol.Questions that appear to not have been answered may not have been required for this submission.Please see the system application for more details.
----------------------------------------------------------------------------------------------------
 $0(1'0(17)250
5(9,(:(56$66,*1('
 $0(1'0(17)250
68%0,77('&<&/(<
 $0(1'0(17)250
029('
 $0(1'0(17)250
$[ZIP_CODE]('<<
 '(9,$7,21)250
$[ZIP_CODE]('<1
 5(3257)250
&5($7('
 5(3257)250
68%0,77('<
 5(3257)250
5(9,(:(56$66,*1('
 &217,18,1*5(9,(:
)250&5($7('
 &217,18,1*5(9,(:
)25068%0,77('<
 &217,18,1*5(9,(:
)2505(9,(:(56$66,*1('
 5(3257)250
$[ZIP_CODE]('<1
 &217,18,1*5(9,(:
)2505(9,(:(56$66,*1('
 &217,18,1*5(9,(:
)250$[ZIP_CODE]('<<
 $0(1'0(17)250
&5($7('
 $0(1'0(17)250
68%0,77('<
 $0(1'0(17)250
$[ZIP_CODE]('<<
 &217,18,1*5(9,(:
)250&5($7('
 &217,18,1*5(9,(:
)25068%0,77('<
Page 47 of 4747
PROTOCOL
BiomedicalProtocol # 14-5529H
 Date Printed: 01/30/2019
Protocol Title: Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
Clinical Research Protocol Title: Dapagliflozin  Augments The Favorable Adaptation ToEndurance Exercise Training
Protocol Type: Biomedical
Date Submitted: 11/01/2018
Approval Period: 11/06/2018-11/05/2019Important Note:
This Print View may not reflect all comments and contingencies for approval. Please check the
comments section of the online protocol.Questions that appear to not have been answered may not have been required for this submission.Please see the system application for more details.
----------------------------------------------------------------------------------------------------
 &217,18,1*5(9,(:
)250$[ZIP_CODE]('<<
 &217,18,1*5(9,(:
)250&5($7('
 &217,18,1*5(9,(:
)25068%0,77('<
 &217,18,1*5(9,(:
)250$[ZIP_CODE]('<<
Methods of statistical analyses
Two-way analysis of variance (before training vs. after training, and Dapagliflozin vs. Placebo) 
with repeated measures on one factor (before vs. after) are used to examine differences in 
primary outcomes resulting from exercise training and/or drug t reatment.  Multiple comparisons 
of factor means will be performed using the Newman-Keuls test.
Page 1of 12Participantâ€™s initials _______ Date _______
Version 01July2016CSU#: 14-5529H
APPROVED: 11/16/2017* EXPI[INVESTIGATOR_152617]: 11/15/2018Consent to Participate in a Research Study
Colorado State University
TITLE OF STUDY:
Does Dapagliflozin Augment The Favorable Adaptation To Endurance  Exercise 
Training?CO-PRINCIPAL INVESTIGATORS:Christopher Bell, Ph.D. Christopher L. Melby, Dr.P.H.
Health & Exercise Science Food Science & Human Nutrition
Colorado State University Colorado State University
Email: [EMAIL_8395] Email: chris.melby@colostat e.edu
Telephone: [PHONE_9149] Telephone: [PHONE_9150]
WHY AM I BEING INVITED TO TAKE PART IN THIS RESEARCH?You are aged between 18-50 years, your body mass index is betwe en 25 and 45 kg/m
2,
you are free of diabetes, you are not pregnant, and/or you are n ot a regular exerciser,
but would like to be.WHO IS DOING THE STUDY? Drs. Bell and Melby [CONTACT_438848]; local medical doctors,  other researchers, and 
a team of trained graduate and undergraduate students are helpin g. [COMPANY_008] 
Pharmaceuticals LP, a company that makes medicine, is providing financial support for 
the study.  
WHAT IS THE PURPOSE OF THIS STUDY? Dapagliflozin ( commercially known as Farxiga; pronounced: far-see-gah) is a new 
medicine for treating type 2 di abetes.  The purpose of the stud y is to discover if taking 
Dapagliflozin will improve peopleâ€™s response to regular exercise.   That is, if people 
perform regular exercise while using Dapagliflozin, will they b ecome fitter and leaner 
than similar people who perform the same exercise but do not use  Dapagliflozin?
Page 2of 12Participantâ€™s initials _______ Date _______
Version 01July2016CSU#: 14-5529H
APPROVED: 11/16/2017* EXPI[INVESTIGATOR_152617]: 11/15/2018WHERE IS THE STUDY GOING TO TAKE PL ACE AND HOW LONG WILL IT LAST ?
The study will take place in the Human Performance/Clinical Research Laboratory
(HPCRL) and in the Health and Exercise Science Cardiovascular T raining Room, both 
of which are located in the Department of Health and Exercise S cience, Moby [CONTACT_438849],
on the main campus of Colorado Sta te University, Fort Collins, Colorado.
The study will take place over approximately 2 years.  You will  be involved for 
approximately 4 months and will be asked to visit the Human Per formance Clinical 
Research Laboratory on 51 different days.
WHAT WILL I BE ASKED TO DO?Here is a brief summary of what you will be asked to do:
You will report to the Human Per formance Clinical Research Labor atory (HPCRL) on 51
separate days:
Visit 1: you will undergo screening : medical history, 12-lead el ectrocardiogram and 
blood pressure assessment at rest and during incremental exerci se to volitional 
exhaustion, blood sampling, and measurement of body composition .
Visit 2: maximal oxygen uptake will be measured.Visit 3: the metabolic response to standardized exercise will b e determined.
Visit 4: an oral glucose tolerance test will be performed, and then skeletal muscle will be 
sampled.Visits 5-48: [ADDRESS_556148], on a daily basis, eit her Dapagliflozin or placebo. 
Visit 49: maximal oxygen uptake and body composition will be me asured.
Visit 50: the metabolic respons e to standardized exercise will be determined.
Visit 51: an oral glucose tolerance test will be performed, and  then skeletal muscle will 
be sampled.
Page 3of 12Participantâ€™s initials _______ Date _______
Version 01July2016CSU#: 14-5529H
APPROVED: 11/16/2017* EXPI[INVESTIGATOR_152617]: 11/15/2018Outline and timing of study visits:
Days -14 to -1
(Weeks -2 to 0)Day 1
(Week 1) for 
12 weeks Days 85 to 91
(Week 13)
Screening VO 2maxResponse to 
standardized 
exerciseOGTT
&
BiopsyInitiation of 
treatment 
(Placebo or Dapagliflozinplus 
exercise)VO
2max Response to 
standardized 
exerciseOGTT
&
Biopsy
VO 2max: Maximal oxygen uptake.  OGTT: Oral glucose tolerance test.  
Here is a detailed description of what you will be asked to do:
Visit 1 â€“ Screening Visit / Medical History / Stress Test / Bloo d Test / Body 
Composition
The first visit to the Human Performance Clinical Research Lab (HPCRL) will be a 
screening visit.  During this visit we will make sure that participation in this study is right 
for you.
This screening visit will in clude the following procedures:
Medical Questionnaire
You will be asked to answer several pages of questions related to your health, any 
illness you may have or have had, and medications you use or ha ve used in the past. 
Blood PressureWe will measure your blood pressu re using a standard blood pres sure cuff (the same as 
in a doctor's office). Blood pr essure will be measured during a ll of the tests performed in
the lab with the exception of body composition.  There are no k nown risks associated 
with this procedure. (Duration: 5 minutes)
Body Composition
We will measure how much fat you have in your body using a test  called dual energy x-
ray absorptiometry (DEXA).  The DEXA test requires you to lie q uietly on a padded 
table while a small probe gives off low-level x-rays and sends them over your entire body.  This test gives very accurate measurements of your body fat and bone mineral 
density.  We will also measure the circumference of your waist and hip using a tape 
measure. (Duration: ~ 15 minutes)
Pregnancy Test (Women Only)
Women who are or could be pregnant should not participate in th is study.  Before the 
body composition test(s) women will be asked to use a pregnancy  test (urine test) to 
confirm they are not pregnant.   
Page 4of 12Participantâ€™s initials _______ Date _______
Version 01July2016CSU#: 14-5529H
APPROVED: 11/16/2017* EXPI[INVESTIGATOR_152617]: 11/15/2018Blood Test
During this visit we will be taking blood from you.  We will be  taking approximately 20 ml 
(~1.5 table spoons); this is a lot less than the amount that is  typi[INVESTIGATOR_438843] a 
person donates blood. Y our blood will be tested for various thi ngs to make sure you are 
healthy enough to consume Dapagliflozin.  Your blood will be ta ken from veins in your 
arms or hands using needles and hollow plastic tubes called catheters. As per the medical monitorâ€™s discretion, you may be asked to have your blood tested periodically during the intervention period.
Exercise Stress Test
You will be asked to perform a vigorous exercise test.  This te st will tell us if your heart 
is healthy.  You will be asked to walk on a motorized treadmill  or ride an exercise cycle 
(cycle ergometer) for approximately 10-15 minutes. The exercise  will become more 
difficult every 2 minutes.  While you are walking/riding we wil l measure your heart rate 
with an electrocardiogram (ECG) and your blood pressure with a cuff placed around your upper arm.  We will also ask you to wear a nose clip (some thing that stops you 
breathing through your nose) and ask you to breathe through a m outhpi[INVESTIGATOR_13959].  This will let 
us measure the gases you breathe. Depending on your age, a physician may supervise the test.  If we do not think your heart is healthy you will be referred to your primary care physician for further testing.  T here is a chance that you may not be allowed to take part 
in our study. (Duration: ~ 60 minutes)
Visit 2 â€“ Maximal Aerobic Capacity
You will be asked to perform a vigorous exercise test. You will  be asked to ride an 
exercise cycle (cycle ergometer) for approximately 10-15 minute s. The exercise will 
become more difficult every 2 minutes.  You will be asked to ex ercise until you become 
so tired you are unable to push the pedals more than 40 revolutions per minute.  While 
you are riding we may measure your heart rate with an electrocar diogram (ECG) and 
your blood pressure with a cuff placed around your upper arm.  We will also ask you to 
wear a nose clip (something that stops you breathing through yo ur nose) and ask you to 
breathe through a mouthpi[INVESTIGATOR_13959].  This will let us measure the gas es you breathe. 
(Duration: ~ 60 minutes)
Visit 3 â€“ Metabolic Response To Standardized Exercise
You will be asked to ride a stationary exercise bike for approx imately [ADDRESS_556149] 10 minutes the intensity will be very, very light.  D uring the second 10 minutes 
the intensity will be increased but will still be moderate.  Du ring the final 10 minutes the 
intensity will be increased again such that it is quite difficu lt, but still achievable.  
Throughout the entire ride we may measure your heart rate with a n electrocardiogram 
(ECG) and your blood pressure with a cuff placed around your up per arm.  We will also 
ask you to wear a nose clip (something that stops you breathing  through your nose) and 
ask you to breathe through a mouthpi[INVESTIGATOR_13959].  This will let us meas ure the gases you 
breathe.  You will only wear the mouthpi[INVESTIGATOR_438844] 5 minutes of each 10-
minute period.
Page 5of 12Participantâ€™s initials _______ Date _______
Version 01July2016CSU#: 14-5529H
APPROVED: 11/16/2017* EXPI[INVESTIGATOR_152617]: 11/15/2018During this visit we will be taking blood from you.  We will be  taking approximately 80 ml 
(~6 table spoons); this is a lo t less than the amount that is t ypi[INVESTIGATOR_438843] a person 
donates blood. Your blood will be tested for various things tha t are involved with your 
nerves, the amount of calories you burn at rest, and insulin an d glucose (blood sugar).  
Your blood will be taken from vei ns in your arms or hands using  needles and hollow 
plastic tubes called catheters.
You will be provided with additional food to eat prior to this visit.
Visit 4 â€“ Oral Glucose Tolerance Test and Skeletal Muscle Samplin g
You will be asked to drink water (300 ml or ~ 10 oz) in approxi mately 5 minutes.  A 
small amount of sugar (75 g of glucose) will have been added to  the water.  This will 
make it taste sweeter and also increase your blood sugar.  After drinking the water you will sit/lie quietly for 2 hours.  You will be able to read and/or 
watch TV and/or listen to music.  We will collect blood from yo u over the 2 hours.  Your 
blood will be analyzed for concentra tions of sugar  (glucose), i nsulin (something that 
helps control blood sugar), and other things that may be help control blood sugar. Your 
blood will be taken from veins i n your arms or hands using need les and hollow plastic 
tubes called catheters.
We will then sample a small pi[INVESTIGATOR_438845].  This test is  commonly called a 
muscle biopsy.  During the muscle biopsy a drug (an anesthetic)  will be injected into an 
area of your thigh to make it feel numb.  A small incision (rou ghly 1/4 inch) will be made 
using a sharp sterile blade.  A  sterile probe will be inserted into your leg and a little 
pi[INVESTIGATOR_88160] (roughly the size of a sweet corn kernel) will be removed.
The whole visit will last approximately 3 hours.Visits 5 â€“ 48 â€“ Supervised Exercise Training
You will report to the Health and Exercise Science Cardiovascular Training Room on 44
separate occasions, spread out over 12-weeks, for supervised ex ercise training. 
Exercise will begin with 3 training sessions per week of 20-40 minutes, and progress 
after 4 weeks to 4 sessions per week of 40-60 minutes. The exer cise will be difficult 
enough to increase your heart rate to 70-80% of your maximum me asured heart rate
reserve. This will feel like moder ate-to-difficult exercise, with a measured rate of 
perceived exertion (RPE) falling between 13-15. If an RPE indica tive of moderate-to-
difficult exercise is not achieved by a heart rate at 70-80% of  heart rate reserve, the 
exercise intensity will be adjusted to achieve an appropriate d ifficulty of exercise. The 
exercise will be treadmill walking/running, stationary cycle ergometer exercise (exercise 
bike), and elliptical ergometer exercise. The exercise will be v aried between, but not 
within, sessions to avoid boredom and potential overuse injuries . In total, you will be 
scheduled to complete 44 exerci se sessions. If you fail to comp lete 40 sessions (~90%), 
Page 6of 12Participantâ€™s initials _______ Date _______
Version 01July2016CSU#: 14-5529H
APPROVED: 11/16/2017* EXPI[INVESTIGATOR_152617]: 11/15/2018or two sessions within a 7-day period you will be removed from the study. Every session 
will begin and end with a 5-minute self-paced warm-up/cool-down . These 5-minute 
periods will not be included in the training duration (for exam ple, a [ADDRESS_556150] of a 5-minute warm-up, 20 minutes of exercise training, and 5 minutes of 
cool-down).
At the same time as Visits 5 â€“ 48: Daily Ingestion of Dapagliflozi no r  P l a c e b o
During the [ADDRESS_556151] 2-weeks the dose will be 5 mg/day.  For the next 10-weeks the 
dose will be 10 mg/day. For a description of Dapagliflozin, see below.
Visit 49 â€“ Maximal Aerobic Capacity and Body Composition
You will repeat the procedures described in visit 2.  You will also undergo measurement 
of body composition (as described in visit 1).Visit 50 â€“ Metabolic Response to Standardized Exercise
You will repeat the procedures described in visit 3.Visit 51 â€“ Oral Glucose Tolerance Test and Skeletal Muscle Sampling
You will repeat the procedures described in visit 4.What is Dapagliflozin?Dapagliflozin is a new medicine that is used to treat people who h ave type 2 diabetes 
(high blood sugar and/or difficulty controlling blood sugar). Da pagliflozin works by 
[CONTACT_438850]â€™s ability to absorb sugar from food and beverages.  It does this by 
[CONTACT_438851] s to absorb sugar.  The sugar  that is not absorbed is 
removed from the body in urine.
ARE THERE REASONS WHY I SHOULD NOT TAKE PART IN THIS STUDY?You will not be allowed to take part in the study for any of th e following reasons:
1. Evidence of serious (clinically significant) heart (cardiovasc ular), lung (respi[INVESTIGATOR_696]),
kidney (renal), liver (hepatic), stomach (gastrointestinal), blood (hematological), nerve 
(neurological), mental (psychiatric), or other disease, or if you have been hospi[INVESTIGATOR_438846] 2 years as a result of these conditions, or are receiv ing medicine 
(pharmacological treatment) for these conditions.
Page 7of 12Participantâ€™s initials _______ Date _______
Version 01July2016CSU#: 14-5529H
APPROVED: 11/16/2017* EXPI[INVESTIGATOR_152617]: 11/15/[ZIP_CODE]. Use of prescription drugs (see exceptions listed below) or her bal preparations in the 
4 weeks before study commencement.
Permitted Prescription Drugs
xBirth Control 
xLess than 7 days, short course antibiotics. Note: Rifampin is not permitted.
Other medicines, for GERD, depression, seasonal allergies and O TC analgesics, may be 
allowed, but will be approved on a case-by-case basis.
3. You are currently enrolled in another clinical study for anoth er investigational drug or 
have taken any other investigational drug within 30 days before the screening visit.
4. You are a smoker: Habitual and/or recent use (within 2 years)  of tobacco.
5. You are considered unsuitable for participation in this trial  for any reason, as judged 
by [CONTACT_10982].6. You have a history of serious hypersensitivity reaction to Da pagliflozin.
7. You have severe kidney problems: renal impairment, end-stage renal disease, or 
dialysis.8. You are pregnant or breastfeeding.9. You have severe hepatic insufficiency and/or significant abno rmal liver function 
based on blood tests.10. You have a history of bladder cancer.11. Your blood pressure during visit 1: 6\VWROLFEORRGSUHVVXUHÂ•PP+JDQGRU
GLDVWROLFEORRGSUHVVXUHÂ•PP+J12. Your blood pressure before visit 5 6\VWROLFEORRGSUHVVXUHÂ•PP+JDQGRU
GLDVWROLFEORRGSUHVVXUHÂ•PP+J13. Patients who, in the judgment of the medical doctor, may be at risk for dehydration.
WHAT ARE THE POSSIBLE RISKS AND DISCOMFORTS? It is not possible to identify a ll potential ri sks in research procedures, but the 
researcher(s) have taken reasonable safeguards to minimize any known and potential 
(but unknown) risks. The Human Perf ormance Clinical Research Labo ratory has 
emergency supplies including a medicine trolley equipped with h eart machines and 
supplemental oxygen. The research team has a great deal of experie nce with all of the 
procedures.  Some of the procedures for which you are being ask ed to volunteer have a 
number of associated risks:
Page 8of 12Participantâ€™s initials _______ Date _______
Version 01July2016CSU#: 14-5529H
APPROVED: 11/16/2017* EXPI[INVESTIGATOR_152617]: 11/15/2018Body Composition
The risks associated with the DEXA are very low.  The maximum r adiation dose you will 
receive in this study is less than 1/1000thof the federal and state occupational whole 
body dose limit allowed to radiation workers (5,000 mrem).  Put another way, the 
maximum dose from any scan we utilize with this DEXA ranges fro m 1.2 mrem (Whole 
body scan) to 12.2 mrem (for several of the regional scans, suc h as lumbar, femur, and 
forearm scans).  The average annual background radiation you al ready receive is at 
least 620 mrem/year.  The more radiation you receive over the c ourse of your life, the 
more the risk increases of developi[INVESTIGATOR_007] a fatal cancer or inducin g changes in genes.  The 
radiation in this scan is not expected to significantly increase these risks, but the exact increase in such risks is not known.  There are no discomforts associated with this 
procedure. Women who are or could be pregnant should receive no unnecessar y 
radiation and should not p articipate in this study.
Exercise Tests and Exercise Training
There is a very small chance of an irregular heartbeat during e xercise (< 1% of all 
subjects).  Other  rare risks of a stress test are heart attack (< 5 in 10,000) and death (<2 
in 10,000).  Wearing a mouthpi[INVESTIGATOR_438847]-clip can sometimes c ause dryness in the 
mouth and mild discomfort. Difficult exercise may make you feel  very tired, light headed 
and nauseous.  Exhausting exercise will, by [CONTACT_108], make yo u feel very tired.  After 
any exercise your muscles might ache.
Blood Collection
When the needle goes into a vein, it may hurt for a short perio d of time (a few seconds).  
Also there may be minor discomfort of having the needle/plastic  tube taped to your arm.  
In about 1 in 10 cases, a small amount of bleeding will occur u nder the skin that will 
cause a bruise.  The risk of forming a blood clot in the vein i s about 1 in 100, and the 
risk of significant blood loss is 1 in 1,000.  Additionally, th ere is a risk that you may faint 
while having blood collected or having the catheter inserted in your vein.Muscle Biopsy
During the procedure you may feel discomfort associated with th e injection of the 
numbing drug (the anesthetic) but during the actual muscle remo val the discomfort 
should be minimal. There is a risk that you may faint during th e procedure. There is also 
a risk of muscle cramp, bleeding, of loss of feeling in your leg , and of damage to a skin 
(cutaneous) nerve.  The risk of i nfection and bruising is extre mely small if you follow the 
instructions for caring for the incision.  A very small and minor scar will remain as a result 
of the incision, but may not be noticeable. These procedures wi ll be performed under 
surgically clean conditions.  Em ergency medical equipment will be available.  You will be 
screened prior to the procedure for history of allergic reactio ns to Novocain (Lidocaine).
Page 9of 12Participantâ€™s initials _______ Date _______
Version 01July2016CSU#: 14-5529H
APPROVED: 11/16/2017* EXPI[INVESTIGATOR_152617]: 11/15/2018Dapagliflozin
Adverse reactions in placebo-controlled studies reported in mor e than 2% but less than 
8.5% of patients treated with Dapagliflozin include:
xFemale genital mycotic infections (fungal or yeast infections), s uch as (listed in 
order of frequency reported): vulvovaginal mycotic infection, v aginal infection, 
vulvovaginal candidiasis, vulvovaginitis, genital infection, genital candidiasis, 
fungal genital infection, vulvitis, genitourinary tract infecti on, vulval abscess, and 
vaginitis bacterial. 
xNasopharyngitis (cold-like symptoms)
xUrinary tract infections, such as (listed in order of frequency r eported): urinary 
tract infection, cystitis, Escherichia urinary tract infection, genitourinary tract 
infection, pyelonephritis, trigonitis, urethritis, kidney infec tion, and prostatitis.
xBack pain
xIncreased urination
xMale genital mycotic infections (fungal or yeast infections), suc h as (listed in order 
of frequency reported): balanitis, fungal genital infection, ba lanitis candida, genital 
candidiasis, genital infection male, penile infection, balanopo sthitis,
balanoposthitis infective, genital infection, and posthitis.
xInfluenza (Flu)
xNausea (Upset stomach)
xDyslipi[INVESTIGATOR_035] (High Cholesterol)
xConstipation
xDiscomfort with urination
xPain in extremity
In a study of 5,936 patients with type 2 diabetes, one patient became ill with diabetic ketoacidosis (a metabolic sickness).  If you experience any of the following 
sensations/symptoms you should seek immediate medical help and contact [CONTACT_1275]: sickly or queasy (nausea), vomiting, stomach (abd ominal) pain, confusion, 
change in breathing pattern and unusual tiredness (fatigue) or sleepi[INVESTIGATOR_008].
Page 10of 12Participantâ€™s initials _______ Date _______
Version 01July2016CSU#: 14-5529H
APPROVED: 11/16/2017* EXPI[INVESTIGATOR_152617]: 11/15/2018In addition, use of Dapagliflozin is also associated with a risk of weight loss (up to 10 lbs 
over 12 weeks).
ARE THERE ANY BENEFITS FROM TAKING PART IN THIS STUDY? There are no direct benefits in participating, however you will  receive a copy of your 
results and information pertinent to your body composition (i.e.  height and weight), and 
metabolic and cardiovascular risk factors. For example, in blood  we will measure 
concentrations of glucose.  You will be provided with a copy of  your DEXA scan; you 
may wish to have this interpreted by a medically qualified prof essional. Finally, this study 
has the potential to identify an additional benefit for people who use Dapagliflozin to treat 
their type [ADDRESS_556152] TO TAKE PART IN THE STUDY?
Your participation in this research is voluntary. If you decide to participate in the study, 
you may withdraw your consent and stop participating at any tim e without penalty or 
loss of benefits to which you are otherwise entitled.
WHAT WILL IT COST ME TO PARTICIPATE? Other than transport to and from the lab, your participation sho uld incur no costs. You 
will not be charged for your supervised exercise training.WHO WILL SEE THE INFORMATION THAT I GIVE? 
We will keep private all resear ch records that identify you, to the extent allowed by [CONTACT_2371].
For this study, we will assign a code to your data (e.g. 1234ABC D) so that the only place 
your name [CONTACT_438852] t he consent and in ou r data spreadsheet that
links you to your code. Only the research team will have access  to the link between you, 
your code, and your data. The only exceptions to this are if we  are asked to share the 
records of the study for audit purposes with the Food and Drug Ad ministration, Health 
and Human Services, [COMPANY_008], and/or the CSU Institutional Review Board ethics committee, if necessary. In addition, for funded studies, the C SU financial management 
team may also request an audit of research expenditures. For financial audits, only the fact that you participated would be shared, not any research da ta. When we write about 
the study to share it with other researchers, we will write abo ut the combined information 
we have gathered. You will not be identified in these written m aterials. We may publish 
the results of this study; however, we will keep your name [CONTACT_438853].
Your identity/record of receiving compensation (NOT your data) may be made available 
to CSU officials for financial audits.
CAN MY TAKING PART IN THE STUDY END EARLY? 
Page 11of 12Participantâ€™s initials _______ Date _______
Version 01July2016CSU#: 14-5529H
APPROVED: 11/16/2017* EXPI[INVESTIGATOR_152617]: 11/15/2018If you do not complete 40 exercise sessions (approximately 90%), or two exercise 
sessions within a 7-day period, you will be removed from the stu dy. If you fail to ingest 
90% of your Dapagliflozin or placebo (75/84 pi[INVESTIGATOR_3353]) you will be rem oved from the study.
Your participation in the stu dy will end if you become pregnant .
WILL I RECEIVE ANY COMPENSATION FO R TAKING PART IN THIS STUDY? 
If you complete all 51 of the visits, and all of the procedures a s described, you may
receive $300 in total. This payment will be paid in installments and prorated as follows: 
you will not receive compensation for visit 1 (the screening visit). You will receive $80 oncompletion of visits 2, 3 and 4.  You will not receive compensa tion for visits 5-48; nor will 
you be charged for this supervised exercise training.  You will  receive $60 for completion 
of visit 49. You will receive $60 for completion of visit 50. You  will receive $60 for 
completion of visit 51. If you attend 100% of your scheduled visi ts, and arrive no later 
than 10 minutes after the scheduled appointment time for all app ointments, you will 
receive a bonus of $40.
Should your participation in the study end early, you will stil l receive feedback pertaining 
to your health and fitness. WHAT HAPPENS IF I AM INJURED BECAUSE OF THE RESEARCH?We will arrange to get you medical care if you have an injury t hat is caused by [CONTACT_87427].CSU will pay for medical expenses for the treatment of a persona l injury that is a direct 
result of the administration of the study drug (CSU will be rei mbursed by [CONTACT_38227]). 
CSU will not provide compensation for lost wages or for any oth er damages, expenses 
or losses, or for medical expenses that have been covered by [CONTACT_401177].Should you sustain an injury that is not the direct result of the study drug, you or your 
insurance company may have to pay for the required care. The Col orado Governmental 
Immunity Act determines and may limit Colorado State University , University of 
Colorado Denver and University of Colorado Hospi[INVESTIGATOR_307]â€™s legal responsibility if an injury happens because of this study. Claims against the University mu st be filed with 
Colorado State University within [ADDRESS_556153] QUESTIONS?  Before you decide whether to accept this invitation to take par t in the study, please ask 
any questions that might come to mind now.  Later, if you have questions about the 
study, you can contact [CONTACT_093], [CONTACT_342201] via email:
[EMAIL_8395]. If you have any questions about y our rights as a 
volunteer in this research, contact [CONTACT_152646]: [EMAIL_3134] ;
[PHONE_3429]. We will give you a copy of this consent form to ta ke with you.
Page 12of 12Participantâ€™s initials _______ Date _______
Version 01July2016CSU#: 14-5529H
APPROVED: 11/16/2017* EXPI[INVESTIGATOR_152617]: 11/15/2018WHAT ELSE DO I NEED TO KNOW? 
A description of this clinical  trial will be available on http://www.ClinicalTrials.gov as 
required by U.S. Law. This webs ite will not include information  that can identify you. At 
most, the Web site will include a summary of the results. You c an search this website at 
any time.  
Your signature [CONTACT_438854].  Your signature [CONTACT_438855] y ou have received, on 
the date signed, a copy of this document containing 12 pages.
___________________________________________ _____________
Signature [CONTACT_438856]
_____________________________________________ _____________
Printed name [CONTACT_438857] o f Day
_________________________________________ _____________
Name [CONTACT_438858]
_________________________________________  
Signature [CONTACT_438859]